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1 ZUSAMMENFASSUNG 
 
Seit der Entdeckung, dass verschiedene Immunzellen über die Fähigkeit verfügen, Tumorzellen zu erkennen 
und zu zerstören, wurden unterschiedliche Ansätze getestet, um unter anderem Natürliche Killerzellen 
(NK-Zellen) zur Therapie maligner Erkrankungen einzusetzen. So wurden mit NK-Zell-basierten Therapien 
wichtige Durchbrüche bei der Behandlung hämatologischer Tumore,  doch nur geringe Erfolge in Patienten 
mit soliden Tumoren erzielt. Dass die Anzahl Tumor-infiltrierender NK-Zellen in vivo zu einer Verbesserung 
der Prognose führen kann, wurde jedoch für mehrere Krebsarten gezeigt. Wir vermuteten daher, dass es 
für das Ausbleiben relevanter therapeutischer Erfolge bei Patienten mit soliden Tumoren zwei Gründe 
geben könnte: Zunächst könnten die infundierten NK-Zellen evtl. nicht effizient in das Tumorgewebe 
eingewandert sein oder aber sie haben ihre Aktivität nach der Infusion in die Patienten rasch verloren. Das 
Ziel dieser Studie war es daher, die anti-Tumor-Aktivität adoptiv transferierter NK-Zellen zu verbessern, 
indem (1) die Anlockung von NK-Zellen in Tumore durch die Expression von chemotaktischen Zytokinen 
(Chemokinen) in Tumorzellen verbessert wird und (2) ein neuartiges Aktivierungsprotokoll etabliert wird, 
welches NK-Zellen mit lang anhaltender Aktivität generiert. Hierfür wurde zunächst ein Tiermodell 
entwickelt, um die in vivo-Relevanz unserer Studien zu belegen. Das Modell ermöglichte das Anwachsen 
humaner Luciferase-transduzierter Melanom-Zellen und NK-Zellen in immunsupprimierten Mäusen, in 
denen die Tumorgrößen durch Lumineszenzmessungen bestimmt werden konnten. Für unser erstes Ziel 
konnten wir weiterhin CX3CL1 als geeignetes Chemokin für die spezifische Anlockung zytotoxischer 
NK-Zellen identifizieren. CX3CL1-überexprimierende Melanom-Zelllinien lockten im Vergleich zu den 
jeweiligen Kontrollzellen NK-Zellen in vitro und in vivo im Xenograftmodell stärker an. Von großer 
Bedeutung ist, dass eine stärkere Kontrolle des Wachstums CX3CL1-positiver Tumore durch NK-Zellen in 
vivo gezeigt werden konnte. Für unser zweites Ziel testeten wir ein neuartiges Stimulierungsprotokoll. 
Cooper et al. haben in einer früheren Studie gezeigt, dass murine NK-Zellen, die mit Interleukin (IL)-12, 
IL-15 und IL-18 (IL-12/15/18) stimuliert worden waren, über lang anhaltende Reaktivität verfügten, 
weswegen wir dieses Aktivierungsprotokoll für humane NK-Zellen testeten. Als Referenz wurden 
IL-15-stimulierte NK-Zellen verwendet. Unsere Untersuchungen zeigten, dass IL-12/15/18-stimulierte 
NK-Zellen durch die verstärkte Expression der α-Kette des IL-2-Rezeptors sensitiver gegenüber IL-2 wurden. 
Demgemäß teilten sich die NK Zellen in vitro und in vivo in den Versuchstieren unter IL-2-Gabe schneller als 
die Kontrollzellen und lieferten größere Zellzahlen. Weiterhin reagierten IL-12/15/18-stimulierte NK-Zellen 
nach längerer in vitro-Kultivierung oder nach Re-Isolation aus Versuchstieren bei Restimulierung mit einer 
verstärkten Produktion von Interferon-γ (IFN-γ). Von großer Bedeutung ist weiterhin, dass die 
IL-12/15/18-Stimulierung eine stark verminderte Expression inhibitorischer Killer cell Immunoglobulin-like 
Receptors (KIR)-Rezeptoren bewirkte, deren niedrigere Expression auf NK-Zellen nach Stimulierung mit 
einer Zunahme der Reaktivität gegenüber Tumorzellen einherging, welche die zugehörigen inhibitorischen 
Liganden exprimierten. Zudem, verglichen mit IL-15-stimulierten Kontrollzellen, zerstörten 
IL-12/15/18-aktivierte NK-Zellen Tumorzellen in vitro stärker und verminderten das Tumorwachstum in 
vivo.  
Zusammenfassend wird in dieser Arbeit beschrieben, dass sowohl die Anlockung von NK-Zellen durch die 
gezielte Expression von CX3CL1 in Tumorzellen, als auch die Aktivierung von NK-Zellen durch IL-12, IL-15 
und IL-18 über ein großes therapeutisches Potential verfügen. In unserem prä-klinischen Mausmodell 
konnten wir eine verstärkte Anlockung von NK-Zellen in CX3CL1-exprimierende Tumore zeigen und für 
beide Ansätze eine verbesserte Tumorabstoßung durch NK-Zellen. Diese Daten verfügen damit über 
erhebliche klinische Relevanz und sollten in das Design klinischer Studien zur NK-Zell-basierten 
Tumorimmuntherapie einbezogen werden. 
Summary 2 
2 SUMMARY  
 
Since the initial observation that various immune effector cells can detect and lyse tumor cells, different 
approaches have been developed in order to harness for instance natural killer cells (NK cells) for the 
treatment of malignant diseases. Despite important breakthroughs in the therapy of hematological 
malignancies, only small successes could be achieved in the NK cell-based treatment of patients with solid 
tumors. Nevertheless, it was reported for several cancer entities that the amount of tumor-infiltrating NK 
cells correlated with a better prognosis. Thus, we were assuming that at least two reasons exist why in 
patients suffering from solid malignancies following NK cell infusion no relevant clinical responses could be 
observed: first, the transferred NK cells could not have properly infiltrated into the tumor tissue or second, 
they could have rapidly lost their responsiveness. Accordingly, the aim of this study was to improve the 
anti-tumor responses of adoptively transferred NK cells (1) by improving NK cell infiltration into tumors by 
over-expressing chemoattracting cytokines (chemokines) in tumor cells and (2) by establishing a novel 
activation protocol in order to generate effector NK cells with sustained effector functions. First, to explore 
the in vivo relevance of our studies, a xenograft mouse model was established. This model allowed for the 
engraftment of human luciferase-transduced melanoma cells and NK cells in immunocompromised mice 
and for the subsequent quantitative detection of tumor cells using optical imaging. Regarding the first aim, 
CX3CL1 was identified as a suitable chemokine that specifically attracted cytotoxic NK cells. Accordingly, we 
have found that CX3CL1-expressing melanoma cells attracted NK cells in vitro in transwell migration assays 
and in vivo in the xenograft model more pronouncedly compared to the respective control cells. 
Importantly, we also showed that the growth of CX3CL1-overexpressing cell lines compared to control lines 
was more potently controlled by NK cells in vivo. With regards to the second aim, we tested a new NK cell 
stimulation regimen in our model. Recently, Cooper et al. reported that murine NK cells stimulated with 
Interleukin (IL)-12, IL-15 and IL-18 (IL-12/15/18) exhibited more potent and sustained reactivity. Based on 
these findings, we investigated the effect of this triple cytokine stimulation on human NK cells. As a control, 
NK cells were stimulated with IL-15 alone. Our study showed that IL-12/15/18-stimulated NK cells 
expressed higher levels of the IL-2 receptor α-chain, rendering the NK cells more sensitive towards IL-2. 
Accordingly, IL-12/15/18-stimulated NK cells proliferated faster both in vitro and in vivo upon 
IL-2-supplementation and yielded higher cell recovery. Furthermore, IL-12/15/18-stimulated NK cells 
produced higher levels of interferon-γ (IFN-γ) after prolonged culture periods in vitro or after recovery from 
immunodeficient mice. Most importantly, IL-12/15/18-stimulation led to a decreased expression of several 
inhibitory NK cell receptors, the so-called killer cell immunoglobulin-like receptors (KIRs) resulting in 
increased reactivity against targets that expressed the cognate ligands. Moreover, compared to 
IL-15-stimulated cells, IL-12/15/18-stimulated NK cells exerted increased cytotoxicity in vitro and, most 
remarkably, also exhibited more potent anti-tumor effector functions in vivo leading to a decreased tumor 
load. 
In summary, this work suggests that both the attraction of NK cells through CX3CL1-expression and the 
activation of NK cells with IL-12, IL-15 and IL-18 harbor great therapeutic potential for novel NK cell-based 
immunotherapies against melanoma and human malignancies in general. In our pre-clinical mouse model 
we could demonstrate a more pronounced NK cell recruitment to CX3CL1-expressing tumors and for both 
approaches an improvement in NK cell-mediated tumor control. These data might be clinically relevant and 
thus we propose that these findings should be implemented into the design of clinical trials for NK 
cell-based tumor immunotherapy. 
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3  INTRODUCTION 
 
3.1 Cancer biology  
3.1.1 Oncogenesis 
Malignant transformation which leads to the development of cancer is a complex process 
that can be initiated by a variety of events, all ultimately being mutagenic such as ultraviolet (UV)- or 
γ-irradiation or DNA intercalating agents. Typically, cancer arises after a multi-step acquisition of 
various genetic or epigenetic mutations that ultimately lead to a fatal deregulation of cellular 
processes involved in DNA repair, cell survival, proliferation and motility. As a result, a healthy cell 
acquires the capability to accumulate mutations and to proliferate in an uncontrolled way, ultimately 
forming a tumor mass from which single cells disseminate to form metastasis at distant sites in the 
body. This spread of tumor disease is often fatal and leads to the death of the respective cancer 
patient. 
The required mutations are typically sub-classified into driver and passenger mutations with the first 
ones being crucial to drive tumorigenesis1. Driver genes typically regulate cell fate, cell survival and 
genome maintenance processes that upon deregulation cause loss of growth control. Compared to 
driver mutations passenger mutations do not per se confer growth advantage. Whole genome 
sequencing of the DNA of cancer patients led to the estimate that a typical tumor contains 2-8 driver 
mutations which are typically accompanied by approximately 30-60 passenger mutations indicating 
the complexity of malignant transformation. Melanoma, which is studied in this thesis, is an outlier 
from this general rule harboring typically approximately 200 mutations per tumor, indicating the 
power of UV irradiation as a mutagen2. This is a clinically relevant feature, as these data prove that 
probably every tumor will be unique in terms of acquired mutations and most likely also 
immunogenicity, which will be discussed later on.  
Many of these mutations are located in so-called oncogenes and tumor-suppressor genes3,4. 
Oncogenes are genes that upon chronic activation, for example due to a mutational event, confer a 
growth advantage of the mutation harboring cell whereas tumor-suppressor genes are genes that 
require de-activation to allow for uncontrolled cell growth. Prototypical oncogenes are myc, human 
epidermal growth factor receptor 2 (Her2/neu), Ras and the Abl gene in the Philadelphia 
chromosome whereas typical tumor-suppressor genes are the retinoblastoma protein (pRb), p53 or 
the phosphatase and tensin homolog (PTEN). 
Importantly, many proteins can harbor mutations at various sites indicating their importance for 
tumorigenesis in general and many tumor entities share similar mutation patterns providing them 
with similar features which led to the classification of the hallmarks of cancer by Hanahan and 
Weinberg that will be discussed under 3.1.25. 
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3.1.2 General hallmarks of cancer 
As introduced previously, the genetic instability that neoplastic cells acquire can cause a tremendous 
amount of genetic and epigenetic mutations that ultimately grant tumor cells their abnormal growth 
and later on disseminating behavior1. Hanahan and Weiberg in 2000 have proposed an organizing 
principle showing that mutations during oncogenesis serve basically one of six purposes6. Due to the 
emerging importance of additional hallmarks in 2011 a new version featuring two new emerging 
hallmarks and two enabling characteristics was released (figure 3.1)5.  
 
 
 
 
 
Due to the importance of those hallmarks for cancer biology they will be briefly introduced below: 
 
a) Enabling replicative immortality 
Tumor cells acquire a state of immortality. Typically, after many rounds of cell division, the telomeres 
of the chromosomes get overly truncated and aggregate ultimately leading to cell death. As tumor 
cells unlike non-immortalized cells express a functional telomerase this chromosomal crisis is avoided 
as the protein constantly adds nucleotide repeats to the end of the chromosomes in tumor cells. 
b) Activating invasion and metastases 
Primary tumors often initiate a sequence of certain steps, the invasion-metastasis cascade, leading to 
the dissemination of single tumor cells. These are transported via lymphatic or blood vessels to 
distant organs which they colonize. This complex process features the de-regulation of adhesion 
molecules like E-cadherin but also tumor-infiltrating bone-marrow derived cells such as macrophages 
that can supply matrix-degrading enzymes and thus facilitate metastasis. 
Emerging hallmarks 
Figure 3.1 – The next generation of hallmarks 
of cancer. Schematic representation of key 
features of tumor cells together with the 
underlying mechanisms allowing for a rapid 
evolution of cancer cells. The represented 
abilities can be observed in virtually any 
patient and tumor entity and are ultimately 
causative for cancer-related deaths (Adopted 
from Hanahan and Weinberg, Cell, 2011; 5, 
646-74)5. 
 
Enabling characteristics 
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c) Inducing angiogenesis 
As cancer cells are metabolically highly active, a tumor permanently needs proper nurturing with 
various metabolites and in addition requires a well-established gas exchange, both processes which 
are mediated by the bloodstream. Thus, for sustained growth tumors require to establish an 
extensive blood vessel system, the generation of which is termed angiogenesis or neo-angiogenesis. 
The vascular endothelial growth factor (VEGF), in this context, is a prototypical pro-angiogenic 
molecule which participates in triggering the angiogenic switch. 
d) Resisting cell death 
As sustained proliferative signaling leads to induction of cell death, for example via Bcl-2 homology 3 
(BH3)-only proteins, anti-apoptotic factors are required to keep malignant cells alive. This is often 
achieved via loss of p53, overexpression of anti-apoptotic factors such as B-cell leukaemia/lymphoma 
2 (Bcl-2) or down-regulation of pro-apoptotic factors such as Bax or Bim. 
e) Sustaining proliferative signaling 
On their way to oncogenic transformation, normal cells constantly need to receive growth and/or 
survival signals. This is achieved, for instance, via autocrine stimulation with growth factors or 
constant, i.e. ligand-independent, signaling of growth factor receptors. One example would for 
instance be a B-Raf mutation yielding a constitutively active version of the protein that can be 
detected in around 40% of melanoma samples7. 
f) Evading growth suppressors  
In line with the sustained proliferative signaling, tumor cells also need to evade growth suppressing 
signaling. One very famous example for a tumor-suppressor gene would be p53, the so-called 
‘guardian of the genome’. As genetic mutations are accumulating, control proteins which can drive 
cells into senescence or apoptosis when DNA damage is overwhelming need to be kept in check. 
Accordingly, p53 is one of the most frequently mutated control proteins in cancer showing point 
mutations in about 50% of all sequenced tumors.  
The acquisition of these six important hallmarks is crucial for cancer cells, yet they may occur in 
varying orders and with different timings in individual cancers. All of the introduced six hallmarks can 
be acquired because of two so-called enabling characteristics that will be introduced briefly in the 
next section: 
a) Genome instability and mutation 
As introduced earlier, genetic instability enables cells or cancer cells to acquire mutations in a 
random way that later on are selected for conferring growth advantage which leads to the outgrowth 
of the most successful or tumorigenic subclones. This instability needs to be achieved by either 
increasing the sensitivity towards mutagenic agents or by circumventing the cellular DNA repair 
machinery to prevent repair of introduced mutations. Important alterations include variations in 
gene copy numbers, mutations in coding parts of DNA but also mutations in non-protein coding DNA, 
for instance in regulatory elements. 
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b) Tumor-promoting inflammation 
Infiltrates of various immune cells can be found in any given tumor. Despite the fact that many of the 
cell types found can control tumor growth, tumor-associated inflammation can severely contribute 
to assist tumor cells in advancing to states of elevated malignancy. Inflammatory environments can 
hence lead to the modification of the extracellular matrix (ECM), to neo-vascularization and even 
effector molecules like reactive oxygen species (ROS) have been shown to be able to foster genetic 
instability and thus drive the evolution of cancer cells. 
Due to immense research efforts that have been put into the understanding of tumor development 
and progression, two new emerging hallmarks were identified and added to the original list. These 
will be briefly discussed in the next section: 
a)  Deregulating cellular energetics 
Tumor cells require many nutrients to fuel their excessive growth. On the other hand, the tumor 
microenvironment is often hypoxic disabling the usage of the citric acid cycle that critically depends 
on normal oxygenation. This fact has been realized in the 1930s by Otto Warburg. Since then it 
became increasingly clear that hypoxia and, for instance, Ras signaling can independently increase 
the hypoxia-inducible factor 1 alpha (HIF1α) which subsequently up-regulates glycolysis. Together 
with the overexpression of glucose transporters like the glucose transporter-1 (GLUT-1) these 
phenomema provide enough energy to drive the uncontrolled proliferation of tumor cells in hypoxic 
tissues.  
b) Avoiding immune destruction 
It has been shown successfully in models of adoptive transfer and/or depletion that amongst others 
cytotoxic T lymphocytes (CTL) and NK cells can control tumor growth in vivo. In line with this it has 
been shown that immuno-suppressed individuals, for example organ recipients, also display a higher 
risk for developing cancer. Also, several studies reported that usually the level of infiltration of tumor 
tissue with T and/or NK cells correlated with better prognosis (these findings will be discussed later). 
These date led to the addition of the hallmark of immune evasion to the existing list.  
 
3.1.3 Melanoma 
Malignant melanoma is a subtype of cancer involving the melanocytes in the basal layer of the 
epidermis (stratum basale). It is overall the third most common malignancy and is notably a very 
aggressive neoplasia that after metastatic spread is characterized by a 5 year-survival rate of less 
than 5%8. Further, although the lifetime risk of developing cutaneous malignant melanoma with 
around 1-2% is comparably low the incidence rate increases faster than for any other malignancy9,10.  
As already introduced, melanoma cells harbor usually more mutations than other cancer entities. 
This is due to the fact that melanocytes are frequently exposed to mutating UV irradiation which is 
part of the spectrum of sunlight. Of note, prominent mutations in melanoma samples are directly in 
line with issues that were discussed under 3.1.2. Like mentioned the proto-oncogene B-Raf is 
mutated in about 40% of melanoma samples but also N-Ras, Bcl-2, PTEN or nuclear factor-κB (NF-κB) 
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frequently exhibit mutations providing progenitors of melanoma cells with growth advantages 
leading to oncogenic transformation7,11.   
One of the reasons why despite increasing incidence the melanoma-related death rate is virtually 
stable is that it is more often detected in its early stages where it can be removed with surgery. 
However, as melanocytes are derived from highly motile neural-crest progenitors they are very 
prone of initiating metastatic spread. Also, melanoma cells are often refractory to most existing 
treatment strategies and can exhibit a pronounced apoptosis-resistance in vitro and in vivo12. Thus, 
novel strategies targeting melanoma are desperately needed.  
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3.2  The immune system 
The human body is exposed to many different pathogens, such as viruses, bacteria or fungi. Yet, it 
evolved an entire system of organs and cellular and soluble components that is able to potently fight 
off virtually any infectious threat. The most important organs being part of the immune system are 
the bone marrow, the spleen, the thymus, lymph nodes, tonsils and the mucosa- and gut-associated 
lymphoid tissues. Importantly, the cells of the immune system are all created by specialized 
hematopoietic stem cells (HSC) in the bone marrow from where they either migrate towards 
secondary lymphoid tissue like the thymus for development or circulate in the blood or lymph to 
detect pathogenic or malignant threats to the body. In order to do so, all immune cells rely on a 
distinct set of receptors with which they discriminate self/healthy from non-self/diseased tissues to 
ensure that their effector potential is only released in danger situations. In vertebrates, the cells of 
the immune system are classically assigned to either the innate or the adaptive immune system. This 
is done according to the type of recognition receptors used and the timing of the subsequent 
immune reaction but also by the ability of the cell to exert immunological memory.  
 
3.2.1  The innate immune system 
The innate immune system is characterized by the usage of receptors that are germline-encoded, 
non-clonally distributed and that recognize a broad array of pathogens. Upon recognition of for 
example a virus an immune reaction is instantly initiated without the need for prior sensitization. 
Therefore, innate immunity serves as a first line of defense against invaders. It consists of various cell 
types as well as soluble factors. The most important cell types of this branch of the immune system 
are monocytes, macrophages, dendritic cells (DCs), granulocytes and NK cells. The soluble factors 
belonging to the innate immune system are comprised of the acute phase proteins (pentraxins like 
the C-reactive protein (CRP) and the mannose binding lectin (MBL)) that are secreted by hepatocytes 
upon challenge with macrophage-derived IL-1, IL-6, tumor necrosis factor-α (TNF-α) and the 
complement proteins. The latter comprise a set of plasma proteins that get activated in a 
triggered-enzyme-cascade and subsequently assist in opsonizing pathogens for phagocytes, lyse 
them directly or produce inflammatory peptides13. 
Upon penetration of a pathogen through epithelium or mucosa the cellular components of the 
innate immune system can recognize structures which are shared by many different pathogens 
(pathogen-associated molecular patterns (PAMPs)) with their cognate pattern recognition receptors 
(PRRs). Important membrane-bound PRRs, for instance, would be toll-like receptors (TLRs), C type 
lectin receptors or scavenger receptors. Notably, besides these membrane-bound receptors there 
are also soluble and intracellular PRRs. The entire PRRs bind to PAMPs, promiscuously expressed on 
various pathogens, such as bacterial lipopolysaccharide (LPS, recognized by TLR4), flagellin 
(recognized by TLR5), double-stranded RNA (recognized by TLR3) or unmethylated CpG (recognized 
by TLR9) conferring self-non-self discrimination capabilities. Of note, these receptors do not reach 
the extent of specificity that receptors of the adaptive immune systems confer.  
When a phagocytic cell (neutrophil granulocytes, monocytes, macrophages, DCs), for instance a 
tissue-resident DC, recognizes PAMPs with its PRRs it will phagocytose the PAMP bearing structure14. 
This triggers the secretion of inflammatory cytokines and chemokines but also allows macrophages 
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and DCs to break incorporated proteins down into peptides that subsequently get presented on 
major histocompatibility complex (MHC) molecules15. After full maturation, which includes the 
up-regulation of the co-stimulatory CD80 and CD86, and homing to the draining lymph node these 
peptides in a MHC context are presented to naїve T cells which thereby get activated14. This 
cross-talk between cells of the innate and adaptive immune system is absolutely crucial for mounting 
adaptive immune responses. In particular DCs, the most professional antigen presenting cells (APC) 
play a crucial role in the cross-talk between innate and adaptive immunity.  
Of note, PRRs are not exclusively expressed on cells of the innate immune system. It has been shown 
for instance that PRRs are also expressed on cells of the vascular endothelium. These endothelial 
cells (EC) upon PRR signaling produce chemotactic proteins and increase the expression of certain 
adhesion molecules such as intracellular adhesion molecule-1 (ICAM-1) and E-selectin. This process, 
being termed endothelium activation, efficiently assists effector cells in extravasating into infected 
tissue (refer to section 3.2.4). 
Another important cell type of the innate immune system is the NK cell. As they are the central cell 
type for this thesis they will be discussed comprehensively in chapter 3.3. 
 
3.2.2 The adaptive immune system 
The innate immune system, as introduced in 3.2.1, harbors PRR-expressing cells that respond quickly 
towards various invading pathogens, keeping the infection under control until several days later the 
adaptive immune system is fully activated. The reason for this delayed type of response is the 
structure of the respective receptors on adaptive effector cells. They require somatic gene 
re-arrangement and are clonally expressed on cells. During development, B and T cells randomly 
recombine their receptor genes which are located in various segments, a process called V(D)J 
recombination. Key to this process are the recombination activation genes (RAG) 1 and 216. The 
entire process leading to the expression of one functional receptor can create up to 1014-1018 
specificities that subsequently get depleted of self-reactive receptors. This selection and depletion of 
autoreactive specificities is called clonal deletion. Due to the random assembly of receptors this 
process is an important pre-requisite to maintain tolerance to self.  
The cells of the adaptive immune system are B and T cells, both of which are generated in the bone 
marrow. Whereas B cells remain in the bone marrow for maturation, T cells egress into the thymus 
where their final maturation takes place. Due to the stochastic expression of receptors with a distinct 
specificity, only few B or T cells directly after an infection express the correct specificity for a given 
pathogen-derived epitope. Thus, a process named clonal expansion is triggered. This process 
generates antigen-specific cells out of very few B or T cells expressing a receptor detecting 
pathogenic molecules. This required expansion explains the delay until full effector functionality can 
be provided. For T cells, this activation is achieved by recognition of cognate peptides in the context 
of MHC molecules on APCs, like for example DCs, with their T cell receptor (TCR). T cells expressing 
the CD4 co-receptor hereby bind to peptides in the context of MHC class II presentation that is 
expressed on APCs whereas cells expressing the CD8 antigen bind to peptides presented on MHC 
class I which is expressed on virtually all nucleated cells. T cells mature in the thymus and later patrol 
secondary lymphoid tissue in search for APCs presenting specifically their cognate peptide:MHC 
complex that can be detected by their TCR. After activation, CD8+ T cells develop into CTLs. These 
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cells mediate direct cytotoxicity against cells presenting their cognate peptide on MHC class I. CD4+ T 
cells can differentiate into Th1 or Th2 cells depending on the cytokine milieu during activation. Th1 
cells are generated in the presence of IL-12 and/or IL-18. They activate macrophages to kill 
intracellular pathogens more efficiently and stimulate B cells to produce opsonizing antibodies. Th2 
cells on the other hand differentiate in the presence of IL-4 and assist in the activation of 
antigen-specific B cells to produce neutralizing antibodies.  
B cells prior to activation express a membrane bound immunoglobulin as B cell receptor (BCR). For 
activation, they require binding to their specific antigen. This antigen subsequently gets internalized 
and peptides of it are presented on MHC class II on the B cell surface. Certain T cell subsets are 
required for B cell activation by binding to the peptide: MHC II complex stimulating the B cell. Thus, 
the TCR recognizes a peptide of the antigen the respective BCR reacted against. Upon activation, B 
cells differentiate either into memory cells or into antibody-secreting plasma cells that are a crucial 
part of the defense against extracellular pathogens or toxins. Different classes of secreted antibodies 
hereby mediate various functions such as antibody-dependent cytotoxicity (ADCC), opsonization of 
pathogens for phagocytes or complement activation. 
Of note, other cells like NKT cells or γδ T cells exert bridging functions or show features of either of 
the two branches. γδ T cells for instance use TCR rearrangement, yet their TCR is working in a 
PRR-like fashion17. NKT cells on the other hand exert a bridging function between the two arms of 
immunity in a way that they get strongly activated by signaling of CD1d in the presence of DC derived 
IL-12 and subsequently activate CD4+ Th1 cells and CTLs18. Notably, there are more cell-types for 
example Th17 or regulator T cells (Treg) that are not introduced in this section. 
 
3.2.3 Tumor immunology 
Besides fighting off pathogenic invaders, the immune system also has developed the ability to 
recognize altered self as target structures and mount an immune reaction against these changed, i.e. 
transformed cells. However, the effector cells and molecules are not always exerting beneficial 
effects, rendering tumor immunity a double-edged sword19. 
Of note, more than 100 years ago in 1909, Paul Ehrlich introduced the concept of immune cells 
controlling cancer growth. After 50 years and many discoveries made in the field of immunology, 
Burnet and Thomas proved that Paul Ehrlich’s assumptions were correct and introduced the 
renaissance or real starting point of modern tumor immunology featuring the concept of tumor 
immune-surveillance. Yet, the similarity of tumor cells to healthy cells were discussed controversially, 
since danger signals like bacterial LPS for instance were clearly missing in a tumor context. Also data 
were differing in several groups. The very first clear cut result was achieved in the 1990s with IFN-γ-/- 
or IFN-γ receptor (IFN-γR)-/- mice that showed defective tumor rejection compared to wild type (wt) 
mice upon carcinogen challenge or injection of tumor cell lines. Several important findings are 
comprehensively reviewed by Vesely et al. and ultimately led to the general appreciation of tumor 
immune-surveillance20. 
A way of summarizing all of the findings in a comprehensive way was introduced by Schreiber and his 
colleagues who were arranging the cancer-immune cell cross-talk throughout several stages and thus 
creating the immunoediting scheme, explaining how immune cells can either be beneficial or 
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detrimental for tumor bearing patients (figure 3.2)21,22. Most importantly, the immune system, in 
addition to the amount of tumor cells, also impacts the quality of the remaining cancer cells by 
actively selecting for non-immunogenic clones, thus explaining the word editing: 
 
Figure 3.2 – The three E’s of cancer immunoediting. The scheme displays the interplay between tumor cells at various 
stages with multiple immune cells, leading ultimately either to tumor destruction (elimination) or outgrowth (escape). 
CTLA-4, Cytotoxic T-Lymphocyte Antigen 4; IDO, indoleamine 2,3-dioxygenase; MΦ, macrophage; NKR, NK cell receptor; 
PD-1, Programmed cell death protein 1; PD-L1, programmed cell death-1 ligand; TGF-β, transforming growth factor- β; 
TRAIL, TNF-related apoptosis-inducing ligand, (Schreiber et al. Science 2011; 6024: 1565-70)19. 
 
As pointed out in section 3.1 mutations can cause malignant disease, if they allow for a growth 
advantage, by conferring the previously introduced hallmarks of cancer. However, several modes of 
intrinsic tumor suppression exist, for instance p53 mediated apoptosis induction due to excessive 
DNA damage or induction of senescence due to oncogene activation23. Upon circumventing these 
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regulatory mechanisms the transformed cell grows out and eventually is detected by the immune 
system due to the expression of markers of non-self. These markers can for instance be activating NK 
cell ligands (see section 3.3.2), some of which are induced upon malignant transformation or 
tumor-associated T cell epitopes24.  
Important signals by the developing tumor that alert the immune system are featuring type I IFNs, 
IL-1, TNF-α, high mobility group box 1 (HMGB1) or hyaluronan fragments from damaged tissue25. 
Importantly, HMGB1 can associate with other molecules and trigger TLR or the receptor for advanced 
glycation end products (RAGE) signaling, inducing inflammation therefore being assigned to the class 
of damage-associated molecular patterns (DAMPs). Notably, perturbances in the tissue integrity by 
neo-vascularization or stromal remodeling due to invasive tumor growth were proposed to be the 
first danger signal for the immune system as they could produce inflammatory cytokines, 
chemokines and molecules such as heat shock proteins (hsps) that activate tissue resident DCs26,27. 
These in turn attract and subsequently activate NK and T cells. 
 
Elimination 
The first phase of immunoediting represents the elimination phase, the stadium in which immune 
cells are fighting to prevent tumor outgrowth. Ideally, this phase from early on involves cells of the 
innate as well as cell of the adaptive immune system. NK cells can detect activating transformation 
induced ligands, like ligands for their activating receptor NKG2D, whereas T and NKT cells can detect 
tumor antigens in the context of MHC or CD124. The activation of these cells leads to the triggering of 
cytotoxic effector mechanisms but also the secretion of inflammatory cytokines such as IFN-γ. 
Likewise, IFN-γ stimulates macrophages to produce IL-12 that in turn stimulates IFN-γ secretion by 
NK cells resulting in a positive feedback loop28,29. Activated macrophages can then kill tumor cells via 
reactive oxygen species, whereas for NK cells TNF-related apoptosis-inducing ligand (TRAIL) and 
perforin dependent mechanisms have been described30,31. This first wave of anti-tumor effector 
mechanisms, as pointed out, is mainly driven by innate effector cells. Of note, high levels of IFN-γ 
also exert direct anti-proliferative, anti-angiogenic and pro-apoptotic functions on tumor cells32–34. 
As already mentioned, tissue resident sentinel DCs will get activated in this milieu either by innate 
cytokines such as IFN-γ or by tumor-infiltrating NK cells themselves, leading to their activation35. Also, 
the micromilieu in the meantime is enriched for hsp and apoptotic cell fragments that harbor 
excessive amounts of tumor antigens36,37. Subsequently, tumor-antigen loaded DCs migrate to the 
draining lymph node to mount an adaptive immune response against these antigens and induce a 
specific anti-tumor T cell response. This response ideally involves a CD4+ Th cell induction that 
subsequently supports the activation of cytotoxic CD8+ CTLs via cross-presentation38. Notably, the 
contribution of CD4+ Th cells to tumor immunity has not been realized for a while. Now, data clearly 
point to an important role of CD4+ T cells39. Accordingly, CD8+ CTLs after their clonal expansion will 
ideally infiltrate back into the tumor tissue, detect specifically antigen-expressing tumor cells and 
respond with cytotoxicity and/or IFN-γ secretion that in turn can activate macrophages, DCs, NK cells 
or exert anti-tumoricidal effects as discussed, possibly leading to the elimination of the tumor.  
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Equilibrium 
If during the elimination phase not the entire tumor burden gets cleared, a population of tumor cells 
co-exists with the effector cells of the immune system in a state of dormancy. This state is called 
equilibrium and is believed to be the longest phase in the process of immunoediting. It thus has been 
estimated that it can take 20 years from the first contact with a carcinogen to clinically manifest 
malignant disease during which most of the time the tumor exists in an occult state in equilibrium 
phase40.  
Animal experiments were proving the existence of this dormant state. Fully immunocompetent 
C57BL/6 mice were treated with low dose 3’-methylcholanthrene (MCA) and due to the low dosing 
did not develop any apparent tumor. Later, upon antibody-mediated depletion of IFN-γ and T cells, 
roughly 50% of the animals quickly developed tumors at the site of MCA treatment41. Of note, NK 
cells were not found to contribute to this state of dormancy as administration of anti-NK1.1 or 
anti-NKG2D did not lead to tumor outgrowth. Similar data that support this hypothesis of the 
existence of an equilibrium phase were also gathered in various mouse models42. Thus, the adaptive 
immune system prevents the outgrowth of resident tumor cells and sculpts their immunogenicity by 
selecting for less immunogenic tumor cells. This renders the equilibrium phase distinct from 
elimination phase that requires both innate and adaptive immunity. 
Despite the equilibrium phase keeping a growing tumor under control, this phase is crucial for the 
creation of an evolutionary force driving the tumor cells to develop escape variants as it keeps high 
immunological pressure on the cancer cells. These variants are more aggressive compared to the 
original tumor cells as they are less immunogenic and eventually cannot be killed by immune cells 
anymore and thus grow out leading to malignant disease. 
 
Escape 
The last step in the immunoediting process is the escape phase. As discussed, during the equilibrium 
phase immune cells shape tumor cells leading to the accumulation of immune-evasive mutations. 
These mutations, or intrinsic mechanisms can be a) loss of immunodominant antigens b) loss of MHC 
class I and/or II antigens or c) defects in the antigen processing machinery43. According to Darwin’s 
survival of the fittest theory, these cloaked, malignant altered-self cells progressively grow leading to 
clinically manifest disease. The described cancer-inherent mechanisms are only one possibility to 
prevent destruction by the immune cells. As shown in figure 3.2, cancer-induced immunosuppression 
of effector cells is another way of evading cytotoxic immune cells and is termed the cancer-extrinsic 
way. To render the microenvironment immunosuppressive several possibilities exist, all of which are 
exploited by tumor cells. First, the secretion of immunosuppressive cytokines directly by tumor cells 
exerts strong tumor-protective functions. The most prominent molecules are IL-10, VEGF44, TGF-β45 
and indoleamine 2,3-dioxygenase (IDO)46. A second possibility is the specific recruitment of 
immunosuppressive immune cells such as Treg or myeloid derived suppressor cells (MDSC). Treg upon 
stimulation with their specific antigenic peptide produce immunosuppressive cytokines such as 
TGF-β or IL-10. Further, via their high expression of CD25 they sequester IL-2, an important molecule 
to promote NK cell and CTL activation and survival. Furthermore they express inhibitory molecules 
such as CTLA-4 or programmed death-1 (PD-1)47. MDSC are a heterogeneous population of immature 
myeloid cells and similarly to Treg, exhibit various functions that suppress the functions of various 
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immune cells. They secrete TGF-β, deplete arginine and tryptophan and are able to nitrate the TCR or 
chemokine receptors of tumor-specific T cells. Interestingly, tumor-derived factors trigger a distorted 
differentiation of immature DCs and myeloid cells thus driving in situ MDSC differentiation. 
Important factors were described to be constitutive signal transducer and activator of transcription 3 
(STAT3) and defective NF-κB signaling48. Notably, previous work from our group showed in a mouse 
model of lymphoma, that tumor-infiltrating MDSC are able to actively recruit Treg via the secretion of 
the chemokines CCL3, CCL4 and CCL5 thus establishing a link between the accumulation of these 
immune-suppressive populations49. Lastly, also the secretion of soluble ligands which block activating 
receptors of immune effector cells has been described50. 
 
3.2.4 Leukocyte migration and the chemokine system 
3.2.4.1 Transendothelial migration 
After their maturation leukocytes are transported in blood or lymphatic vessels through the body 
searching for inflamed tissue. To help and clear an infection, lymphocytes for instance from the 
blood stream need to specifically detect where they are needed and pass through a dense layer of EC 
to migrate to the site of the infection. Etravasation is a multi-step process which is introduced in the 
following section (figure 3.3)51. 
First, the EC in proximity to the site of infection needs to display an activated phenotype. Notably, 
PRR-activated, tissue-resident macrophages secrete for instance TNF-α. This cytokine can trigger the 
secretion of Weibel-Palade-bodies in proximal EC, leading to the elevated expression of E-selectin52. 
Also TLR-stimulation of EC, for instance TLR4 stimulation via LPS can directly induce P-selectin. 
The first step of transmigration requires a loose attachment of leukocytes to the EC, a process 
termed capturing that leads to rolling of the respective cell on the EC layer. This interaction is mostly 
dependent on the selectin family of adhesion proteins, the L-, P- and E-selectins with L-selectin being 
expressed on most leukocytes and E- and P-selectin being expressed by inflamed EC52. The P-selectin 
glycoprotein ligand 1 (PSGL1) has a role as ligand for all three selectins and can be expressed on EC 
and almost all leukocytes. Triggering of leukocyte selectin can subsequently lead to integrin 
activation via g protein-coupled receptor (GPCR) and MAPK signalling53. The likewise activated 
integrins after binding to their ligands slow down rolling. Depending on the cell type one of various 
interactions is possible, for instance the interaction between leukocyte functional antigen 1 (LFA1) 
and ICAM1 or the very late antigen 4 (VLA4) and the vascular cell adhesion molecule 1 (VCAM1)54. Of 
note, the VLA4-ICAM1 axis for instance mostly recruits monocytes and T cells. Thus, on the pattern of 
adhesion molecule expression specific effector cells can be recruited. For the firm arrest of slowly 
rolling leukocytes in addition chemokines are required. This is a family of chemoattractant cytokines 
that orchestrate the tissue distribution of leukocytes55. They will be introduced in detail later in this 
section. The origin of the chemokines can be either the EC itself, as they produce chemokines upon 
activation by inflammatory cytokines, cells in the blood stream for instance platelets, that deposit 
CCL5 on the luminal side or effector cells on the abluminal side or immune cells in the tissues56,57. 
Notably, the chemokines are mostly deposited on glycosaminoglycans (GAG) on the EC surface. It 
was shown that this interaction is crucial for efficient recruitment and that GAG binding might 
increase the half-life time of chemokines58. Binding to a cognate chemokine instantly increases the 
affinity and valency of the integrins to their respective EC-bound ligands leading ultimately to a firm 
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arrest of the receptor bearing lymphocyte on the EC59. The signaling underlying this mechanism - 
characteristically for heterotrimeric G proteins - involves Ca2+- flux induced by phospholipase C 
signaling which produces inositol-1,4,5-trisphosphate (InsP3) and diacylglycerol (DAG). Ca2+ and DAG 
together activate various GTPases such as RAP1 or RHOA that modulate the actin-binding protein 
talin-1 to activate the integrins60–63. 
 
Figure 3.3 – The updated leukocyte adhesion cascade. Shown are the three traditional steps in bold and recently added 
steps leading to leukocyte transmigration through EC. The most important adhesion molecules involved in each step are 
indicated in boxes. ESAM, endothelial cell specific adhesion molecule; ICAM1, intracellular cell adhesion molecule 1; LFA1, 
leukocyte functional antigen 1; JAM, junction adhesion molecule; MAC1, CD11b/CD18; MAdCAM1, mucosal vascular 
addressin cell adhesion molecule 1; PECAM1, platelet endothelial cell adhesion molecule; PI3K, phosphatidylinositide 
3-kinase; PSGL1, P-selectin glycoprotein ligand 1; VCAM1, vascular cell adhesion molecule 1; VLA4, very late antigen 4, (Ley 
et al. Nature Reviews Immunology 2007; 9: 678-89)51.  
Finally, the firmly attached cell needs to transmigrate through the layer of inflamed EC it is fixed to. 
Some cell types such as neutrophils or monocytes can crawl the surrounding vessel parts in order to 
find the best suited spot for transmigration. This crawling is mostly CD11b/CD18 (MAC1) and ICAM1 
dependent64. To migrate past the EC layer to the basement membrane, two possibilities exist for 
migrating leukocytes. The first option is the paracellular migration. Here it has been shown that 
inflammatory stimuli and integrin signaling in EC re-distribute junction molecules facilitating 
transmigration of leukocytes through less tightly attached ECs. Here, various stimuli activate different 
junctional molecules. Due to the complexity, the details will not be discussed in this thesis51. The 
second possibility to migrate past ECs is transcellularly65,66. This mode requires vesiculo-vacuolar 
organelles (VVOs). These specialized membraneous paths through EC seem to require neutrophil 
adhesion to EC, cytokine activation of the respective EC and high ICAM1 levels. Leukocytes thus can 
inefficiently but quickly migrate through these channels in the cells65,67,68. Having passed the EC layer 
extravasating leukocytes need to pass the basement membrane and eventually the pericyte sheath. 
Notable, whereas the EC layer can be passed usually in 2-5 minutes, the basement-membrane can 
require more than 15 minutes. Interestingly, similar to GAG, heparin-sulphate in the 
basement-membrane can bind chemokines and thus provide freshly extravasated leukocytes with 
further migratory stimuli. Having invaded the inflamed tissue, effector leukocytes next follow the 
chemokine gradient to reach the site of inflammation. 
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3.2.4.2 The chemokine system 
Chemokines are a chemotactic family of cytokines of 8-10 kDa of size that orchestrates the complex 
distribution of leukocytes (circulation, homing and retention)69. They are the only cytokines that 
signal via G-protein coupled receptors and share a very similar folding, due to a distinct motif 
containing 4 cysteine residues. Figure 3.4 gives an overview over most of the so far identified 
chemokines and their cognate receptors. 
 
The segregation of chemokines into families is done by analyzing the cyteine-containing N-terminal 
motif. If the first two cysteines are separated by one amino acid, the chemokine belongs to the 
CXC-family of chemokines. This family is also called the α-chemokine family. If no amino acid 
separates the first two chemokines it is assigned to the CC-family which is also called the 
β-chemokine family. Some identified chemokines do not fit into this classification for instance XCL1 
or lymphotactin, harboring only 2 instead of 4 cysteines in this motif, CX3CL1 or fractalkine that 
harbors three amino acids between the first two cysteines and SLC the 6Ckine with a total of 6 
cysteines in that motif. Notably, the system evolved to be highly redundant, as usually several 
chemokines bind to one receptor and one receptor to various chemokines. 
The chemokines were primarily identified as chemotactic proteins. They are secreted by various cell 
types, amongst others by platelets, EC, microglia, monocytes, macrophages, fibroblasts, T cells and 
Figure 3.4 – Chemokine receptors and their ligands. Color 
codes indicate the respective chemokine group. Lines 
indicate respective specific receptor-ligand pairs. The 
system today contains more than 50 chemokines and 20 
chemokine receptors. BCA-1, B-cell-attracting chemokine 
1; CTACK, cutaneous T-cell-attracting chemokine; ELC, 
Epstein–Barr-virus-induced gene 1 ligand chemokine; 
ENA78, epithelial-cell-derived neutrophil-activating 
peptide 78; GCP-2, granulocyte chemotactic protein 2; 
Gro, growth- regulated oncogene; IL-8, interleukin 8; 
IP-10, interferon-inducible protein 10; I-TAC, 
interferon-inducible T-cell α chemoattractant; MCP, 
monocyte chemoattractant protein; MDC, 
macrophage-derived chemokine; MEC, mucosae- 
associated epithelial chemokine; MIG, monokine induced 
by interferon γ; MIP, macrophage inflammatory protein; 
NAP-2, neutrophil-activating peptide 2; RANTES, regulated 
on activation, normal T-cell expressed and secreted; 
SDF-1, stromal-cell-derived factor 1; SLC, secondary 
lymphoid-tissue chemokine; TARC, thymus and 
activation-regulated chemokine; TECK, thymus-expressed 
chemokine (Proudfoot Nature Reviews Immunology 2002; 
2: 106-15)91. 
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many more70. After secretion they exert two functions. First, they are crucial mediators of efficient 
leukocyte extravasation and tissue invasion and second they guide effector cells along the chemokine 
gradient from the vessel to the chemokine producing cell. Their cognate receptors are all serpentin 
receptors that span biological membranes 7 times and signal as described under 3.2.4.1. Of note, this 
signaling is highly sensitive to pertussistoxin as this compound efficiently ADP-ribosylates the Gi unit 
of the heterotrimeric complex. Also, chemokine receptors frequently get internalized after they 
bound their cognate ligand71. 
As discussed under 3.2.4.1 lymphocytes eventually leave the blood or lymph through inflamed or 
activated EC. After passing the basement membrane they need to migrate in the interstitium 
towards the source of the chemokine to reach the inflamed tissue. This chemotaxis is crucial for 
immune cell infiltration of inflamed tissue70,72. Signaling mainly involves PI3K with the chemokine 
gradient inducing a guiding system in the leukocytes that translates into polarization of the cell. This 
polarization ultimately leads to directed migration through tissue73,74. Chemokines are therefore 
presented or anchored at the ECM via GAG or heparin-sulphates. These molecules were also 
reported to be relevant for chemokine transport and stability75,76. Migrating leukocytes thus 
integrate signals from various chemokines that are either free or presented by the ECM and polarize 
accordingly, a process that was reported to depend on LFA1, the phosphatidylinositide 3-kinase 
(PI3K), Syk, Bruton’s tyrosin kinase (Btk) and Rho GTPase74,76–80. Importantly, infiltrating leukocytes 
express a variety of proteolytic enzymes enabling them to aggressively invade different tissues by 
digesting their way through ECM81,82. 
In addition to the classical chemokine receptors, most of which are displayed in figure 3.2.2, there 
are 5 atypical chemokine receptors. They are called CXCR7, Chemokine-binding protein 2 (CCBP2) 
also called D6, C-C chemokine receptor type 11 (CCRL1), C-C chemokine receptor-like 2 (CCRL2) and 
Duffy antigen/chemokine receptor (DARC) also called Duffy. Importantly, due to mutations that 
abolish efficient binding of small, heterotrimeric G proteins to the receptor they do not signal 
properly and thus serve as scavenger receptors or interceptors of chemokine signaling83. DARC 
likewise binds to many inflammatory chemokines. Its expression on erythrocytes is important as it 
serves as a chemokine sink. Also by presenting chemokines on venular endothelial cells it assists 
leukocyte emigration at the sites of inflammation84. Similarly it was shown that D6 is expressed on EC 
of lymphatic vessels, depriving activating chemokines from the lymph. Accordingly, D6-/- mice 
exhibited higher levels of inflammatory cytokines as excess activating chemokines were not 
sequestered85.  
In the last years, it was increasingly recognized that chemokines exert more functions than just 
chemoattraction. Various effects on leukocytes and correlations to various diseases have been 
reported. The CCL25-CCR9 axis for instance was shown to be important for thymic T cell 
development, whereas several chemokines have been shown to increase NK cell proliferation and /or 
cytotoxicity86–88. However, de-regulation or overexpression of chemokines can lead to various 
diseases for instance asthma via the CCL11-CCR3 axis that attracts eosinophils or the CXCL10-CXCR3 
axis that attracts Th1 cells to promote inflammation in lesions of patients with multiple sclerosis89,90. 
Not surprisingly, various modalities have been tested to block chemokine receptor signaling to 
decrease the infiltration of overly inflamed tissues91. 
As chemokine receptor signaling also triggers survival pathways, tumor cells are exploiting that 
pathway in that they express chemokine receptors and produce the respective chemokines to create 
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an autocrine growth stimulation loop. Also, various chemokines have been described to promote 
angiogenesis and metastatic dissemination, which in many cases correlates with bad prognosis. 
Especially CXCL8 has been reported several times to be a marker of poor outcome in melanoma 
patients92,93. Compared to the often detrimental effects of CXCL8 expression in the tumor cells it was 
shown for a variety of other chemokines that their high expression improves prognosis due to 
stronger infiltration by cytotoxic effector cells92,94. The outcome of chemokine overexpression is 
therefore hypothesized to be strongly dependent on the immunogenicity and the entity of the tumor 
but most importantly on the presence of cognate receptors on the tumor cells.  
 
3.2.4.3 CX3CL1/fractalkine 
CX3CL1 is a very distinct chemokine in that it is the only known chemokine that has a three amino 
acid spacer between its two N-terminal cysteines and in that it can be expressed in a 
membrane-bound and soluble form, mostly by EC95. The actual chemokine domain is located at the 
N-terminus on top of a mucin-like stalk. Interestingly, both versions exhibit distinct functions. The 
membrane-bound chemokine mostly functions as an adhesion molecule for CX3CR1-expressing cells 
such as monocytes, DCs and NK cells whereas the soluble form is a potent chemokine, which induces 
migration of the formerly mentioned CX3CR1 positive cells96. Remarkably, 5 naturally occurring gene 
polymorphisms exist for CX3CR1, with the V249I and the T280M reportedly exhibiting reduced 
signaling97. Importantly, in a setting of renal transplantation an increased risk of developing cancer 
was found for homozygous carriers of the V249I and the T280M alleles pointing towards an 
anti-tumorigenic role of the CX3CL1-CX3CR1 axis.  Several proteases have been reported to mediate 
CX3CL1-shedding, amongst others a Disintegrin and metalloproteinase domain-containing protein 10 
(ADAM10), ADAM17 and cathepsin S98–100. Notably, CX3CL1 is also heavily expressed in the central 
nervous system by neurons whereas the receptor is mostly expressed by microglia101. Here, neuron 
derived CX3CL1 confers protection from glutamate excitotoxicity via microglia derived adenosine 
which ultimately prevents damage102.  
In the periphery, CX3CL1 has been reported to impact the lineage commitment of myeloid precursors 
to the macrophage/DC lineage and is used to discriminate resident monocytes from inflammatory 
monocytes blood with the first one being CX3CR1high 103,104. So it was shown that EC upon 
inflammation exhibit de novo CX3CL1-expression which leads to the extravasation of resident 
monocytes, that differentiated into macrophages and modulated the immune response in the 
inflamed tissue105. NK cell activation by DCs was also critically impaired, when CX3CL1 expressed by 
DCs was blocked. NK cells showed extensive KIR phosphorylation and thus Src homology region 2 
domain-containing phosphatase (SHP-1) recruitment leading to an abrogation of NK cytotoxicity106.  
Notably, CX3CR1- and CX3CL1-expression have also been reported on various tumor types with 
contradictory results. So Shulby et al. were reporting CX3CR1-positive prostate cancer cells that upon 
binding of CX3CL1 elicited phosphatidylinositol-3-kinase (PI3K) survival signaling. Also colonization of 
the bone marrow was found by them to be CX3CR1-mediated107. Further, hypoxia was reported to 
induce CX3CL1-expression on EC which was shown to induce their proliferation and tube formation 
thus potentially increasing angiogenesis. These data argue for a possible tumor growth promoting 
role of CX3CL1108. For breast cancer two studies were reporting opposite results. Whereas a study 
performed by Tsang et al. reported a worse outcome for CX3CL1high breast cancer bearing patients 
despite higher counts of tumor-infiltrating lymphocytes (TIL) another study on breast cancer by Park 
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et al. showed that high levels of CX3CL1 correlate with good prognosis109,110. Importantly, it was 
shown that CX3CL1 is a direct target gene of p53111. This suggests that upon DNA damage the 
up-regulation of CX3CL1 arrests cytotoxic cells at the damaged cells facilitating their elimination by 
immune cells.  Thus, CX3CL1 might be beneficial for clearance of pre-malignant or malignant cells. 
Indeed, it was reported that high expression of CX3CL1 can lead to better prognosis. Thus, for 
prostate carcinoma and gastric adenomacarcinoma high levels of CX3CL1 were predictive of 
prolonged disease-free survival. Of note, in none of the clinical studies CX3CR1-expression by tumor 
cells was evaluated, possibly explaining the trememdous variance between several studies. Still, 
several reported data clearly suggest the potential exploitability of the CX3CL1-CX3CR1 axis for 
cancer immunotherapy112.  
Thus, like many other chemokines, CX3CL1 is a multi-functional chemokine affecting many cell types 
not only in terms of migration. Therefore, modifying expression levels in vivo requires a 
comprehensive analysis of all processes that potentially are affected to exclude unwanted side 
effects. 
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3.3 Natural killer cells 
Natural killer cells are important effector cells of the innate immune system that comprise about 
5-15% of peripheral blood lymphocytes in humans. As innate cells, they use a broad array of 
activating and inhibitory germline-encoded receptors for activation and not just one clonally 
expressed receptor like B or T cells. 1975, in the first back-to-back reports that identified NK cells 
both groups mentioned the inherent and MHC unrestricted natural cytotoxicity of NK cells against 
syngeneic and allogeneic tumor cells113,114. Besides, they exert various effector functions against 
stressed, infected or transformed cell, shape adaptive immune responses and contribute to 
placentation115,116. Due to their central role in this thesis the most important aspects of NK cell 
biology will be discussed in this chapter. 
 
3.3.1  Origin and development of NK cells 
Developmentally, there are still some controversies about the origin of NK cells. However, it is widely 
accepted that NK cells in adults are derived from bone marrow-resident HSCs via a so-called CLP, the 
common lymphoid progenitor117. This lineage- CD34+ progenitor cell upon signaling via the early 
acting receptors Fms-like tyrosine kinase 3 (flt3), c-kit, IL-3 or IL-7 de novo expresses the IL15 
receptor complex consisting of the β- and the common γ-chains CD122 and CD132 respectively, 
turning the NK cell progenitor into an IL-15R+ NK cell precursor118–120. Importantly, IL-15 signaling has 
been identified to be crucial for NK cell development in various models. Thus, the acquisition and 
signaling of CD122, the IL-15 receptor β-chain, allows for NK cell differentiation and maturation120,121. 
The source for the IL-15 was determined to be bone marrow stromal cells120. Notably, it was shown 
that IL-15 in vivo is presented complexed to CD215, the α-chain of the IL-15 receptor to the dimeric 
IL-15 receptor (IL-15R β-chain CD122, common γ-chain CD132) on the target cell122. The signaling via 
the IL-15R then induces the final differentiation of mature CD56bright NK cells. However, the exact way 
of the genesis of CD56dim cells remained elusive for quite some time. Therefore, various models have 
been suggested: 
a) A distinct NK cell precursor that upon cytokine signaling would develop into CD56dim NK cells 
b) A possible common progenitor might develop with signals other than IL-15 into KIR+, CD16+ 
and CD56dim NK cells 
c) CD56bright NK cells are direct progenitors of CD56dim NK cells 
Interesting observations in this respect were made by Jacobs et al. who showed that upon bone 
marrow transplantation a substantial percentage of all newly developed NK cells displayed a 
CD56bright CD16- phenotype (> 50%). CD56dim NK cells were developing later after engraftment of the 
bone marrow cells123. This finding potentially indicated that CD56dim NK cells might develop out of 
CD56bright NK cells, explaining their slower kinetics of repopulation. Indeed, it could be shown in later 
studies that CD56dim NK cells most likely develop out of CD56bright cells as already proposed in 
1986124,125. 
In general, NK cell development has been extensively worked on. This research lead to the 
identification of several transcription factors, 2 of which were recently shown to be involved in NK 
cell differentiation, namely T-bet and eomesodermin (Eomes)126. Other transcription factors like Id2, 
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GATA-3, Ikaros or E4BP4 have also been described, yet their exact interplay, especially 
spatio-temporarily needs more investigation127.  
Several other regulators of NK cell development have been described, such as Notch signaling and 
miRNA regulation in humans. The Notch ligands Jagged2, Delta1 and Delta4 enhanced the 
differentiation of CD34+ hematopoietic progenitor cells into NK cells in vitro128. Of note, this impact of 
the Notch pathway is regulated by miRNAs, adding another regulatory element to NK cell 
differentiation129. Also it is noteworthy that even not fully matured NK cells, so-called NK 
developmental intermediates (NKDIs) can exert potent effector functions130. Further, external factors 
can interfere with proper NK cell development. Importantly, the immunosuppressive factor TGF-β 
that was mentioned in 3.2.3 has been reported to interfere with NK cell differentiation thus 
providing a possible link between malignant disease and de-regulated NK cell development131.  
Last, the site of differentiation classically was believed to be the bone marrow although not all 
developmental stages were detected there. Also, a growing body of evidence is pointing out that 
stromal cells from spleen, liver or secondary lymphoid tissue can also provide important early 
differentiation factors such as Flt3 or IL-7. Accordingly, all developmental stages of NK cells have 
been found in human secondary lymphoid tissue. Thus, it is hypothesized that bone marrow derived 
progenitors egress the bone marrow and home to various organs such as the uterus, the liver, the 
spleen or lymph nodes to finish their development132–134. Of note, this cascade of events – migration 
into the primary site of development, maturation, egress – is highly similar compared to the T cell 
maturation in the thymus. Of note, developing NK cells in the bone marrow in mice have been 
described to be retained in the bone marrow via the CXCR4-CXCL12 axis. Upon maturation, they 
egress via the up-regulation of sphingosin-1-phosphate-5 (S1P5) receptor135. It is currently unclear if 
similar mechanisms exist for other organs. 
 
3.3.2 Cytokine-activation of NK cells 
As other immune effector cells, NK cells require signaling to acquire their full functional potential and 
thus differentiate into effector cells. Here, inflammatory cytokines such as IL-2, IL-15, IL-12 or IL-18 
but also type I IFNs play pivotal roles. As the production of these stimulatory cytokines is triggered by 
danger signals, NK cells assure to be only fully activated when for instant pathogens or malignant 
transformation are detected. This cytokine-mediated activation can be achieved by either DCs, 
neutrophils or CD4+ T cells136–138. Due to the importance of especially IL-12 and IL-18 later in this 
thesis, in this the most important NK cell-activating cytokines are briefly introduced. 
IL-2 and IL-15 both share very similar receptor complexes and thus signaling pathways121. Both 
receptors share the same β- and γ-chain. Yet, they have distinct α-chains which increase the affinity 
of the heterodimeric shared receptor for IL-2 or IL-15, respectively. Compared to the α-chain of the 
IL-2 receptor (CD25) the α-chain of the IL-15 receptor (CD215) does not require the binary complex 
of the β- and the common γ-chain to exhibit high-affinity binding to its ligand. In the absence of 
cytokines, janus kinase (Jak)1 associates with the β- and Jak3 with the γ-chain of the receptor. LIgand 
binding activates the two tyrosine kinases which activate STAT3 and STAT5, respectively. These STATs 
dimerize and after translocation into the nucleus serve as transcription factors. Also, the β-chain gets 
phosphorylated which creates src homology 2 (SH2) docking sites triggering Ras/Raf/MAPK pathways 
ultimately leading to activator protein 1 (AP-1) activation. Further the PI3K-Akt pathway, src kinase 
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signaling and NF-κB signaling get activated leading to the induction of anti-apoptotic Bcl-2 promoting 
cell survival. Importantly, IL-15 has been shown to exert activation more potently, when it is 
presented on trans on the α-chain of the IL-15 receptor by for instance a DC122. Of note, cellular 
sources of IL-2 are activated T cells only whereas IL-15 can be provided mostly by monocytes, DCs 
and bone marrow stromal fibroblasts. Also, besides NK cell activation IL-15 signaling has been shown 
to be a critical prerequisite for NK cell development, as IL-15-/- or IL-15R-/- mice lack NK cells under 
steady state by promoting NK cell development from hematopoietic precursors120. Importantly, both 
cytokines strongly increase cytotoxicity for tumor targets that are resistant against NK cells that 
haven’t been stimulated with cytokines. This is due to a STAT5 mediated up-regulation of perforin 
but also because of the well-known up-regulation of various activating receptors due to the IL-2- and 
IL-15-signalling139. 
IL-12 belongs to the family of monokines and thus is produced by by monocytes, macrophages and 
DCs. Its heterodimeric receptor comprises the β1- and the β2-chain that upon binding to IL-12 gets 
autophosphorylated at the β2-chain thus recruiting Tyk2 and Jak2 that subsequently activate STAT4 
that activates the AP-1 transcription factor. Of note, it was reported that signaling of IL-2 also 
strengthens the IL-12 signaling cascade in NK cells by up-regulating the IL-12R and STAT4140. Due to 
the potent stimulation mediated by simultaneous signaling by IL-2 and IL-12, joint signaling of the 
cytokines was found to cause apoptosis of NK cells, possibly indicating a negative regulator of NK 
immunity. This process was found to be dependent on TNF-α141. Notably, IL-12 was shown to be a 
strong inducer of IFN-γ and increased the cytotoxicity of human and murine NK cells by upregulating 
perforin levels142. 
IL-18 also belongs to the monokines and thus, like IL-12, is produced by monocytes, macrophages 
and DCs, but also constitutively by non-immune cells such as keratinocytes or osteoblastic stromal 
cells. Similar to IL-12, its receptor is a heterodimer that consists of the IL-18Rα- and β-chain but it 
structure- and functionwise. Upon binding of IL-18 β-chain of the receptor transmits the signal via 
Myeloid differentiation primary response gene 88 (MyD88) and interleukin-1 receptor-associated 
kinase (IRAK)/TNF receptor associated factors (TRAF)6 to ultimately activate NF-κB in the respective 
cell. In addition, STAT3 and MAPK signaling were shown to be involved in the signal transduction. 
IL-18 signaling alone however has been reported to be an intermediate strong inducer of cytotoxicity 
and IFN-γ production due to the weak constitutive expression of the receptor143. However, 
expression of the IL-18R is inducible by IL-12 and type I IFNs leading to a synergistic effect between 
the two cytokines144. Accordingly, with IL-12 supplementation in vitro or in vivo where IL-12 is 
present IL-18 has been shown to be crucial for NK cell activation145,146. Several mechanisms regulating 
the bioavailability of IL-18 further suggested its importance. So it is synthesized as a pro-protein 
(proIL-18) that needs either intracellular cleavage by the producing cell via caspase-1 prior to 
secretion or extracellular cleavage by proteinase-3147,148. Proteinase-3 is expressed by activated 
neutrophils and monocytes which thus assist in NK activation. Also the existence of a soluble 
binding-protein (IL-18 BP) has been reported that was suggested to regulate the availability of free 
IL-18 by sequestering excess IL-18149. 
 
3.3.3 Activating receptors and their ligands 
As effector cells of the innate immune system NK cells rely not on a single recombined receptor but 
on a broad array of germline encoded activating and inhibitory receptors to distinguish “self” from 
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“non-self” or “altered-self”116. A comprehensive overview of various receptors on mouse and human 
NK cells is displayed in figure 3.5. With all other receptors binding to target cell derived ligands, CD16 
or constant Fcγ-receptor IIIa (FcγRIIIa) is an exception in a way that it binds to the Fc part of 
antibodies belonging to the IgG class. It is therefore enabling NK cells to exert ADCC against various 
antibody coated cellular targets, leading to the exocytosis of perforin/granzyme loaded vesicles. 
The other receptors have in common that their ligands, if they have been identified, are 
stress-induced and thus are expressed or up-regulated upon viral infection, DNA damage or 
malignant transformation150.  
NKG2D is expressed on almost all NK cells in mice and humans and also on subsets of T cells where it 
acts as a co-stimulatory molecule. It is a homodimer that signals via DNAX activation protein 
(DAP)-10 in humans or via DAP-10 or DAP-12 in mice151. Notably, in humans the NKG2D signaling 
leads to cytotoxicity and cytokine secretion152. The cellular ligands of NKG2D include MHC class I 
chain-related gene (MIC)-A, MIC-B and UL16 binding protein (ULBP) 1-6. MIC-A and MIC-B have been 
described to be up-regulated upon malignant transformation, due to the DNA damage response or 
upon heat shock response pathway signalling153. Sonja Textor from our group could further 
demonstrate that p53 induction causes an up-regulation of ULBP-1 and -2154. Of note, some of the 
ligands are weakly expressed on non-malignant cells, yet below the threshold for activating NK cells. 
In mice, the respective NKG2D ligands are the retinoic acid early transcript-1 molecules (Rae-1) α, β, 
γ, δ, ε, the murine UL16-binding-like transcript-1 (MULT-1) and histocompatibility 60 (H-60). 
Importantly, the contribution of NKG2D to tumor surveillance has been demonstrated in mouse 
models of spontaneous prostate adenocarcinoma and B cell lymphoma155. Further evidence for the 
importance of NKG2D in a tumor context comes from the observation that the receptor is targeted in 
immune-evasion strategies of tumors. Tumor-derived TGF-β has been shown to down-modulate 
NKG2D levels. Also, it was shown that tumor cells shed MICA thus blocking functional NKG2D 
receptors with the cleaved soluble ligand and therefore preventing the induction of tumor cell lysis50.  
 
Figure 3.5 – Summary of receptors 
being expressed by human and 
murine NK cells. NK cells express 
various activating and inhibitory 
receptors tuning their reactivity. In 
addition they harbor various 
receptors integrating signals from 
cytokines or chemotactic proteins 
or adhesion molecules. Relevant 
abbreviations are explained in the 
text, (Vivier et al Science 2011; 
6013: 44-49)116. 
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Another activating, yet co-stimulatory receptor is DNAM-1, a protein that is expressed on almost all 
human and only 25-50% of murine NK cells and in addition on T cell subsets where it was shown to 
exhibit co-stimulatory functions and on macrophages156. The ligands of this receptor are CD112 
(Nectin-2) and CD155 (polio virus recptor, PVR) and they were implicated in some anti-tumor 
reactions in which they mediated tumor regression157. Notably, in the same study it was observed 
that in the absence of DNAM-1, the growing tumor cells were expressing higher levels of DNAM-1 
ligands, thus indicating immunoediting mediated by DNAM-1. Further, similarly to NKG2D ligands, 
DNAM-1 ligands are also up-regulated in the presence of genotoxic stress, for instance inhibitors of 
replication and can be shed from tumor cells158. 
An entire class of activating NK cell receptors is comprised by the so-called natural cytotoxicity 
triggering receptors (NCRs). They all belong to the Ig-superfamily. So far, 5 members (NKp30, NKp44, 
NKp46, NKp65 and NKp80) have been identified. Notably, only NKp46 is expressed on murine NK 
cells whereas human NK cells express all of the NCRs Of note, only NKp44 requires NK cell 
stimulation with inflammatory cytokines such as IL-2 or IL-15 to get expressed159. The signaling leads 
for each of them to a cytotoxic response and the secretion of cytokines. Of note, cellular ligands for 
some of them remain elusive. 
NKp30 signals via CD3ζ and the Fc receptor gamma chain (FcRγ) with its ligands being identified as 
B7-H6 and the HLA-B-Associated Transcript 3 (BAT3/BAG6)160,161. BAT3 is an intracellular protein that 
gets released in response to stress and triggers NKp30 expressed by NK cells outside the target cell. 
Also B7-H6 has been reported to be shed from the cell surface, again implying an immune-escape 
mechanism162. Further, Nathalie Fiegler in our group found that B7-H6 expression is negatively 
regulated by histone deacetylase (HDAC) inhibitors163. 
NKp44 associates with DAP-12 and its recently identified cellular ligand is the mixed-lineage 
leukemia-5 protein (MLL-5)164. Notably, an inhibitory cellular ligand, the proliferating cell nuclear 
antigen (PCNA), has been described that assists tumor cells in evading NKp44 immunity by blocking 
the receptor165. 
NKp46 equally to NKp30 signals via CD3ζ and FcRγ. Also the binding to heparan sulfate proteoglycans 
has been reported for both receptors166. Besides these interactions no tumor derived ligand has been 
described so far; yet, hemagglutinin as a viral ligand has been reported to bind to this NCR167. NKp46, 
coded for by the Ncr1 gene was believed for a long time to be NK cell specific which is why several 
knock in or knockout mice have been generated using the Ncr1 promoter. However, later it was 
found out that it is also expressed on a small population of NK-like T cells and more importantly on 
lymphoid tissue inducer (LTi) like cells in the gut mucosa168,169. Yet, upon Ncr1 knockout, a worse 
prognosis was observed in a syngeneic B16 model of melanoma compared to wild-type mice and also 
in human disease NKp46 signalling was shown to contribute substantially to tumor control170,171.  
NKp65 and NKp80 exhibit common features such as signal transduction via a hemi-ITAM domain and 
genetic linkage with the genes coding for their ligands. NKp65 in this respect binds to the 
keratinocyte-associated C-type lectin (KACL) and NKp80 to the activation-induced C-type lectin (AICL) 
with the latter being expressed on myeloid cells after TLR stimulation and of note on NK cells after 
stimulation with IL-12/15/18172–174. 
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Notably, as for many tumor entities melanoma metastases have been reported to express abundant 
NKp44- and NKp46-ligands and these ligands were shown to be important for tumor surveillance by 
NK cells171. 
 
3.3.4  Inhibitory and killer Immunoglobulin-Like Receptors (KIRs) 
Similar to other cytotoxic cells, the activity of NK cells is tightly regulated by a panel of inhibitory 
receptors counteracting potential overstimulation and thus preventing immunopathology175. The KIR 
proteins belong to the Ig-superfamily of proteins, harboring either 2 or 3 immunoglobulin (Ig)-like 
domains and either a short or a long cytoplasmatic tail176. They are expressed by NK cells, but also by 
αβ and γδ T cells. Importantly, only the KIR molecules with a long cytoplasmatic tail signal via ITIMs 
thus exerting a negative signal, whereas the KIRs with a short cytoplasmic tail signal via ITAM 
mediated recruitment of DAP12 and thus activate the NK cell (figure 3.6)177. They comprise the 
biggest group of inhibitory receptors and detect MHC class I molecules that are expressed on 
virtually all nucleated cells. Upon perturbation of MHC class I expression like during viral infection or 
malignant transformation this inhibitory signalling is lost leading to the activation of NK cells in line 
with the “missing self” theory if activating, i.e. stress-induced, ligands are present178.  
The KIR family in humans, the lectin-like Ly49 molecules in mice and CD94/NKG2A heterodimers in 
both species are the most relevant and best-studied inhibitory receptors. Of note, the KIR loci in 
human and the Ly49 loci in mice are highly polymorphic both in terms of gene numbers (14 genes 
and 2 pseudogenes) and alleles present179. Other inhibitory molecules include amongst others for 
instance Killer cell lectin-like receptor subfamily G member 1 (KLRG1), T cell immunoreceptor with Ig 
and ITIM domains (TIGIT), NKR-P1A or Leukocyte immunoglobulin-like receptor subfamily B member 
2 (LILRB2)150,180. These molecules detect cadherins (KLRG1), CD155 and CD112 (TIGIT) or a broad 
array of HLA-A, -B, -C and -G alleles (LILRB2) and thus complement the capability to distinguish “self” 
from “altered self” or “missing self”. All mentioned receptors signal via ITIMs that subsequently 
recruit and activate the phosphatases SHP1 and SHP2, thus decreasing the absolute signal strength. 
KIR binding takes place at the α1-helix of the HLA protein. Especially the binding of KIR2DL depends 
on one certain amino acid at position 80 from the C terminus. Whereas KIR2DL1 binds all HLA C 
alleles that harbor a Lys80 residue (C2 epitope) KIR2DL2/L3 detects and binds to all alleles with an 
Asn80 (C1 epitope). The mechanism, determining which NK cell is expressing what KIR molecule is 
believed to be a random process that is mediated via DNA-methylation of the other KIR loci, thus 
silencing all other KIR genes but the expressed ones181.  
Importantly, NK cells in one given individual can vary in terms of which KIR alleles are expressed and 
the level of expression creating different populations of KIR positive NK cells182. The fact that KIR 
alleles are expressed in a largely random manner unlinked from the host’s HLA haplotypes is 
troublesome as this potentially could cause NK cell mediated autoimmunity179. Therefore, an 
education system exists in which developing NK cells are acquiring self tolerance if they fail to bind to 
self-HLA183. This state of hyporesponsiveness not only affects reactivity to self but impacts 
stimulation with MHC class I negative tumor cells or plate-bound antibodies against various 
stimulatory receptors. The same phenomena can be observed when mice or human individuals lack 
HLA class I molecules184,185. This HLA-dependent education of NK cells thus has also been termed 
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licensing and allows the acquisition of the full cytotoxic effector potential only if negative regulatory 
circuits are properly installed180. 
 
 
 
Of note, if the acquisition of effector functions upon engagement of a cognate HLA molecule 
(arming) or the acquisition of hyporesponsiveness if no KIR is engaged (disarming) is the active 
process is currently under active debate180. It was further shown that on one given NK cell the 
number of KIRs expressed for HLA molecules in one individual correlates with the responsiveness 
showing that the higher the possible degree of inhibition by self is the more reactivity is granted by 
the licensing system186. Importantly, neither hypo- nor responsiveness are stably imprinted in NK 
cells. It was shown in a mouse model that ‘licensed’ NK cells upon transfer into a MHC I-/- host 
acquire a state of reduced responsiveness187. 
 
3.3.5 Triggering of NK cell effector function 
The integration of the signals of the various introduced activating and inhibitory receptor is decisive 
for the NK cell to trigger or not to trigger an effector function. This could be either a cytotoxic 
response or the secretion of cytokines. 
 
Cytotoxic response 
Upon recognition, target cells can get killed by one of two means: either via the perforin/granzyme 
secretion pathway or via membrane-bound death receptors both of which are displayed in figure 
3.7:    
Figure 3.6 – Activating and inhibitory KIR 
molecules and their respective ligands. 
HLA-C group 1 refers to HLA-C alleles 
harboring an Asn80 whereas HLA-C group 2 
refers to HLA-C alleles harboring a Lys80 
(Rajalingam Korean journal of hematology 
2011; 4:216-28). 
Natural killer cells                            Introduction 27  
 
Figure 3.7 – NK cell modes of inducing cytotoxicity. Displayed are schematic representations of how NK cells mediate a 
cytotoxic response. (Left part) Induction of apoptosis via the release of perforin/granzyme containing lytic granules (right 
part) death inducing ligands on the surface of NK cells trigger caspase mediated apoptosis in cells expressing the respective 
receptors; c-FLIP, Cellular FLICE (FADD-like IL-1β-converting enzyme)-inhibitory protein (Smyth et al. Nature Reviews Cancer 
2002; 11: 850-61). 
Like other effector cell such as CTLs NK cells store pre-formed perforin and granzymes in secretory 
vesicles that upon triggering of the pathway cluster around the microtubule-organizing center 
(MTOC) which guides the vesicles in a directed way towards the target cell to prevent damaging 
bystander cells. Both components are cooperating in a way that perforin presumably forms pores in 
the target cell membrane thereby disrupting the membrane integrity and allowing the entry of the 
apoptosis inducing granzymes188. This family of serin-proteases upon passing the membrane through 
perforin-induced pores intracellularly activates caspases, which subsequently trigger the apoptotic 
program in the target cell. Notably, granzymes via the activation of various molecules such as  IL-8 or 
IL-6 also have also been shown to promote inflammation188,189. The importance of the lytic 
perforin/granzyme pathway has been demonstrated in knock-out animals. Here, perforin-/- animals 
exhibited a less efficient tumor control after transplantation of tumor cells and after MCA 
treatment190. Notably, also ADCC is mediated in a perforin dependent way. Interestingly, cell-surface 
bound cathepsin B and CD107a protect NK cells and CTLs from taking damage from their own 
granzyme release191,192.  
The second way of inducing cytotoxicity is via death receptors. Three ligand-receptor pairs, namely 
FasL-Fas, TNF-TNFR and TRAIL-TRAILR, have been well studied. The ligands induce the recruitment of 
various adaptors ultimately leading to the formation of the death-inducing signaling complex (DISC) 
upon binding to their cognate receptors193. Subsequently, the caspases 8 and 10 get activated via 
proteolysis and initiate apoptosis. This pathway similarly to the perforin/granzyme pathway has also 
been shown to be or high relevance in pre-clinical tumor models194. 
 
Cytokine secretion 
In addition to the cytotoxic response NK cells are important sources of various cytokines such as 
IFN-γ, TNF-α or IL-10 and of chemokines such as CCL3/4/5 or CXCL8. Of note, some of the 
chemokines are potent attractors of DCs which is why NK cells and DCs often co-localize in inflamed 
tissue195. IFN-γ due to its pleiotropic functions and its early discovery in NK cells is considered to be 
the signature cytokine of NK cells which is why they have been assigned to the group I innate 
lymphoid cells (ILCs) according to a recently proposed classification scheme196. Various functions of 
IFN-γ have been discussed already and will be discussed later. To briefly summarize some of it main 
functions IFN-γ has been shown to have anti-proliferative effects on tumor cells, exert 
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anti-angiogenic functions, induces apoptosis sensitivity on tumor cells via upregulation of caspase, 
FasL and TRAIL and induces MHC class I up-regulation thus promoting CTL immunity just to mention 
the effects on tumor cells; in addition it activates macrophages and DCs and promotes CTL 
maturation197. Due to its various roles, it is complexely regulated involving induction of expression via 
IL-12, the effect of which can be further enhanced by IL-1, TNF-α or IL-18. Interestingly, the 
combination of TNF- α and IFN-γ both of which can be secreted by NK cells have been shown to 
trigger tumor senescence when they are present simultaneously198. 
Importantly, cytokine secretion is regulated differently as compared to the release of cytotoxic 
granules. As cytokine secretion is mediated via recycling endosomes it uses a distinct pathway from 
cytotoxicity which allows for differential regulation199. 
 
3.3.6 Phenotype and physiological functions of NK cells 
NK cells as part of the innate immune system rely on an array of germline-encoded receptors that 
screen for delicate differences in the levels of activating and inhibitory ligands on their potential 
target cells. The integrated signals determine ultimately, if the NK cell reacts or not175. This general 
mechanism holds true for balancing the reactivity of both CD56bright and CD56dim NK cells, the two 
main NK subsets that are discussed in this chapter. 
 
3.3.6.1  Phenotype of NK cell subsets 
Around 10% of NK cells in peripheral blood exhibit a CD56bright phenotype. This subset has been 
described to be less mature and is endowed with less spontaneous killing activity compared to 
CD56dim cells125,200. Yet, it was shown that upon IL-2 or IL-12 activation cytotoxicity can reach similar 
levels as in CD56dim cells201,202. Further, this subset produces significant amounts of inflammatory 
cytokines and chemokines such as CCL3 and CCL4 shortly after activation200. Notably, the 
combination and concentration of monokines varies for individual effector cytokines such as for the 
granulocyte macrophage colony-stimulating factor (GM-CSF), IL-10 or IFN-γ, allowing the 
determination of the predominant effector cytokine according to the monokine milieu200.  
As compared to these cells, the second population with a low expression of CD56 shows higher 
spontaneous cytotoxicity201. In line with this, it was also reported that this subset expresses higher 
levels of NCRs and importantly significantly higher levels of perforin. Classically, this subset was 
described to secrete little amounts of inflammatory cytokines, yet a recent study showed that 
depending on the stimulation this subset can be a very potent producer of IFN-γ and TNF-α as well203. 
However, in several in vitro studies the CD56dim cells were less efficient producers of cytokines either 
after co-culture with LPS-activated macrophages or PMA200. Of note, this subset is characterized by 
the co-expression of CD16, the low-affinity Fcγ receptor IIIa (FcγRIIIa), allowing them to react to 
target cell bound antibodies, a process termed antibody dependent cytotoxicity (ADCC)204. 
These most important findings and several relevant others have been summarized in figure 3.8205. 
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Figure 3.8 – Phenotype and function of the two major human NK cell subsets. NK cells with a bright expression of the 
CD56 antigen exert classically more regulatory functions due to their high cytokine production capability whereas NK cells 
with an intermediate expression level of CD56 are more prone to exert cytotoxicity. They differ in terms of the expression 
of various receptors and molecules as indicated. LAK, lymphokine activated killer, (Cooper et al. Trends in Immunology 
2001; 11: 633-40). 
Importantly, CD56dim NK cells express higher levels of killer cell immunoglobulin-like receptors (KIRs) 
and the inhibitory LILRB2, whereas they express less CD94-NKG2A compared to CD56bright NK cells. 
This indicates a different regulatory circuit for the two subsets subsequently allowing differential 
activation by one given target205. Also, only on CD56dim NK cells the expression of CD57 can be seen, a 
marker for terminally differentiated effector cells further indicating that CD56bright NK cells might be 
less mature compared to CD56dim cells206. In terms of cytokine-receptor expression, it is noteworthy 
that only CD56bright NK cells seem to express c-kit and the heterotrimeric IL-2 receptor IL-2Rαβγ 
granting higher responsiveness to IL-2. This was shown to translate into much higher in vivo and in 
vitro proliferation after IL-2 stimulation compared to CD56dim cells202. Of note, the CD56dim NK cells in 
general were reported to proliferate poorly, regardless of the stimulation207. Importantly, also the IL-
18 receptor was found to be expressed at higher levels on CD56bright NK cells208. 
 
3.3.6.2  Homing of NK cell subsets 
Owing to the differential expression of chemokine receptors, the two introduced subsets exhibit 
significant differences in their homing behavior (figure 3.9)205,209. Notably, Campbell et al. in 2001 
based a subtype classification on the expression of chemokine receptors. Thus, the first subset, 
including the CD16bright cells, expressed CXCR1, CXCR3, CXCR4 and CX3CR1 but not CCR1-7, CCR9 and 
CXCR5. The second subset includes the CD16dim cells that expressed high levels of CCR7 but low 
CXCR3 and CXCR4210. Inflammatory cytokine signaling has been shown to maintain the expression of 
constitutively expressed CXCR4 and CCR7 but in addition induces the expression of inflammatory 
receptors such as CXCR1 or CXCR3211.  
As mentioned, it was shown that L-selectin and CCR7 – typical molecules for homing to secondary 
lymphatic tissue – are exclusively expressed on CD56bright NK cells. Accordingly, this subset responds 
to CCL19 and CCL21, chemokines that are abundantly expressed in secondary lymphoid tissue such 
as  lymph nodes and other secondary lymphoid tissue such as the tonsils where CD56bright cells 
comprise the predominant NK population210,212. Possibly, DC derived CXCL10 and NK cell derived CCL3 
and CCL4 might cross-recruit NK cells in these tissues into close proximity to the DC allowing the two 
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populations to activate each other. The amounts of secreted CCL3 exceed after IL-2 stimulation the 
amount of IFN-γ which is why it was suggested to call CLL3 and not IFN-γ the prototype NK 
cytokine213. Of note, here T cells are waiting to be stimulated, responding to stimulation with IL-2 
production that at low levels stimulates the high affine IL-2R of CD56bright cells that in turn respond 
with high IFN-γ levels skewing the T cell response into a Th1 direction. Thus it is very tempting to 
assume, that especially the CD56bright cells are involved in shaping adaptive immunity. CD56dim cells on 
the other hand express high levels of CXCR1 and CX3CR1 thus exhibiting very distinct homing 
properties from CD56bright cells210. The mentioned receptors readily guide them into inflamed tissue 
whereas under steady-state conditions they make up around 90% of NK cells in peripheral blood or 
spleen.  
For tumor biology, several chemokines have been reported to facilitate NK cell accumulation in situ. 
In a mouse model, Marco Wendel from our group could show that CXCL9, CXCL10 and CXCL11 are 
crucial in recruiting CD27+ murine NK cells, mostly in an IFN-γ-dependent way94. Further, CX3CL1 was 
successfully shown to recruit NK cells in a syngeneic model, reducing tumor load in the respective 
animals compared to controls112. Besides those, amongst others CCL19 and CCL2 have been reported 
to efficiently recruit NK cells to the tumor thus reducing the tumor burden. In line with the finding 
that certain chemokines exhibit various functions on NK cells and that extravasating cells need to 
digest themselves a way through the basement membrane it was reported that CXCL12 induces the 
expression of marix degrading enzymes on the NK cell surface214. Thus, chemokine signaling not only 
induces migration but also promotes invasion of, amongst others, tumor tissue. 
 
Figure 3.9 – Roles of chemokines and chemokine receptors in health and disease. Schematic representation of some of 
the most important chemokine-chemokine receptor interactions in NK biology. CMV, cytomegalovirus; EAE, experimental 
autoimmune encephalomyelitis; HIV-1, human immunodeficiency virus-1; MS, multiple scelrosis; PLN, peripheral lymph 
node; RA, rheumatoid arthritis (Maghazachi Curr Top Microbiol Immunol 2010; 341:37-58)209. 
Further, during infection, the CCR5-CCL5 axis has been shown to play an important role for the 
accumulation of NK cells at the respective infected site, for instance during HIV or toxoplasma gondii 
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infection. Notably, chemokines have been identified that mediate NK cell recruitment in 
autoimmunity. Thus, it was shown that the CCR5-CCL3/CCL4/CCL5 axis recruits CD56bright NK cells into 
synovial fluids of patients suffering from rheumathoid arthritis whereas the CX3CR1-CX3CL1 axis as 
shown to contribute to to NK cell migration into lesions of multiple sclerosis (MS) patients. 
Accordingly, in CX3CR1-/- mice NK cell recruitment into inflamed brain areas was abrogated  leading 
to more severe symptoms of disease, although other studies show opposite result. As MS is a 
Th1-driven disease NK cells in those lesions are likely to interfere with Th1 generation. Yet, because 
of inconsistent data, it is hard to speculate what the mechanism might be.  
 
3.3.6.3  Physiological functions of NK cells 
Owing to the two specialized subsets and their presence in various organs NK cells contribute to 
various physiological processes some of which will be discussed next115.  
 
NK cells in malignant disease 
It has been demonstrated in in vivo mouse models via antibody-mediated depletion of NK cells that 
these cells contribute to immune-surveillance of spontaneously arising, transplanted or 
carcinogen-induced tumors178,215. Although mouse models gave valuable insights into the control of 
tumor growth by NK cells, the studies most frequently were performed under conditions not clearly 
dissecting the specific role of NK cells. This is due to the lack of markers that are exclusively 
expressed on NK cells. In human disease evidence that NK cells in parts can control tumor growth 
came from epidemiological observations or from the analysis of tumor samples216. Several groups 
analyzed excised tumor samples in terms on NK cell infiltration levels and correlated the NK levels in 
situ with the prognosis of the patients. Importantly, to detect NK cells in all of these studies the CD57 
antibody was used; the epitope CD57 only is expressed on about 70% of CD56dim NK cells and besides 
also on T cell subsets217–219.  Thus, it will be important to repeat those studies using a marker that 
specifically and exclusively stains all NK cells. Yet, figure 3.10 shows that for various cancer entities 
NK cell infiltration correlated positively with the patient survival. 
 
Figure 3.10 – Contribution of NK cells to in vivo tumor control. Plotted is the cumulative survival for patients grouped 
according to the level of NK cell infiltration as determined by CD57 staining. Figures are withdrawn from three publications 
as cited (Colorectal carcinoma: Coca et al. Cancer 1997; 12: 2320-8, Squamous cell lung cancer: Villegas et al. Lung Cancer 
2002; 1: 23-8, Gastric carcinoma: Ishigami et al. Cancer 2000; 3: 577-83)217–219. 
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Importantly, several studies were pointing out that tumors are enriched for the CD56bright NK cells 
subset of NK cells220,221. Several mechanisms can cause this phenomenon. First, CD56bright NK cells 
could be preferentially attracted into tumor tissue. Also, infiltrating NK cells could potentially 
re-differentiate into CD56bright NK cells. Last, the NK cells with the bright expression of CD56 could 
proliferate more pronouncedly or be more resistant to an apoptosis inducing milieu. In line with the 
latter it has been shown that CD56bright NK cells are more resistant to apoptosis induction via ROS 
that are possibly present in the tumor stroma222. It furthermore was shown in a mouse model that in 
general NK infiltration increases with the susceptibility of tumor cells to NK cell recognition223. Yet, 
although many tumor cells express activating ligands for NK cells do not infiltrate properly. Here, it 
was shown for various cancer entities that NK cells rather do not deeply infiltrate tumor tissue but 
get stuck in the stroma224. Interestingly, published data were showing that upon down-regulation of 
MHC class I higher infiltration of CD8+ CTLs but reduced numbers of NK cells could be found, implying 
a selective exclusion of anti-tumor reactive cells. In other studies however, NK mediated control of 
metastasis could be observed225. 
As discussed, usually only few NK cells properly infiltrate into tumor tissue, not representing the 
blood resident population distribution. In situ, reactivity against tumor targets frequently is lost, 
representing a major problem for NK cell based immunotherapy as well as for T cell based therapy226–
228. Notably, in a recent study performed in the Rosenberg group showed that NK cells after 
re-infusion into melanoma patients persisted but completely lost their anti-tumor reactivity 
indicating the presence of NK-suppressive mechanisms229. They observed a significant 
down-regulation of the activating NKG2D after ex vivo analysis of peripheral blood NK cells. Also the 
observed shedding of activating ligands off of tumor cells decreased the level of functional receptor 
molecules as soluble versions block the respective binding sites50,230. Further, tumor cells have been 
shown to releas FasL bearing vesicles that induce apoptosis on Fas expressing immune cells231. Also 
via the expression of B7-H3 and/or nonclassical HLA molecules such as HLA-G or –E tumor cells 
potentially can avoid NK cell mediated destruction232,233. In other studies, lower levels of CD3ζ or Lck 
have been described in tumor-associated NK cells causing less IFN-γ but higher IL-10 production234,235. 
Impressively, de-regulation of NK cells affects already NK differentiation in the bone marrow, as 
depicted in a recent study for multiple lineages of tumors, including thymoma, breast cancer, colon 
cancer, and mela- noma cell lines236. As overexpression of IL-15 restored NK cell genesis, it is likely 
that the disturbed maturation of NK cells (same cytotoxicity, less IFN-γ) was due to interference in 
the IL-15 signaling pathway in the bone marrow. Also, besides the intracellular signaling machinery, 
the expression levels of activating receptors are often decreased in situ. This can either be  due to 
internalization after constant ligand exposure as it was described for NKG2D and DNAM-1 but also 
immunosuppressive cytokines like TGF-β that eventually are enriched in the microenvironment are 
de-regulating the expression of activating receptors on NK cells237–239. Besides, the 
tumor-microenvironment per se differs already dramatically from healthy tissue by the means of 
hypoxia, acidity and glucose levels some of which have been shown to interfere with NK cell 
activation in general240. 
Also cellular factors interfere with NK reactivity in tumors. Treg and myeloid derived suppressor cells 
(MDSC) both have been reported to suppress NK cell responses and proliferation in mouse models 
and in human, in parts via the expression of membrane-bound TGF-β241,242.  
Notably, a sustained supply of NK cell derived IFN-γ could break the tolerance inducing milieu by 
preventing M2 macrophage differentiation, stimulate DC maturation - thus subsequently prevent Treg 
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recruitment and TGF-β entrichment - but also could stop neo-vascularization of the developing 
tumors, rendering NK cells potentially important players in the prevention of tumor outgrowth. Yet, a 
proper infiltration is required and a sustained activation of these potent effector cells is needed as 
they succumb quickly in for example Treg- and/or TGF-β-enriched microenvironments. Importantly, 
cancer stem cells that were often reported to be resistant to classical chemotherapeutical 
treatments and/or ionizing irradiation have been reported to be sensitive to NK cell mediated lysis 
rendering NK cells attractive effector cells for immunotherapy243. 
 
NK cells during infectious disease 
As elucidated in mouse models of NK cell depletion or reconstitution, NK cell activity is a critical 
determinant for the susceptibility to viral infections. Amongst others, herpes simplex virus-1, 
influenza virus or the murine cytomegalovirus MCMV were shown to be under critical control of NK 
cell immunity244. This was also most impressively demonstrated by a case-study of Biron et al. who 
were reporting the case of a young girl lacking NK cells thus suffering from severe varicella and CMV 
infections245. Of note, in murine CMV infection the respective virus-specific molecule that is detected 
by the activating Ly49H receptor has been identified as m157246. Likewise, Ly49H+ NK cells expand 
upon virus infection. Importantly, also mice lacking the expression of important effector molecules 
like the IFN-γ receptor or mutations in humans affecting for instance this receptor dramatically 
increased the susceptibility towards CMV infection244,247. Notably CMV infection also in humans leads 
to the expansion of a certain NK cells subset that expresses the NKG2C receptor248. 
 
NK cells as immune-regulatory cells 
Due to the secretion of multiple inflammatory cytokines and their ubiquitous presence it is not 
surprising that NK cells cross-talk with various other effector cells of the innate or adaptive immune 
system. One of the best-studied interactions is the bidirectional interaction with DCs either in 
peripheral tissue or secondary lymphoid tissues249. Here, NK cells have been shown to promote the 
maturation of monocyte derived DCs (moDC) via TNF-α, IFN-γ, HMGB1 and also via NKp30 
stimulation250–254. This maturation led to a substantial increase in the secretion of proinflammatory 
cytokines of DCs like IL-12 and IL-18 which in turn stimulated CD4+ T cells to develop into IFN-γ 
producing Th1 cells and augmented IFN-γ production in CD8+ T cells250,251,253. Further, activated DCs 
signaled back to the NK cells. Thus, activated DCs have been described to enhance CD69 expression, 
proliferation, IFN-γ secretion and cytotoxicity of NK cells via secretion of the monokine IL-12, TNF-α 
or type I IFNs249. For the induction of proliferation, also the contributions of B7 molecules on moDCs 
and CD28 on NK cells, trans-presented IL-15 as well as secreted IL-12 have been reported in the 
DC-stimulated NK proliferation255,256. In terms of cytokine induction, it has been demonstrated that 
the CX3CL1-CX3CR1 axis mediates the polarized secretion of IL-12 from DCs towards NK cells that in 
turn produce IFN-γ257. Importantly, DCs also augmented the lytic capability of NK cells which was 
largely mediated by IL-12 and the CX3CL1-CX3CR1 axis256,257.  
Notably, NK cells also increase the turnover of DC as they exert cytotoxic effects against immature 
DCs via NKp30 and to a lesser extent via NKp46 and NKG2D250. Furthermore, NK cell killing of for 
example tumor cells in vivo releases antigens for DCs cross-presentation that subsequently can 
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mount efficient CD4 and CD8 T cell responses. In this context it has been shown that apoptotic tumor 
cells are the best DC-based vaccine to induce antigen-specific T cell responses258,259. 
Besides this cross-talk with DCs, NK cells also directly impact effector cells of the adaptive immune 
system. Thus it was shown, that NK cell derived IFN-γ directly promotes Th1 differentiation in 
inflamed conditions260. Also, activated CD4+ T cells are direct targets for killing for activated NK cells, 
especially during blocking CD94-NKG2A what led to the hypothesis that NK cells might prevent 
autoimmunity by shaping the T cell repertoire261,262.   Notably, it was shown that administration of 
daclizumab led to an expansion of CD56bright NK cells which correlated with a decline in circulating 
CD4+ T cells and CTLs. This NK mediated, cell-to-cell-contact dependent contraction of the T cell 
compartment led a substantial decrease of lesions in the brain263. 
Similar to immature DCs, activated macrophages can be targets for NK cells. In line with this, NK cells 
and macrophages co-localize in the red pulp of the spleen and in peripheral tissues. Thus, in one 
mouse model it was shown that NK mediated elimination of hyperactivated macrophages prevented 
immunopathology264. 
 
NK cells during pregnancy 
Importantly, a distinct subset of NK cells, the so-called uterine NK cells or uNKs recently has been 
reported to secrete pro-angiogenic factors such as VEGF or the placental growth factor (PLGF)265. The 
enrichment of this subset is observed in pregnant endometrial tissue where they support the 
vascularization and thus the nurturing of the developing placenta. Notably, decidual NK cells have 
also been reported to dampen Th17 responses via IFN-γ secretion thus establishing maternal-fetal 
tolerance266.  
 
3.3.7  NK cell “memory” 
One major feature that is used to distinguish adaptive from innate immune responses is the efficient 
formation of an antigen-specific memory-compartment. After their clonal expansion following 
activation T-cells undergo a contraction phase which eliminates more than 90% of the expanded 
progeny. Antigen-specific cells that still exist after this contraction phase subsequently form a unique 
cell subset. They differ from their antigen-un-experienced counterparts in that they re-create 
themselves, thus are long-lived, and by exhibiting an enhanced response upon re-challenge with 
their specific antigen. This enhanced secondary response is typically characterized by a fast 
expansion of the memory cells yielding high numbers of effector cells early after infection and by 
elevated levels of effector molecules compared to the first immune reaction267. This program is 
imprinted after the original activation. Here, amongst others, epigenetic mechanisms are thought to 
contribute to the memory-phenotype. As NK cells use germline-encoded receptors they are thought 
to lack antigen-specificity. As antigen-specificity of effector cells was thought to be crucial for the 
formation of a memory compartment, NK cells were believed for a long time to be uncapable of 
mounting memory responses. 
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However, recently several reports have built a substantial body of evidence demonstrating 
memory-like features in the NK cell compartment268–270. So far, three ways of inducting NK cell 
memory have been described in mice that are summarized in figure 3.11269. 
 
Figure 3.11 – The three reported ways of turning NK cells into memory cells. So far, the recognition of the m157 antigen 
from MCMV together with IL-12R signaling (left panel), simultaneous IL-12, IL-15 and IL-18 stimulation (middle panel) and 
the recognition of haptens or certain other specific antigens together with CXCL16 (right panel) triggered memory-induction 
of NK cells (Min-Oo et al. Trends in immunology 2013; 6:251-8). 
Of note, the three aforementioned possibilities to induce NK cell memory exhibit differences (see 
below). Importantly, elevated recall responses of CMV- and hapten-challenged NK cells were shown 
to be specific for m157-expressing cells or the exact chemical compound used for sensitization which 
is why the term ‘memory’ will be used referring to these modes of memory induction.  Compared to 
that, cytokine-activation enhances the reactivity of NK cells towards a broad array of stimuli. Due to 
the antigen-unspecific nature of this recall-response the term memory-like will be used. 
 
Virus-induced memory 
It has been established, that MCMV infection in mice drives the expansion of Ly49H positive NK cells 
that recognize the viral m157 protein. This phase is followed by a contraction phase generating a 
pool of survivors that persists for more than 2 months. Notably, the persisting cells are capable of 
conferring protection against re-challenge by exhibiting robust secondary expansion and enhanced 
effector functions271,272. These processes were shown to be strictly m157 and thus antigen-specific 
and they critically depended on the presence of the inflammatory cytokine IL-12 and STAT4 
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signaling273. However, the real determinant inducing the infection-mediated memory formation 
remains elusive. IL-12 might be only important to drive expansion, possibly supported by IL-15. Yet, 
the importance of antigen-driven expansion still needs to be elucidated. Further factors 
pre-determining the population after the contraction phase are also yet to be determined. Evidence 
from T cells with which NK cells share some features are pointing to an involvement of Bcl-2 or 
Bim274,275. Notably, by a comprehensive microarray analysis Ly6C and CD49a were shown to 
discriminate memory NK and T cells from their naїve or effector counterparts276. Similar memory-like 
responses could be also found in other models of infection277. Notably, a model of genital herpes 
simplex virus-2 (HSV-2) showed elevated antigen-specific recall responses. Yet, the responsible 
antigen-specific receptor remained elusive leaving the need to clarify what factors in which infection 
drive NK cell memory formation278. 
Importantly, expansion of NK cells subsets upon infection have also been reported for human 
patients for instance after human cytomegalovirus (HCMV) infection279. The expanded subset 
expressed high levels of the activating CD94-NKG2C receptor. Notably, a long-lived population of 
NKG2C positive cells persisted in patients and proliferated rapidly upon reactivation with the progeny 
exhibiting high effector functions280. Interestingly, these features were transferable as after HSCT 
NKG2C positive NK cells from CMV positive donors expanded in CMV positive recipients whereas 
NKG2C positive NK cells from CMV negative did not, indicating a recall response against HCMV281. 
Also, upon infection of HCMV positive individuals with hantavirus or chikungunya virus an NKG2C 
positive subset also expanded and persisted until viral clearance, suggesting a possible role of these 
cells for the control of various viral infections282,283.  
 
Memory-like NK cells induced by inflammatory cytokine signaling  
The first report on the cytokine-induced generation of a long-lived NK cell population that exerted 
elevated functionality compared to control cells was published 2009284. After an overnight activation 
of murine splenic NK cells with IL-12, IL-15 and IL-18 these induced memory-like cells exhibited 
massive in vivo proliferation and elevated IFN-γ levels upon ex vivo re-stimulation by various means 
for up to three weeks after transfer. The authors al could demonstrate that the progeny from the 
stimulated cells also exhibited similar functionality, indicating that the memory-like properties were 
passed on to the daughter generations. Of note, no markers have been described yet to discriminate 
cytokine induced memory-like NK cells from naїve or activated NK cells. It is further unclear what the 
exact mechanism underlying the induction of memory-like functionality is. Clues are withdrawn from 
T cell immunology. It was shown, that during differentiation and the acquisition of novel 
functionalities like during Th1/Th2 differentiation epigenetic mechanisms are involved. Thus, it is 
tempting to speculate that similar epigenetic marks might contribute to the cytokine-imprint in NK 
cells285,286. 
Importantly, Jing Ni from our group demonstrated a superior anti-tumor effect of cytokine-induced 
memory-like NK cells in a mouse model of lymphoma287. As IL-12/15/18 stimulated cells exhibited a 
markedly elevated level of CD25 expression, they were sensitive towards IL-2 derived from activated 
CD4 positive T cells. The cytokine led to a substantial induction of proliferation of IL-12/15/18 
pre-activated NK cells. Importantly, relevant data concerning cytokine-induced human memory cells 
were acquired during this thesis and will thus be introduced later in detail.  
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Of note, the exact mechanism of the cytokine-mediated imprint to date is unknown. Also, this form 
of memory-like responses has only been induced and observed in vitro. It remains to be clarified if for 
instance during acute infections high levels of inflammatory cytokines can induce this type of 
antigen-unspecific memory in vivo and if so, what the physiological function of this cell population is. 
 
Liver restricted memory 
Pioneering work in the field of hapten-induced memory formation of NK cells was performed by 
O’Leary et al.288. They showed that transfer of hepatic but not splenic NK cells from RAG2-/- mice after 
hapten-sensitization into naїve mice co-transferred contact hypersensitivity. This was found to be 
specific for the compound used for sensitization of the donor animals. Related compounds used for 
re-challenge did not induce this type of memory-reaction. Notably, the hapten-specific NK cells were 
critically dependent upon the chemokine receptor CXCR6 for their function, the ligand of which, 
CXCL16, is abundantly expressed on liver sinusoidal endothelial cells289. Importantly, 
hapten-stimulation did not lead towards preferential proliferation of the CXCR6 positive subset288. 
This type of reaction was not only inducible with haptens, but also with viral antigens derived from 
influenza, vesicular stomatitis virus (VSV) or human immunodeficiency virus type-1 (HIV-1)289. As 
introduced, influenza HA binds to NKp46, yet HA-deficient influenza strains still vaccinated animals. 
Thus, the relevant receptor-ligand pair is completely elusive. Data point towards a role of NKG2D 
signaling in hapten mediated memory formation yet the mechanism remains to be defined288. Of 
note, no hapten or virus-like-particle (VLP) induced NK cell memory formation to date has been 
published for human NK cells. 
 
Of note, the three known paths that induce NK cell memory exhibit very unique features like organ 
distribution of memory cells or effector functions. However, the likewise induced memory or 
memory-like NK cells share the longevity and the possibility to mount recall responses. Importantly, 
specific receptors for many memory-inducing agents like haptens are elusive. Furthermore, the 
molecular mechanism of how NK cells exactly memorize prior stimulations is completely unknown. 
Importantly, memory or memory-like NK cells exhibit various features that might either be causative 
for immunopathologies such as inflammatory diseases but on the other hand potentially could be 
used to treat for example malignant diseases. Here, mouse models are urgently needed to 
demonstrate the role of memory or memory-like NK cells and to investigate if their elevated 
functionality can be exploited to treat diseases such as tumors. 
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3.4  Anti-tumor immunotherapy 
In various previous sections the interplay between NK cells or immune cells in general and cancer 
cells has been introduced (refer to sections 3.1.2, 3.2.3 and 3.3.5). As pointed out, it was recognized 
by the scientific community that immune cells or immuno-modulatory drugs can help substantially to 
control tumor growth in cancer patients. Thus several strategies have been investigated to translate 
basic scientific findings from “bench to bedside” (figure 3.12)290. This section will introduce different 
relevant avenues of experimental anti-tumor immunotherapy with a focus on NK cells. 
 
Figure 3.12 – Timeline of the most important breakthroughs in cancer immunotherapy. BCG, bacille Calmette-Guérin; 
IFNα, interferon-α; IL-2, interleukin-2; MHC, major histocompatibility comples; TNF, tumor necrosis factor; VIN, vulvar 
intraepithelial neoplasia (Lesterhuis et al. Nature Reviews Drug Discovery 2011; 8:591-600). 
 
Vaccine-based strategies 
Protective vaccinations so far only could be developed for virus-induced cancers with well-defined 
viral antigens. One prominent example is the vaccination against the human papillomavirus (HPV), 
some serotypes of which are known to cause cervical carcinoma291. With an estimated 15% of 
cancers being virally induced, vaccination against immunodominant epitopes of for example hepatitis 
B virus (HBV) or Epstein-Barr virus (EBV) potentially holds great adjuvant potential. Other 
tumor-antigens are typically self proteins. They include mutated oncogenes or tumor suppressor 
genes (specific for tumor cells, for instance mutated p53), overexpressed cellular proteins (for 
example Her2/neu), tumor antigens produced by oncogenic viruses (for example HPV), oncofetal 
antigens (for example the carcinoembryonic antigen (CEA)), altered glycolipids or glycoproteins, 
differentiation antigens (for example tyrosinase or Melan-A) or cancer testis antigens (for example 
NY-ESO-1). Of note, recently effort was put into categorizing them due to their physiological 
relevance292. Accordingly, in many cases negative selection as part of the TCR quality control can 
prevent reactive TCRs to pass the quality control in the thymus thus deleting potentially 
tumor-reactive TCR specificities. Therefore, several approaches such as peptide vaccination, tumor 
cell vaccines, DNA/RNA vaccines or vaccinations with peptide-loaded DCs failed in inducing 
substantial clinical responses293. Still, the first cell-based vaccine inducing T cell responses against 
prostate cancer (Sipuleucel-T) was food and drug administration (FDA)-approved few years ago.  
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Cytokines 
Despite low response rates of around 15% and severe side effects both IL-2 and IFN-α have been 
used for treatment of renal cell carcinoma and advanced melanoma294,295. Toxic side effects are 
tremendous, leading to death in 1.5% of the patients due to capillary leak syndrome and thus organ 
failure296. Yet, in addition to the systemic application of IL-2 and IFN-α local application of IL-2 and 
TNF-α have been reported to induce beneficial effects for patients with soft-tissue sarcomas or 
melanoma297,298. Of note, IL-2 therapy, regardless if injected locally or systemically, can induce Treg. 
 
Immune-targeted agents 
Immune-targeted agents comprise the newest class of therapeutical regimen. One famous example 
is ipilimumab, a cytotoxic T lymphocyte-associated antigen 4 (CTLA4) blocking antibody. CTLA4 is a 
potent attenuator of immune responses which is why CTLA4-/- mice die from lymphoproliferative 
disease shortly after birth. It is mainly expressed on CD4-positive T cells including Treg and 
CD8-positive CTL299. Of note, in a large randomized trial ipilimumab was found to be the first 
treatment in 30 years to give a survival benefit in metastatic melanoma patients300. Thus, ipilimumab 
recently was FDA approved for the treatment of melanoma. Likewise, several other so-called 
checkpoint molecules have received attention for blocking mAFbs such as PD1, PDL1 or B7-H3. 
Notably, blocking an inhibitory axis such as PD1-PDL1 or CTLA-4-B7 molecules can result in 
autoimmunity301. 
 
Adoptive T cell transfer  
For the infusion of large numbers of T cells several T cell sources such as tumor-infiltrating 
lymphocytes (TIL) or peripheral blood were tested. Also, geneticaly modified effector cells were 
evaluated for safety and clinical response. Compared to the previously introduced methods adoptive 
cell therapy (ACT) is not relying on activating endogenous immune cells but rather supplies 
exogenously autologous or allogeneic effectors in high numbers. The first study showing in 
melanoma patients that isolated TIL upon re-infusion into patients exert tumoricidal activity was 
published in 2002302. 50% of the patients who received high-dose infusions of ex vivo expanded and 
activated TIL showed an objective clinical response with 10% obtaining complete response. Based on 
these results a more targeted approach is appealing. After the characterization of the tumor-specific 
TCRs with the highest affinity, these could be cloned and used to create TCR-transgenic effector T 
cells for re-infusion into patients, possibly potentiating the effects that were observed with bulk 
expanded TIL. First studies using TCR transgenic T cells were performed using T cells recognizing 
melanoma antigen recognized by T cells 1 (MART1) and/or glycoprotein 100 (gp100) and response 
rates of 20-30% were obtained303. 
 
NK cell-based therapy 
For therapy, activated autologous or allogeneic NK cells are used. Besides peripheral blood as a 
source of NK cells, also stem cells or induced pluripotent stem cells (iPSC) have been used for NK cell 
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generation. Further, NK cell lines were tested some of which were genetically modified to allow them 
to secrete activating cytokines or to express chimeric antigen receptors304.  
Several models and/or trials that implemented systemic cytokine application to either activate 
endogenous or transferred NK cells showed that cytokine administration comes with the risk of 
life-threatening toxic side effects and cytokine-induced NK apoptosis. Still, a safe application of ex 
vivo expanded and activated NK cells showed clinical responses against some entities such as 
metastatic renal cell cancer (RCC), malignant glioma and breast cancer305–307. Yet, Parkhurst et al. 
showed that transferred NK cells persisted but without IL-2 reactivation exerted no cytotoxicity 
against tumor cell lines ex vivo229. Similar findings were reported for colorectal carcinoma, non-small 
cell lung cancer and RCC. In these settings, the presence of matched MHC class I molecules in situ 
was thought to contribute to preventing full functionality of activated, autologous NK cell. The 
transferred cells during their development were licensed in the patient who receives the cell product 
and thus express receptors that are inhibiting the NK cell reactivity against the tumor. 
Importantly, Ruggeri et al. were using KIR-HLA mismatched donors for allogeneic hematopoietic stem 
cell transplantation (HSCT). As in any given individual a subset of NK cells is present that only 
expresses one KIR molecule with which it was licensed against an HLA molecule of the donor that is 
missing in the recipient, an allo-reactive population is transferred. Indeed, in an acute myeloid 
leukemia (AML) patient group, the KIR-HLA mismatch in graft versus host (GVH) direction in 34 
patients showed no rejection, importantly no toxicities and a decreased 5 year relapse rate of 5% as 
compared to 75% when no mismatch was present308. Later on it was shown that KIR2DS1+ NK cells 
from HLA C1 positive donors are the mediators of the anti-AML effect309. Yet, controversial data exist 
emphasizing the need for a comprehensive analysis which donor is the best for which patient; thus 
Pende et al. could show that KIR2DL1 incompatibility is more potent than KIR2DL2/L3 incompatibility 
with the latter only working if KIR2DS1 is co-expressed310. After the success of the aforementioned 
studies other groups were also trying to exploit the allo-reactivity of KIR ligand mismatched NK 
donors229.These trials showed minimal toxicity of allo-reactive NK cells, more pronounced anti-tumor 
effects against non-small cell lung cancer and persistence of transferred cells in patients with 
metastatic melanoma, RCC and others311. In line with these findings, experiments using anti-KIR 
monoclonal antibodies (mAbs) that blocked the KIR-HLA interaction were performed. Most 
importantly, the pan-KIR blocking antibody 1-7F9 increased NK lysis of HLA Cw*03+ tumor cells 
whereas healthy cells were spared, suggesting a therapeutical window for KIR blockade. Also, the 
survival of animals in a xenograft model of AML was significantly increased by 1-7F9 administration 
with NK cells compared to NK cells alone, indicating the potency of the blocking312. Of note, in 
another model of EBV-transformed B cells, KIR blocking per se did not increase NK cell mediated lysis 
but improved the effect of ADCC313. These results state the superiority of allo-reactive over 
autologous NK cells. Yet, the exact pre-requisites of an ideal donor and the ideal allo-reactive subset 
need to be defined more precisely. 
The use of NK cell lines as allogeneic NK cell source has several advantages. They can be easily 
maintained and expanded in vitro allowing for the large-scale production of NK cells. Further, they 
allow for the use of one NK cell product for various application or patients thus eliminating 
deviations by donor-to-donor variabilities. Of note, the NK-92 line was found to be safe and 
potentially exhibits beneficial effects in malignant melanoma, RCC and advanced lung cancer 
patients314,315. Thus, so far it is the only cell line that was FDA approved for tumor therapy. Of note, 
due to their virtual complete lack of KIR molecules NK-92 are potent mediators of allo-reactivity. Due 
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to the feasibility of NK cell lines, several groups were trying to enhance the endogenous anti-tumor 
effect of for instance NK-92 cells by genetic means. Cytokine gene transfer of for example IL-2 or 
IL-15 was shown to increase survival and activation316. Also, NK cells were shown to exert increased 
reactivity against for instance CEA or HER2/neu expressing targets after introduction of a chimeric 
antigen receptor (CAR) against CEA or HER2/neu, respectively317. This retargeting could substantially 
increase their clinical applicability.  
 
Other agents  
As against virtually any molecule of choice a specific monoclonal antibody (mAb) can be produced, 
self-proteins can easily be targeted by the respective mAb. Compared to the restrictions of T cell 
therapy due to the thymic negative selection of self-reactive TCRs, this confers a major advantage as 
many tumor-antigens are self antigens. The most widely used antibody is rituximab, a chimeric 
anti-CD20 antibody used against non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia. If 
applied together with CHOP therapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) it 
achieves 76% of complete remissions318. For the treatment of solid tumors several mAbs have been 
approved. Cetuximab for instance targets the epidermal growth factor receptor (EGFR) and 
trastuzumab HER2/neu. Notably, the first approved mAb with anticancer-activity that did not target 
cancer cells directly was Bevacizumab, a mAb directed against VEGF319. Besides depleting molecules 
such as VEGF or blockade of relevant growth receptors mAbs also recruit other effector cells or 
molecules such as the complement system or Fc receptor expressing effector cells such as 
neutrophils, monocytes or NK cells that can mediate ADCC. Importantly, whereas natural cytotoxicity 
was reported several times to be decreased in tumor patients, tumor-infiltrating NK cells were shown 
to potently elicit ADCC without re-activation229,320. This indicates the big potential antibody-therapy 
could have on NK cell anti-tumor immunity. Further, in pre-clinical models various arming-strategies 
of antibodies have been tested such as conjugates with radioactive particles or toxins321. Also 
bispecific antibodies were evaluated that for instance bind to CD3 and a tumor-antigen, thus 
localizing effector cells in very close proximity to their targets321. 
Importantly, also topically applied adjuvants have been tested for tumor-therapy and were approved 
by the FDA. For instance, imiquimod containing a TLR7 agonist has proven efficacy against 
pre-malignant lesions, low-grade epithelial tumors and VIN322. 
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4 AIM OF THE STUDY 
 
 Malignant melanoma currently exhibits a bad prognosis for tumor patients and its incidence 
is increasing. Few promising treatment strategies exist and despite the identification of many 
melanoma-associated antigens, T cell-based strategies often are not applicable due to the frequently 
observed down-regulation of HLA class I molecules. As the selective or complete loss of HLA class I 
expression renders the tumor cells sensitive towards NK cell mediated lysis, we wanted to investigate 
innovative approaches to improve existing NK cell-based immunotherapy strategies against 
malignant melanoma. 
So far, little success was achieved in clinical studies using NK cells against non-hematological 
malignancies leaving an urgent need for improved protocols. Amongst others, there are two 
explanations why in the performed studies no beneficial effect could be observed: 
a) The NK cells did  not infiltrate properly into the tumor tissue 
 
b) In situ or systemic immunosuppression by tumor-derived factors renders NK cells anergic, 
preventing an effective anti-tumor response 
 
Thus, to investigate possibilities to overcome these two major restrictions, we focused on the 
following aims: 
a) The identification of chemokines that improve the homing of cytotoxic human NK cells to 
and their infiltration into tumor tissue.  
 
b) The characterization of a novel activation protocol prior to infusion that allows for more 
persistent anti-tumor reactivity. Notably, it was reported that murine NK cells exhibited an 
induced “memory like” phenotype upon short term activation with IL-12, IL-15 and IL-18 
mounting elevated responses after re-stimulation284. Thus, we wanted to perform a 
comprehensive phenotypical and functional analysis of IL-12/15/18-stimulated human NK 
cells focusing on more sustained reactivity and cytotoxicity against tumor cell lines.  
Both approaches subsequently should get evaluated in a xenograft mouse model of malignant 
melanoma that we set up for these studies. 
 
These strategies are instrumental to tackle existing problems with NK cell-based anti-cancer 
immunotherapy. The findings that will be obtained in this study are potentially of very high clinical 
relevance as they might help to improve immunotherapy against melanoma and malignant diseases 
in general.  
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5 MATERIALS AND METHODS 
 
5.1  Materials 
5.1.1  Mouse strains 
All mice used were bred in the DKFZ animal facilities. NOD-SCID mice were received from the barrier 2 (DKFZ, 
Heidelberg) and NSG mice from the barrier 1 (DKFZ, Heidelberg), respectively. Mice were housed under specific 
pathogen-free conditions and used in experiments typically at 6-12 weeks of age. All experiments were 
performed according to local animal experimental ethics committee guidelines. 
 
5.1.2  Cell lines 
Name Cell type Medium 
721.221 mutant (parental) 
Human EBV transfected B lymphoblastoid 
cell line IMDM 
721.221 mutant HLA-Cw*03 
721.221 mutant HLA-Cw*04 
721.221 mutant HLA-Cw*07 
721.221 mutant HLA-Cw*15 
A549 Human alveolar adenocarcinoma line RPMI 
HCT116 wtp53 Human colorectal carcinoma line RPMI 
HUVEC Human umbilical vein endothelial cells Endothelial Cell Growth Medium 
K562 Human myelogenous leukemia line RPMI 
Ma-Mel-86b Human melanoma line RPMI 
Phoenix-ampho Human embryonic kidney line DMEM 
SK-Mel-28 Human melanoma line RPMI 
U937 Human histiocytic lymphoma line RPMI 
UKRV-Mel-02 Human melanoma line RPMI 
 
All cell culture media were supplemented with 10% FCS, 2 mM L-glutamine, 100 IU/ml penicillin and 
100 µg/ml streptomycin and were regularly tested for the presence of mycoplasma using the 
multiplex contamination assay available at the core facility for genomics at the DKFZ, Heidelberg. 
E.coli host strains 
Product Source  Catalogue number 
JM109 Promega P9751 
MAX Efficiency® DH5αTM Competent Cells Invitrogen 18258-012 
One Shot® TOP10 Chemically Competent E. coli Invitrogen C4040-10 
 
5.1.3  Cell culture products 
Product Source  Catalogue number 
15 ml conical tubes Greiner 188271 
24-well flat-bottom with lid – Standard TC BD 353047 
24 well transwell migration plates Corning 3421 
40 μM cell strainer FalconTM BD 352340 
5 ml round-bottom polypropylene test tubes BD 352008 
5 ml round-bottom polystyrene test tubes w/ cell strainer BD 352235 
50 ml conical tubes FalconTM BD 352070 
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70 μM cell strainer FalconTM BD 352350 
96-well flat-bottom with lid – Standard TC BD 353972 
96-well U-bottom with lid – Standard TC BD 353077 
Cryovial, 2 ml sterile Roth E309.1 
Filter tips: 10, 20, 100, 200, 300 and 1000 μl Biozym 770010,-50,-280,-300,-400 
Petri dishes (60 mm) TPP 93060 
Safe lock tubes: 0.5, 1.5 and 2 ml Eppendorf 13625, 12682, 12776 
Serological pipettes: 5, 10, 25 and 50 ml, sterile Costar 4487-4490 
Standard tissue culture flask/filter screw caps – 75 cm2 TPP 90076 
Standard tissue culture flask/filter screw caps – 150 cm2 TPP 90151 
Tissue culture flask/filter screw caps – 182 cm2 Greiner 660175 
 
5.1.4  Cell culture media and reagents 
Product Source  Catalogue number 
Biocoll Separating Solution Biochrom AG L6115 
Dimethylsulfoxide Hybri Max (DMSO) Sigma Aldrich D2650 
DMEM (1x) (High Glucose) with L-Glutamine, 4500 mg/L 
D-Glucose, w/o Sodium Pyruvate Sigma Aldrich D6429 
D-PBS (1x) w/o Ca, Mg, Sodium Bicarbonate Sigma Aldrich D8537 
EDTA BioChrom AG L2113 
Endothelial cell growth medium PromoCell C-22010 
Fetal Bovine Serum, Origin: EU approved Gibco 10270 
Gelatine Sigma G1393 
Geneticin (G418) Gibco 10131-027 
Human serum, type AB, converted PAA C05-002 
Ionomycin Sigma Aldrich I3909 
LB-medium Roth X968.2 
L-Glutamine 200 mM (100x), 29.2 mg/ml Gibco 25030 
Penicillin/Streptomycin-Solution: 10,000 U Penicillin, 
10,000 μg/ml Straptomycin Sigma Aldrich P4333 
Phorbol 12-myristate 13-acetate (PMA) Sigma Aldrich P1585 
Puromycin Sigma Aldrich 58-58-2 
RPMI 1640 (1x) with L-Glutamine Sigma Aldrich R8758 
Stem cell growth medium (SCGM) CellGenix 20802-0500 
Trypsin-EDTA 0.25% Gibco 25200 
Trypan Blue Sigma Aldrich T8154 
Trypsin-EDTA (1x) HBSS w/o Ca, Mg with EDTA Sigma Aldrich T3924 
 
All sera were heat-inactivated at 56°C for 30 minutes prior to usage in culture media. 
For all bacteria cultures 1x LB medium with appropriate antibiotics was used. 
 
5.1.5  Magnetic cell sorting (MACS) 
Product Source  Catalogue number 
LS Columns Miltenyi 130-042-401 
Human NK cell isolation kit Miltenyi 130-092-657 
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5.1.6  Kits 
Product Source  Catalogue number 
Antarctic phosphatase NEB M0289S 
BCATM Protein Assay Kit Pierce 23227 
Bioplex cell lysis kit Biorad 171-304011 
HiPure Plasmid Maxi-Prep Kit Invitrogen K210007 
Human CX3CL1 ELISA R&D DY365 
Human IFN-gamma ELISA BioLegend 430101 
Luciferase assay system Promega E1500 
pGEM-T-easy Promega A1360 
QIAprep spin Mini-Prep Kit Qiagen 27106 
QIAquick GelEx Kit  Qiagen 28706 
QIAquick PCR purification kit Qiagen 28104 
T4 DNA ligase NEB M0202S 
 
5.1.7  Antibodies 
Primary antibodies Clone Company Catalogue number 
B7-H6 1.18 G. Moldenhauer, DKFZ - 
CD107a-FITC H4A3 BioLegend 328606 
CD112 L14 - - 
CD155 SKIL4 BioLegend 337610 
CD16-APC Cy 7 3G8 BioLegend 302018 
CD16-FITC 3G8 BD Pharmingen 555406 
CD16-PE 3G8 BioLegend 302008 
CD16-PerCP Cy 5.5 3G8 BioLegend 302028 
CD25-APC BC96 BioLegend 302610 
CD3-FITC HIT3a BioLegend 300306 
CD3-PE HIT3a BioLegend 300308 
CD3-PE-Cy7 SK7 BioLegend 344816 
CD45-Pacific Blue HI30 BioLegend 304029 
CD56-APC HCD56 BioLegend 318310 
CD56-PE Cy7 HCD56 BioLegend 318318 
CD69-APC FN50 BioLegend 310910 
CX3CL1-PE 51637 R&D IC365P 
CX3CR1-PE 2A9-1 BioLegend 341604 
CXCR1-PE 8F1/CXCR1 BioLegend 320608 
CXCR2-PE 5E8/CXCR2 BioLegend 320706 
CXCR3-AF488 TG1 BioLegend 334907 
DNAM-1-PE TX25 BioLegend 337106 
KIR2DL1/S1-FITC HP-MA4 BioLegend 339505 
KIR2DL2/L3-PE DX27 BioLegend 312605 
KIR3DL1-PE DX9 BioLegend 312707 
MICA AMO1 Bamomab AMO1-100 
MICB M363 Amgen - 
NKG2D-APC 1D11 BioLegend  320808 
NKG2D-Fc - R&D 1299-NK-050 
NKp30-APC P30-15 BioLegend 325210 
NKp44-APC P44-8 BioLegend 325109 
NKp44-Fc - R&D 2249-NK-050 
NKp46-AF647 9E2 BioLegend 331910 
NKp80-APC 5D12 BioLegend 346707 
Pan-MHC class I W6/32 BioLegend 311412 
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Isotype antibodies Clone Company Catalogue number 
CD99-Fc - R&D 3905-CD-050 
mIgG1 MOPC-21 BioLegend 400124 
mIgG1-AF647 MOPC-21 BioLegend 400130 
mIgG1-APC MOPC-21 BioLegend 400122 
mIgG1-FITC MOPC-21 BioLegend 400108 
mIgG1-PE MOPC-21 BioLegend 400112 
mIgG2a G155-178 BD Pharmingen 554645 
mIgG2a-FITC MOPC-173 BioLegend 400210 
mIgG2a-PE G155178 BD Pharmingen 554648 
mIgG2b-FITC MPC11 BioLegend 400310 
mIgG2b-PE 133303 R&D IC0041P 
rIgG2b-PE eB149/10H5 eBioscience 12-4031-82 
 
Secondary antibodies Company Catalogue number 
gah-Fc-PE Jackson ImmunoResearch Laboratories 109-116-097 
gam-Fc-PE Dianova 115-116-071 
 
5.1.8  Chemicals and biological reagents 
Product Source  Catalogue number 
7-AAD viability staining solution BioLegend 420403 
Agarose Sigma A9539 
AlamarBlueTM cell viability reagent Life technologies DAL1025 
Carboxyfluorescein succinimidyl ester (CFSE) Sigma-Alrich 21888 
Chloroquin Sigma-Aldrich C6628  
51Chromium Perkin Elmer NEZ020005MC 
Collagenase IV Cell Systems LS004188 
Colorless RPMI Sigma-Aldrich 11835-030 
CX3CL1 PeproTech 300-31 
CXCL10 PeproTech 300-12 
CXCL12 PeproTech 300-28A 
CXCL8 PeproTech 200-08 
DNAse I Sigma-Aldrich DN25 
dNTPs Promega U1511 
Ethidiumbromide AppliChem A1152.0025 
Evan’s Blue dye Sigma-Aldrich E2129 
GoTaq Promega M3001 
Heparin-sodium, 25.000 units Braun 1708.00.00 
Hyaluronidase type V Sigma-Aldrich H6-254 
IL-12 Peprotech 200-12 
IL-15 R&D 247-IL-005 
IL-18 MBL B003-5 
IL-2 TecinTM, teceleukin from Roche, received from NIH 
Isofluran B  Braun 6724123.00.00 
MatrigelTM BD 356231 
Nuclease-free water Ambion AM9937 
Polybrene Sigma-Aldrich 28728-55-4 
Stay BrightTM Luciferin BioVision 7903-1G  
TMB liquid substrate system for ELISA Sigma-Aldrich T0440 
Triton X-100  Sigma-Fluka T9284 
Human IgG Sigma-Aldrich I4506 
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5.1.9  Enzymes and markers 
Product Source  Catalogue number 
BamHI-HF NEB R3136S 
DNA-Ladder NEB N3200S 
PacI NEB R0547S 
PvuI NEB R0150S 
SalI-HF NEB R3138S 
XhoI NEB R0146S 
 
5.1.10  Plasmids 
Oligonucleotide Source 
pBabe-puro Stock of D080, originally from Robert Weinberg 
pDONR221-CX3CL1 Gene repository, Genomics core facility, DKFZ, Heidelberg 
pGL2A Günter Küblbeck, DKFZ, Heidelberg 
pMX-neo Stock of D080, originally Cell Biolabs, Inc. 
pCL-ampho Stock of D080 
 
5.1.11  Oligonucleotides  
All Oligonucleotides were ordered from MWG, Germany. 
Oligonucleotide Sequence 5’ – 3’ 
CX3CL1 forward TTTGGGATCCCATGGCTCCGATATCTCTGTC 
CX3CL1 reverse TTTTCTCGAGTCACACGGGCACCAGGACAT 
Intra-CX3CL1 sequencing CTAAGGCTGAGGAACCCATC 
Luciferase primer sequencing GCGTTTTGTTGACTCCATCC 
pMX-neo forward sequencing GGCAGCCTACCAAGAACAAC 
pMX-neo revers sequencing CTGGTTGCTGACTAATTGAGATGC 
Psi PlusPack primer CCGCCTCCTCTTCTTCCATC 
  
5.1.12 Solutions 
Solution Ingredients 
10x PBS 1.37 M NaCl, 27 mM KCl, 100 mM Na2HPO4 (anhydrous), 20 mM KH2PO4 
2x HBS 50 mM HEPES with 12 mM dextrose, 10 mM KCl, 280 mM NaCl, 1.5 mM Na2HPO4 (pH 7.05) 
50x TAE 242 g Tris Base, 57.1 ml 100% acetic acid, 100 ml 0.5 M EDTA (pH 8.0) ad. 1 liter 
ACK lysis buffer 0.829 g NH4Cl, 0.1 g KHCO3, 0.38 mg EDTA ad. 100 ml ddH2O 
CaCl2 2 M CaCl2 
DNA loading dye 5x 0.25%  (w/v) Orange G, 30% (v/v) glycerol, 10 mM EDTA, 10mM Tris-HCl (pH 7.4) 
FACS buffer 1x PBS, 3% FCS, 0.02% (v/v) NaN3 
Freezing medium 1x FCS, 10% DMSO 
Homing buffer RPMI-1640, 0.5% BSA 
MACS buffer 1x PBS, 3% FCS, 0.5 mM EDTA 
Primary cell culture medium 1x SCGM, 10% human serum, 1% pen/strep 
 
 
 
 
Materials                                                                                                                    Materials and methods 48 
5.1.13 Laboratory equipment, tools and material
Equipment Name Company 
Analytical scale 
Classic Plus PB602-S 
Mettler Toledo 
Adventurer OHAUS 
Anesthesia machine 
Vapor 19.1 Drägerwerk AG 
XGL-8 Xenogen 
Animal irradiator OB 58/902-1 Buchler 
Bacterium incubator Innova 42330 New Brunswick Scientific 
Caliper Calimax Wiha 
Cell culture incubator Heraeus BBD6220 Kendro 
Centrifuge 
Heraeus Multifuge 4KR Kendro 
Heraeus Multifuge X3R Thermo Scientific 
Heraeus Multifuge 3SR+ Thermo Scientific 
Heraeus Biofuge pico M&S Laborgeräte GmBH 
Sorvall Evolution RC Thermo Scientific 
- WIFUG 
Counting chamber Neubauer chamber Blau Brand 
ELISA microplate reader Multiscan Fc  Thermo Fischer 
ELISA plate ELISA plate, Microlon 96 W Greiner bio one 
Flow Cytometer 
FACSTM Calibur 
BD FACSTM Aria I 
FACSTM Canto II 
Flow hood 
Hera Safe Kendro 
Cell Gard, Lab Gard Nuaire 
Freezer -20°C Premium, Comfort, Profi line Liebherr 
Freezer -86°C VIP series Sanyo 
Fridge 
Premium, Profi line Liebherr 
- VWR, International 
Geldocumentation UV Flächenstrahler Konrad Benda 
Ice machine Ice maker Hoshizaki 
Imaging machine IVIS-100 Xenogen 
Lumaplate LumaPlateTM-96 Perkin Elmer 
Lumaplate reader TopCount NXTTM Perkin Elmer 
Luminescence reader Orion L microplate Luminometer Berthold Detection Systems 
Magnetic stirrer MR3001 K Heidolph 
Microscope Wilovert 30 Hund Wetzlar 
Multichannel pipette Transferpette-12, -8 Gilson 
Multistepper Multipipette plus Eppendorf 
N2 tank Cryosystem 6000 MVE 
Needles MicrolanceTM 3 (25 G, 27G and 30G) BD 
One-way scalpel Feather disposable Scalpel Feather 
PCR machine PTC-200 MJ Research 
pH meter pH211 Hanna Instruments 
Photometer NanoPhotometerTM Implen 
Pipettes Pipetman (various sizes) Gilson 
Pipetboy CellMate II Matrix 
Power supply Power Pack basic BioRad 
Pump 
PC2004 Vario Vacuubrand 
BVC21 Vacuubrand 
Vacusafe Integra 
Red light lamp Heat Glo 75 W ExoTerra 
Shaver Aesculap GT415 Braun 
Surgery equipment (scissor, forceps…) - Dimeda, A. Dumont&Fils 
Syringe 
DiscarditTM II 5 ml BD 
TBC-Spritze 1 ml mediware 
Thermomixer Compact, Comfort Eppendorf 
Vortexer VortexGenie 2 VWR/Scientific Industries 
Water bath Heraeus Julabo TW20 Kendro 
White 96 well plate Costar™ 96-Well white Corning 
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5.2  Methods 
5.2.1  Cell culture methods 
5.2.1.1  Thawing of cells 
For thawing of cells, the respective cryovials were withdrawn from the liquid nitrogen tank and 
thoroughly sprayed with 70% ethanol. Thawing was done by adding pre-warmed medium with a 1 ml 
pipette and transferring the thawed cell suspension into Falcon tubes with pre-warmed medium. The 
Falcon tube was filled up with medium and the cells were centrifuged (1200 or 1500 rpm, 5 min, RT). 
After removal of the supernatant the cells were resuspended in pre-warmed medium and put into 
appropriate cell culture flasks for culture (37°C, 5% CO2) for at least 7 days prior to usage. 
 
5.2.1.2 Passaging and antibiotics treatment of cells 
The culture medium of adherent cells was decanted or removed with a vacuum pump and 
trypsin-EDTA or PBS-EDTA was added until the cell layer was properly covered. The flasks were 
incubated at 37°C until all cells detached upon rocking of the flask. The cells were then transferred 
into pre-warmed medium in Falcon tubes and were centrifuged (1200 rpm, 5 min, RT). The 
supernatant was removed from the pellet and the cells got resuspended in fresh medium and either 
split at appropriate ratios into fresh cell culture flasks for culture (37°C, 5% CO2) or were used for 
individual assays. 
Suspension cells were resuspended properly by rocking the cell culture flask and an appropriate 
volume of medium was removed by either decanting or with a vacuum pump. Fresh medium was 
added so that the cells were diluted in a range from 1:2 up to 1:50. 
HUVEC cells have been cultured in flasks that were coated with 1% gelatin for 2 hours. For 
detachment of HUVEC cells, Trypsin-EDTA at a concentration of 0.25% was used. 
To select the three melanoma lines either for pBabe-puro-eGFP-2A-CBGr99 or pMX-neo-CX3CL1 
transductants the following titrated concentrations of antibiotics have been used: 
 Puromycin G418 (geneticin) 
Ma-Mel-86b 0.75 µg/ml 750 µg/ml 
SK-Mel-28 1 µg/ml 750 µg/ml 
UKRV-Mel-02 2 µg/ml 750 µg/ml 
  
 
5.2.1.3 Freezing of cells 
Suspensions of the cells were centrifuged (1200 or 1500 rpm, 5 min, RT) and after removal of the 
supernatant by decanting or with a vacuum pump the cell pellet was resuspended in an appropriate 
volume of freezing medium and 1 ml aliquots were frozen for 1-3 days at -80°C. Subsequently, the 
frozen vials were transferred into liquid nitrogen for long-term storage. Typically, a mycoplasma-test 
according to the guide lines of the core facility for genomics was performed prior to freezing the 
cells. 
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5.2.1.4 Counting of cells 
If necessary, the respective cell suspension was pre-diluted and an aliquot was further diluted with 
an appropriate volume of trypan blue solution (0.05 % w/v) mixed 1:1 with PBS for live-dead 
discrimination. Live cells were counted with a Neubauer counting chamber (0.1 mm depth) and the 
total cell number was calculated using the following formula: 
Total live cell number = Counted cells/counted squares* dilution * 104 
 
5.2.2 Molecular biological methods 
5.2.2.1 Cloning of the eGFP-2A-CBGr99 insert into pBabe-puro 
As shown in figure 6.1, the expression cassette for eGFP-2A-CBGr99 luciferase was cut out of the 
pGL-2A vector kindly provided by Günter Küblbeck (DKFZ, Heidelberg) using BamHI and XhoI to cut 
the insert and PacI and PvuI to degrade the remaining backbone. The target vector pBabe-puro was 
digested with BamHI and SalI, creating identical overhangs for XhoI. The digests were performed in a 
total volume of 20 µl using 5 µg DNA and appropriate buffers according to the manufacturer’s 
instructions. After 4 hours of incubation at 37°C loading dye was added to the restriction products 
and the mixtures were loaded quantitatively on a 1% agarose gel containing 0.1% ethidiumbromide. 
The gel was prepared of 1x TAE that was also used as a running buffer (90 volts). An appropriate 
DNA-ladder mix was added on one lane of the gel to allow for determination of size and quantity of 
the DNA fragments. Fragments displaying the correct sizes were cut out of the gel using one-way 
scalpels under UV light (long wavelength, 366 nm) and were subjected to the QIAquick gel extraction 
kit following the manufacturer’s instructions. The concentration of the respective DNA products was 
determined with a spectrophotometer and used for a ligation reaction with a total volume of 12 µl 
using 50 ng of vector backbone and a stochiometric vector insert ratio of 1:3. 1 µl of T4 DNA ligase 
was used per ligation reaction. The Ligation was allowed to proceed o.n. at 16°C.  The next day the 
mixture was heat-inactivated at 65°C for 10 minutes and used for transformation of competent 
bacteria (5.2.2.3). 
 
5.2.2.2 Cloning of CX3CL1 into pMX-neo 
As shown in figure 6.11, we first PCR amplified the full length CX3CL1 DNA out of the 
pDONR221-CX3CL1 with primers introducing a 5’-BamHI and a 3’-XhoI restriction site (see materials 
section) using the following conditions: 
 
 
 
 
 
 pDONR221-CX3CL1 
1:10 diluted DNA 1 µl 
5x Colorless GoTaq buffer 10 µl buffer D 
dNTPs 1 µl 
For primer 2.5 µl 
Rev primer 2.5 µl 
GoTaq polymerase 0.5 µl 
Nuclease-free water 32.5 µl 
25 mM MgCl2 3 µl 
 Temp. [°C] Time [s] 
1x 98°C 120 
30x 98°C 10 
 65°C 30 
 72°C 60 
1x 72°C 600 
1x 4°C infinite 
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The samples were supplemented with gel loading dye and separated on a 1% agarose gel containing 
0.1% ethidiumbromide and purified out of a gel section as described previously. The purified nucleic 
acids were then cleaned using the PCR purification kit in order to decrease the concentrations of 
organic solvents. The respective products were ligated into the pGEM-T vector according to the 
manufacturer’s instructions and the ligation product was used for bacterial transformation (5.2.2.3). 
Upon verification of the pGEM-T-CX3CL1 construct via sequencing (5.2.2.4) the plasmid was used to 
clone the entire ORF into the pMX-neo vector. First, a preparative digestion was performed for 4 
hours at 37°C using 5 µg of the respective plasmids and 1.5 µl each of XhoI and BamHI in a 20 µl 
reaction volume containing 2 µl 10x buffer 4 (NEB). 30 minutes prior to the end of the reaction, 2.5 µl 
antarctic phosphatase buffer and 2.5 µl antarctic phosphatase (both NEB) were added to the 
pMX-neo reaction. The respective digests were analyzed via agarose gel-electrophoresis as described 
and fragments showing the correct sizes were excised out of the gel. The gel extraction and PCR-
purification protocol were performed in a row according to the manufacturer’s protocol. The cut 
fragments were used in a ligation reaction (total volume 10µl, 100 ng backbone, backbone-insert 
ratio 1:3, 1 µl T4 DNA-ligase) over night at 4°C after a 30 minutes pre-incubation at RT. The ligation 
product was then used for transforming competent cells. 
 
5.2.2.3 Transformation of bacteria and preparation of mini-prep cultures 
Chemically competent bacteria were thawed on ice and aliquoted in 50 µl steps per condition. 
Typically, 7 µl of the ligation reaction or respective controls or 1 µl of plasmid DNA were added to the 
bacteria and the reaction was incubated for 30 min on ice. The mixture then was put into a 
pre-warmed waterbath (42°C) for 60 seconds and was cooled on ice again after the heat-shock. 250 
µl of SOC medium were added and the cells were incubated for 1 further hour at 37°C prior to plating 
of the reaction on LB-agar plates containing an appropriate antibiotic. The next day individual 
colonies were picked with a sterile 200 µl pipette tip and added to 5 ml of LB-medium containing the 
selection antibiotic for over-night culture. Mini-preps were performed using the Mini-prep kit 
(Qiagen) according to the manufacturer’s instructions and the plasmid DNA was subjected to 
appropriate analytical control digestions and sequencing as described. 
 
5.2.2.4 Sequencing and maxi-prep 
All sequencing reactions have been performed by MWG using appropriate sequencing primers (see 
materials section) and were evaluated in silico with nucleotide BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastn&PAGE_TYPE=BlastSearch&LINK_LOC=blast
home). Upon confirmation of correct insertion, 2 ml of the respective mini-prep culture were added 
to 200 ml of LB-medium supplemented with an appropriate antibiotic for selection. After an 
overnight expansion at 37°C maxi-preps were performed according to the manufacturer’s 
instructions (Invitrogen) and validated via analytical digestions and sequencing. 
 
 
 52 Methods                                                Materials and methods 
5.2.2.5 Retroviral transduction of cell lines 
2*106 phoenix-ampho cells were seeded the day prior to transfection in T75 flasks.  The next day, the 
cells received fresh medium containing 25 µM chloroquine and a transfection mix was prepared (9 µl 
plasmid of interest, 1 µl pCL-ampho, 506 µl ddH2O, 74 µl CaCl2, 600 µl 2x HBS dropwise while mixing 
the reaction). The mixture got added dropwise onto the phoenix-ampho cells and after 6 hour 
incubation time the medium was exchanged. Two days later, virus-containing supernatant was 
harvested from the phoenix cells, filtered, supplemented with 8 µg/ml polybrene and added to 
subconfluent target cells of choice. After 1 or 2 days and extensive washing (1200 rpm, 5 min, 25°C), 
the cells were transferred into the S1 lab and analyzed for transgene expression. 
 
5.2.3 Magnetic-activated cell sorting (MACS) 
NK cells were purified out of heparinized fresh peripheral blood or leukocyte concentrates from the 
blood bank in Mannheim, Germany according to the manufacturer’s protocol (Miltenyi). Yet, a 45 
minute adhesion step was included prior to magnetic labeling of the cells and typically only 75% of 
the recommended staining antibodies were used. The purity of the NK cell fraction was determined 
via CD3 and CD56 staining and usually was > 90%. 
 
5.2.4 Fluorescence-activated cell sorting (FACS) 
5.2.4.1 Staining and analyzing of cells 
Typically, between 5*103 and 2*106 cells were washed 2x with cold FACS buffer (1200 or 1500 rpm, 5 
mins, 4°C) and were resuspended in 50 µl of huIgG or FACS buffer containing appropriate dilutions of 
primary antibodies or fusion proteins. After 30 minutes of incubation in the dark on ice (60 minutes 
for fusion proteins), the cells were washed 2x with FACS buffer and if necessary a suitable secondary 
fluorochrome-conjugated antibody was added for 30 minutes on ice in the dark. The cells were 
washed twice and transferred in 50 µl of 1:40 diluted 7-AAD into FACS tubes for analysis on a BD 
FACS CaliburTM or BD FACS Canto IITM after adjustment of the lasers using appropriate single 
stainings. All displayed results were produced by gating on living cells as determined by 7-AAD 
staining using the FlowJo 9.3.2 software (Treestar). 
 
5.2.4.2 Sorting of cells 
For sorting of pBabe-puro-eGFP-2A-CBGr99 transduced tumor cells, expanded and 
puromycin-pre-selected tumor cells were harvested using PBS-EDTA, filtered through a 40 µm cell 
strainer to remove cell clusters and stained with 7-AAD to exclude dead cells. Settings were done 
with appropriate single stainings and eGFPhigh tumor cells were sorted through a 100 µm nozzle into 
100% FCS for further expansion and long-term culture. The cells were sorted on a BD FACS AriaTM II. 
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5.2.5 In vitro assays 
5.2.5.1 In vitro quantification of luciferase-activity 
1*105 cells were put into 1.5 ml eppendorf tubes, washed with PBS (2100 rpm, 3 mins) and lysed 
with 150 µl of lysis buffer (Luciferase Assay System, Promega). After one freeze-thaw cycle (-80°C) 
the thawed suspension was centrifuged (13.000 rpm, 1 min) and the supernatant was transferred to 
a clean eppendorf tube and got frozen at -20°C until measurement. For detecting the luciferase 
intensity, 30 µl of the supernatant were loaded on a white 96-well plate and the signals were read 
out on a luminometer with the following settings: 
Injection volume: 50 µl, delay: 2.05 s, measurement: 10 s 
 
5.2.5.2  CD107a mobilization assay 
1*105 NK cells were co-cultured with tumor cells at an effector:target ratio of 1:2 or 1:1 in RPMI-1640 
supplemented with 10% FCS and 1x pen/strep for 30 min in the presence of FITC conjugated anti-
CD107a or the respective isotype control. 1 µg GolgiStop (monensin) was added/well to increase 
accumulation of CD107 protein in the Golgi complex. The assay was continued for 4 further hours 
prior to staining the cells for flow cytometric analysis. 50 ng/ml PMA and 1 mM ionomycin were used 
as a positive control. 
 
5.2.5.3 51Cr release assay 
Target cells were harvested with PBS-EDTA or an aliquot was taken from suspension cells and the 
suspension was centrifuged (1200 or 1500 rpm, 5 min, RT). The pellet was resuspended in 500 µl 
assay medium (RPMI-1640, 10% FCS, 1x pen/strep) and labeled with 100 µCi 51Cr for 90 minutes. 
Effector cells were adjusted to 1.5*106 cells/ml for a 50:1 E:T ratio or to less when few cells were 
available and got titrated in 1:1 dilution steps into the wells of a 96 well plate (round bottom). After 
excessive washing (1200 rpm, 5 min, RT) the target cells were counted and adjusted to 3*104 
cells/ml. 100 µl of labeled target cells were added to the serial dilution of effector cells or to the 
minimum (assay medium) or maximum (10% triton-x10) lysis wells. The plates were incubated for 4 
hours at 37°C and after centrifugation (300 rpm, 3 min, RT), 100 µl of supernatant were transferred 
onto lumaplates. After drying for 1-3 days, the plates were read out and the specific release was 
calculated:    
Specific release [%] = (mean cpm (sample) – mean cpm (min))/(mean cpm (max) - mean cpm (min)) 
 
5.2.5.4  Enzyme-linked immunosorbent assay (ELISA) 
IL-15 or IL-12/15/18 stimulated NK cells were used at various timepoints after the pulse in in vitro 
restimulation assays. Co-cultures were set up in a total volume of 200 µl with all stimulation media 
consisting of SCGM, 10% human serum, 1% pen/strep and 100 IU/ml of IL-2 and either no addition 
(medium background), 10 ng/ml IL-12 and 50 ng/ml IL-15 or K562 in a E:T ratio of 1:1. After 24 hours, 
cell-free supernatant was harvested and used for detection of IFN-γ via ELISA (BioLegend). 
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For the detection of CX3CL1 shedding of the respective transductants, 1*106 cells were seeded in a 6 
cm dish in RPMI-1640 with supplemental. After 24 hours, the medium got replaced by migration 
medium and was conditioned by the tumor cells for further 24 hours. Cell-free supernatant was 
harvested after centrifugation (1200 rpm, 5 min, RT) and used for the human CX3CL1 ELISA (R&D) or 
frozen at -20°C. 
All samples were used undiluted or were diluted up to 1:2000 with assay reagent. The ELISAs for 
IFN-γ and CX3CL1 were used according to the manufacturer’s instructions. Samples for the CX3CL1 
ELISA from tumor biopsies after lysis were subjected to a protein concentration determination assay 
(BCA-kit, Pierce) and were adjusted to 1 mg/ml prior to usage (refer to section 5.2.5.4). 
 
5.2.5.5 Transwell-migration assay  
All chemotaxis assays were performed in 24-well transwell chambers using 5-µm pore polycarbonate 
filters (Corning). NK cells, typically after 1-3 days in medium containing 200 IU/ml IL-2, were washed 
with chemotaxis buffer and adjusted to a concentration of 2*106 cells/ml. 600 µl of chemotaxis 
buffer containing various doses of recombinant chemokines or supernatant from tumor cells 
cultured for 24 h in chemotaxis buffer (after adjustment to the ideal CX3CL1 concentration) were 
added to the lower chamber of the transwell. After adding 2*105 NK cells into the upper wells or into 
input tubes the plates were incubated for 4 h at 37°C to allow for migration. 500 µl of the medium in 
the lower well containing the migrated NK cells were harvested after thorough flushing of the 
membrane and the well. The samples were stained together with the input samples for flow 
cytometric analysis with appropriate antibodies. For internal standardization, equal numbers of 
beads were added to equal volumes of stained cells. All samples were acquired until a certain 
number of beads was detected, thus standardizing for the flow rate of the FACS. Plotted is the % 
specific migration: 
Specific migration [%] = (number of cells (sample)-number of cells (medium))/number of cells (input)*100 
In some experiments the membranes have been coated with human vascular endothelial cells. 
Therefore, the membranes have been treated with 100 µl 1% gelatin for 2 hours prior to seeding of 
1*105 HUVEC cells/membrane. HUVEC medium was added to the upper and lower well until after 4 
days the layers were dense as detected by Evans Blue dye test for endothelial cell permeability. 
Briefly, medium was removed and into the lower well 600 µl colorless RPMI were added, whereas 
100 µl of 4% BSA and 0.67 mg/ml of Evans Blue in colorless RPMI were added to the upper well. After 
4 hours, the Evans Blue dye concentration in the lower well was detected spectrometricaly at 620 nm 
and compared to the concentration when no gelatin was present. Permeabilities under 5% were 
considered to be indicative of a dense HUVEC layer. The specific migration through these coated 
membranes was calculated as described before. 
 
5.2.5.6  AlamarBlueTM cell viability assay 
1.000 cells of various cell lines were added per well of a 96 well flat bottom plate in 200 µl of control 
medium (RPMI-1640, 10% FCS, 1x pen/strep) or in medium containing various concentrations of 
chemokines as indicated. After 20 hours, alamarBlueTM dye was added in a 1:10 ratio (20 µl) and the 
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reaction was incubated for further 4 hours at 37°C. After a total of 24 and 48 hours after seeding the 
absorbances of the wells were read out at 570 nm. 
 
5.2.5.7 CFSE-labeling of NK cells 
NK cells were harvested and adjusted to 1*107 cells/ml in PBS. A solution of 4 µM CFSE in PBS was 
freshly prepared and mixed in a 1:1 ratio (v/v) with the NK cell dilution. The cells were labeled for 15 
minutes in the dark at room temperature while spinning before the reaction was stopped with pure 
FCS. The cells were washed with PBS (1500 rpm, 5 min, RT) before they were used for injection or for 
in vitro assays. 
 
5.2.6 In vivo assays 
5.2.6.1  Intravenous and subcutaneous tumor injections and adoptive NK cell transfer 
Tumor cell lines as indicated were harvested in the exponential growth phase with PBS-EDTA. After 
two washing steps with PBS (1200 rpm, 10 mins, 4°C) the cells were counted twice and adjusted 
appropriately. For intravenous injections the cells were filtered through a 40 µm cell strainer to get 
rid of aggregates prior to adjusting the cell concentration. For intravenous (i.v.) injections the animals 
were pre-warmed with a red light lamp for 5 minutes and later on were fixed in an injection tube. 
The tail veins were cleaned with spitacid prior to injection of 200 µl of the respective solutions 
through 30 G needles containing the indicated tumor doses. For subcutaneous injections, the mice 
were anesthetized with isofluran and the tumor cells were injected into the subcutis of the 
pre-shaved left flank of the animals. Tumor growth was measured 3 times weekly with a caliper and 
is displayed as a product of three diameters. In some experiments, matrigel-tumor mixtures were 
injected. Therefore, matrigel was thawed on ice and tumor cells were mixed 1:1 with ice-cold 
matrigel prior to injection of the indicated cell numbers in 200-300 µl cell-matrigel solution. 
Accordingly, NK cells were washed and adjusted in PBS (1500 rpm, 10 mins, 4°C). I.v. injections were 
performed as described. For peri-lesional injections, the NK cell solution was injected subcutaneously 
through a 27 G needle roughly 1 cm away from the tumor plug. In some experiments NK cells were 
labeled with 2 µM CFSE for 15 minutes in the dark as described prior to i.v. injection into animals. 
 
5.2.6.2 Application of cytokines 
When indicated, 20.000 IU of recombinant human IL-2 in 200 µl of PBS or PBS as a control were 
injected i.p. into NSG mice. 
 
5.2.6.3 Acquiring of bioluminescent signals 
Mice were imaged at the indicated time points using the IVIS® imaging system-100 (Xenogen). 
D-luciferin was dissolved in D-PBS to a final concentration of 30 mg/ml and was injected i.p. at a dose 
of 150 mg/kg (typically 200 µl) 10 minutes prior to the acquisition of the bioluminescent signal 
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intensity (BLI). General anesthesia was induced with 5% isoflurane in a chamber and was continued 
during the acquisition with 2.5% isoflurane via nose cones. After acquiring photographic images of 
each mouse, luminescent images were acquired with various (60 s - 300 s) exposure times depending 
on the luminescent intensity of the cell line used. Acquisitions have been repeated until a maximal 
signal could be detected. Usually, all animals have been injected 2x with 200 µl of luciferin to ensure 
saturating levels of the compound. The resulting grayscale photographic and pseudo-color 
luminescent images were automatically superimposed by the IVIS Living Image Software (Xenogen, 
version 2.50.1). Regions of interest (ROI) were manually drawn around the signal to quantify the 
emitted photons. Luminescence was integrated over these ROIs and is expressed as relative light 
units (RLU) [photons/s/cm2/sr] in all respective experiments.  
 
5.2.6.4 Organ dissection and preparation of single cell suspensions 
Blood  
The mice were killed by asphyxiation with CO2 and blood was collected from the retro-orbital vein 
after removal of the eyeball. Withdrawn blood was supplemented with heparin for flow cytometric 
analysis. Likewise heparinized blood was added quantitatively into 25 ml 1x ACK for 8 mins before 
stopping the reaction with excessive amounts of PBS. Unlysed, remaining cells were washed with PBS 
(1500 rpm, 10 mins, 4°C), counted and used for staining or re-stimulation. For serum preparation, 
un-heparinized blood was incubated for 2 hours at 37°C, clothed blood was removed from the vessel 
wall and the samples were centrifuged (3 min, max speed) prior to collection of the serum that was 
stored at -20°C. 
 
Spleen 
Animals were sacrificed by dislocation of the neck. Spleens were removed and stored in ice-cold PBS 
until further processing. For mechanical disruption, spleens were minced through a 70 µm-pore 
strainer. The cell suspension got washed (1500 rpm, 10 mins, 4°C), counted and was used directly for 
staining. 
 
Liver 
After sacrifice of the animals as described, the mice were perfused by injecting 5-10 ml of PBS with a 
25 G needle into the heart. Livers were removed and cut into small pieces prior to digestion with 
0.05% collagenase type IV in PBS (20 mins, 37°C). The digested organs then got minced through a 70 
µm-pore strainer and washed with PBS (1600 rpm, 10 mins, 4°C). Afterwards, the cells were minced 
through a 40 µm-pore strainer and loaded onto 6 ml of lympholyte for density gradient 
centrifugation (1500 rpm, 26 min, 22°C, acceleration 5, brake 1). The leukocyte ring was harvested 
together with the serum and washed with PBS (1500 rpm, 10 min, 4°C) prior to counting and staining. 
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Lung and tumor 
Animals were sacrificed and perfused with PBS as described. Lungs and tumors or tumor-matrigel 
plugs were removed, cut into pieces using forceps and scalpels and were digested with 5 mg/lung of 
hyaluronidase type V and DNAse I (30 min, 37°C). Digested tissues got minced through a 70 µm-pore 
strainer and washed with PBS (1500 rpm, 10 min, 4°C). After mincing the suspension through a 40 
µm-pore strainer it got loaded onto 6 ml of lympholyte for density gradient centrifugation (1500 rpm, 
26 min, 22°C, acceleration 5, brake 1). The leukocyte ring was harvested together with the serum and 
washed with PBS (1500 rpm, 10 min, 4°C) prior to counting and staining. 
In some experiments pieces of tumors have been removed, weighed and used for the preparation of 
tumor lysates. Therefore, the samples have been treated with the cell lysate kit (Biorad) according to 
the manufacturer’s instructions. 
 
5.2.6.5 Ex vivo re-stimulation of blood cells 
For some experiments, blood cells have been used for an ex vivo re-stimulation assay. After counting, 
5.000 bulk blood cells were used per re-stimulation in a total volume of 200 µl (SCGM + 10% human 
serum + pen/strep + 100 IU/ml IL-2) with either medium, 10 ng/ml IL-12 and 50 ng/ml IL-15 or K562 
at a 1:1 E:T ratio. After 19 hours, supernatant was removed for an IFN-γ ELISA. To standardize the 
IFN-γ levels, the percentage of NK cells as detected by FACS analysis was used to extrapolate all 
samples to the level of IFN-γ which 50.000 NK cells would have produced. 
 
5.2.7  Statistical analysis 
If not stated differently, p-values were calculated using Student’s t-test with two-tailed distribution 
and two-sample equal variance parameters. The Mantel-Cox test was used for comparison of survival 
curves. P-values for Student’s t-test and the Mantel-Cox test were calculated using the GraphPad 
Prism or Microsoft Excel software. Values of p < 0.05 were considered to be statistically significant. 
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6 RESULTS 
 
6.1 Establishment of xenograft mouse models of melanoma 
6.1.1 Generation of pBabe-puro-eGFP-2A-luc 
In order to investigate the therapeutic potential of human NK cells against malignant disease in vivo, 
we aimed at setting up a minimally invasive imaging model. As the usage of optical imaging 
compared to other technologies such as positron emission tomography (PET), magnetic resonance 
imaging (MRI) or computer tomography (CT) does not require long acquisition times or extensive 
training, we created a retroviral vector allowing for the overexpression of the green click beetle 
luciferase323,324. In various reports the quantification of luciferase-derived signals enabled researchers 
to locate and quantify tumor cells or to monitor various cellular processes325–328. We decided to use 
the green click beetle luciferase CBGr99 from the yellow click beetle (Pyrophorus plagiophthalamus) 
as the spectral peak at 543 nm is less absorbed by tissue as compared to the more commonly used 
firefly luciferase (spectral peak at 560 nm). Therefore, it has been shown by Miloud et al. that the 
CBGr99 exhibits stronger signals in vivo compared to other luciferases upon subcutaneous, 
intraperitoneal or intravenous transplantation of luciferase-positive cells329. Finally, the use of the 
2A-sequence of the porcine teschovirus-1 (P2A) guarantees for the stochiometric expression of the 
two genes it links330,331. By cloning out the eGFP stop codon and in-frame inserting the 2A-CBgr99 
construct a single bicistronic mRNA coding for both proteins is transcribed. The 2A-sequence 
co-translationaly cleaves itself giving rise to two independent protein products332. The efficiency of 
this process has been reported to be 100%. Of note, the protein being coded for 5’ of the 2A 
sequence carries most of the amino acids coded for by the 2A gene whereas the protein being coded 
for 3’ of the 2A sequence carries a proline at its N-terminus. Thus, using eGFP as a reporter gene, 
sorting for eGFPhigh cells also selects for CGBr99high cells. 
As shown in figure 6.1 A, we used the expression cassette from the pCMV-eGFP-2A-CBGr99 plasmid 
(i.e. pGL-2A) kindly provided by Günter Küblbeck (DKFZ, Heidelberg). As we wanted to create a 
retroviral vector with the possibility to select for transductants with antibiotics, we used the 
commercially available pBabe-puro as a backbone. Using the indicated restriction enzymes (also refer 
to the respective Materials and Methods section), the expression cassette was inserted into 
pBabe-puro and the respective pBabe-puro-eGFP-2A-CBGr99 construct was used for transduction of 
the three melanoma cell lines Ma-Mel-86b, SK-Mel-28 and UKRV-Mel-02. After pre-sort selections 
with pre-determined doses of puromycin, eGFPhigh cells were sorted out and we compared the eGFP 
levels quantitatively to the untransduced parental lines via flow cytometry (figure 6.1 B). As shown, 
high eGFP positivity could be achieved for all three lines. 
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Figure 6.1 – Cloning strategy for pBabe-puro-eGFP-2A-CBGr99. A) Restriction digestion of pGL-2A with BamHI and XhoI 
gives rise to the full length expression cassette eGFP-2A-CBGr99. This insert is ligated into the pBabe-puro backbone after 
digestion with BamHI and SalI, creating an un-digestable combined SalI/XhoI site. B) Exemplary eGFP-expression profiles of 
three melanoma cell lines after retroviral transduction, puromycin selection and FACS sorting. The red line indicates the 
signal of the sorted transductants, the grey filled signal the untransduced parental lines. One of two experiments is shown. 
 
6.1.2 Evaluation of two mouse strains for xenotransplantation experiments 
To test if the transduced cell lines (refer to 6.1.1) are suitable for in vivo bioluminescent intensity 
(BLI) measurements, we first determined if the transduced CBGr99 gene is functional in the created 
cell lines. As shown in figure 6.2 A, all cell lines exhibited varying but high levels of luciferase activity 
in vitro. Of note, all lines were emitting photons several 1000-folds higher than the background.   
 
Figure 6.2 – NSG mice show higher engraftment of human tumor lines and NK cells as compared to NOD-SCID mice. A 
Either lysis buffer or a cell lysate from 1*105 cells transduced with pBabe-puro-eGFP-2A-CBGr99 were subjected to an in 
vitro luciferase quantification assay. Plotted is the mean ± SD (n = 2) of the RLU/s. One of two experiments is shown. B 
NOD-SCID or NSG mice have been left untreated or were irradiated 1 day prior to the  i.v. injection of 5*105 SK-Mel-28 cells 
transduced with pBabe-puro-eGFP-2A-CBGr99. Shown are the respective acquired images on day 7 (left panel) and the 
quantification of the signals (right panel) as mean ± SD (n =2). C NOD-SCID or NSG mice have been irradiated 4 hours prior 
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to the i.v. injection of either 1.75*106 (NOD-SCID) or 0.7*106 NK cells (NSG) that have been activated with 20 ng/ml IL-15 for 
16 hours. Until the end of the experiment on day 4 (NOD-SCID) or 6 (NSG), the mice received daily i.p. injections of 20.000 
IU IL-2. Shown is the percentage of human NKp46+ cells amongst living cells. w/o without, * p < 0.05, *** p < 0.001 
(student’s t-test). 
However, the in vitro generated data do not clarify if the cells are suitable for in vivo applications. We 
thus next investigated, if the transduced cells generate a detectable signal in vivo, what the most 
permissive mouse strain for human tumor and NK cell engraftment is and if pre-conditioning by 
whole body irradiation is necessary for successful xenotransplantion. We therefore injected 5*105 
SK-Mel-28 transduced with pBabe-puro-eGFP-2A-CBGr99 i.v. into either NOD-SCID or NSG (complete 
name NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice that either received or not 3.5 Gy whole body irradiation 
one day prior to tumor injection. NSG mice were derived from NOD-SCID mice by The Jackson 
Laboratory by breeding in a null-allele for the interleukin-2 receptor gamma chain (IL2Rγ). As both 
strains lack adaptive immunity and show no complement activity and various defects in innate 
immunity, for example reduced DC and macrophage function they are both widely used in 
xenotransplantation experiments333–335. Due to the lack of the common γ-chain receptor NSG 
compared to NOD-SCID mice in addition show various defects in cytokine signaling (affected are IL-2, 
-4, -7, -9, -15 and -21). Most importantly, they are void of murine NK cells that can potentially reject 
xenotransplanted cells in NOD-SCID mice. In line with that, it was shown that tumor cells and 
hematopoietic stem cells engraft more potently in NSG mice333,336. 
As shown in figure 6.2 B, NSG mice engrafted tumor cell lines with higher efficiency compared to 
NOD-SCID mice as detected by luciferase quantification, regardless if the mice have been irradiated 
or not. Systemic irradiation with 3.5 Gy was enhancing the tumor take to a significant degree in these 
animals. Of note, we observed the same engraftment promoting effect of γ-irradiation on tumor 
engraftment in NOD-SCID mice when we increased the tumor dosage (data not shown). 
Most importantly, as shown in figure 6.2 C, NSG mice were also able to engraft human NK cells more 
potently as compared to NOD-SCID mice. Of note, the injected cell numbers for IL-15- and 
IL-12/15/18-stimulated NK cells were not the same, as depicted in the figure legend. However, as 
fewer injected NK cells persisted better in the blood of NSG compared to NOD-SCID mice after a 
longer time in vivo, we concluded that NSG mice are superior to NOD-SCID mice in terms of 
engrafting adoptively transferred human NK cells. Since also tumor cells engrafted more potently 
most of the experiments shown were performed with NSG mice unless stated differently. 
To determine if γ-irradiation prior to i.v. tumor injection also impacts the survival of recipient 
animals, we injected untreated or irradiated NOD-SCID mice i.v. with melanoma cell lines. As shown 
in figure 6.3 A, pre-conditioning with γ-irradiation of the animals decreased the survival time of 
recipient mice, most likely due to a higher tumor take. Also, only animals that have received 
irradiation showed macroscopically visible metastases on the lungs (data not shown). 
As some of the planned experiments required subcutaneous tumor inoculation, we injected 
Ma-Mel-86b cells subcutaneously into either γ-irradiated (3.5 Gy) or unirradiated NOD-SCID mice and 
recorded the tumor growth. As compared to i.v. tumor cell inoculation, irradiation in this model was 
showing detrimental effects in terms of tumor growth (figure 6.3 B). Until three weeks after the 
injection the tumor was hard to palp in animals that have received 3.5 Gy of total body irradiation. At 
this time the unirradiated group already showed a tumor size of almost 1 cm3. These data were 
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highly reproducible and in any experiment that required a subcutaneous tumor injection the animals 
thus were not irradiated prior to tumor cell injection. 
 
 
6.1.3 Characterization of melanoma target cell lines 
As discussed previously, melanoma cells often show critical down-regulation of HLA class I expression 
compared to healthy tissue337,338. This leads to diminished T cell recognition but also to less inhibition 
of tumor infiltrating NK cells rendering them attractive targets for NK cell-based immunotherapy. 
After we have screened multiple lines, we have decided to use Ma-Mel-86b, SK-Mel-28 and 
UKRV-Mel-02 based on growth behavior and the expression levels of activating and inhibitory 
ligands.  
The most important activating and inhibitory ligands were analyzed by flow cytometry. The ligand 
profile of the three lines is shown in figure 6.4 A. Of note, all cell lines expressed high levels of 
DNAM-1-ligands and detectable levels of NKp44-ligands with SK-Mel-28 being the only MHC class 
I-positive cell line. The expression of DNAM-1- and NKp44-ligands were of particular importance as a 
previous report showed that the DNAM-1-DNAM-1-ligand and the NCR-NCR-ligand axes substantially 
contributed to the control of melanoma growth in vivo171.  
To investigate if the observed phenotype translates into a solid NK cell-activation upon tumor cell 
contact, 51Cr release assays were performed that, compared to CD107a mobilization assay, 
quantitatively detect target cell killing.  As shown in figure 6.4 B the MHC class I-negative cell lines 
Ma-Mel-86b and UKRV-Mel-02 exhibited comparably little donor to donor variability whereas the 
killing of SK-Mel-28 substantially varied between different donors, possibly due to the KIR 
heterogeneity in between varying donors339,340. 
 
Figure 6.3 – Irradiation promotes tumor engraftment after 
intravenous, but delays tumor growth after subcutaneous injection. A 
The indicated doses of the used melanoma cell lines were injected i.v. 
into NOD-SCID mice that have been irradiated one day prior to injection 
or have been left unirradiated (n = 3-5/group). Shown is the percent 
survival. ** p < 0.01 (Mantel-Cox). B NOD-SCID mice (n = 4/group) have 
been left unirradiated or were irradiated with 3.5 Gy one day prior to 
s.c. injection of the indicated dose of Ma-Mel-86b cells.  
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Figure 6.4 – Characterization of activating and inhibitory ligands on three melanoma lines and their susceptibility 
towards NK cell mediated lysis. A Staining of various activating ligands and MHC I levels on the three melanoma cell lines 
Ma-Mel-86b, SK-Mel-28 and UKRV-Mel-02. The grey filled signal is derived from the respective isotype staining and the red 
line represents the specific staining as indicated. All stainings have at least been repeated once. B 51Cr release assay with NK 
cells activated with 200 IU IL-2/ml for 1-3 days. Shown is the mean ± SD (n = 3). In total 5 – 12 donors have been tested. 
 
6.1.4 Titration of CBGr99-transduced tumor lines for intravenous injection 
As shown in figure 6.2 B the melanoma cells upon transduction with the 
pBabe-puro-eGFP-2A-CBGr99 plasmid were producing a detectable luminescent signal in the lungs of 
NSG mice upon i.v. injection. However, as ultimately the model needs to display the anti-tumor 
effect of adoptively transferred NK cells the correlation of the detected BLI with the amount of tumor 
cells was determined. Therefore, various doses of the CBGr99-transduced melanoma lines 
Ma-Mel-86b and SK-Mel-28 were injected i.v. into irradiated NSG mice and the BLI was detected 
three days after tumor cell inoculation.   
As shown in figure 6.5 A-C differences in the tumor load could be accurately detected despite the 
low resolution of the imaging modality. Both lines tested showed a satisfying degree of linearity 
between the tumor load and the respective signal intensity as depicted by the r2 value (figure 6.5 C). 
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Figure 6.5– The quantification of the BLI correlates with the tumor load in vivo. A 1-3 NSG mice per group have been 
irradiated with 3.5 Gy 4 hours prior to the injection of various doses of CBGr99-transduced Ma-Mel-86b or SK-Mel-28. The 
images shown were acquired 3 days after the injection. B Quantification of A. Shown is the mean ± SD of the BLI (n = 1-3). C 
Linear regression of respective tumor dosage - BLI datasets. 
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6.2 Improved NK cell surveillance of CX3CL1-positive tumors 
6.2.1 Identification of the CX3CL1-CX3CR1 axis as a potential tool for immunotherapy 
One of the possibilities to improve existing NK cell-based immunotherapy strategies against 
malignant disease that needs more investigation is the targeted attraction of cytotoxic effector NK 
cells into tumor tissue. As described previously, NK cells are not a homogenous cell population but  
consist of the CD56dim CD16+ subset and the CD56bright CD16- subset with the CD56dim subset 
comprising approximately 90% of the peripheral blood NK cells186. As in the context of malignant 
disease often a) little NK cell infiltration can be observed341 with b) most of the infiltrating cells 
belonging to the CD56bright NK cell subset220,221,342, we wanted to identify a suitable chemokine that is 
able to potently attract the CD56dim subset in order to restore full NK cell immune-competence in 
situ. Of note, the CD56dim subset has been reported to exert more cytotoxic functions whereas the 
CD56bright subset classically produces higher levels of various cytokines205,343. 
As several reports were showing that CX3CL1 is one of the chemokines that attracts the CD56dim 
subset with high specificity, we stained purified human NK cells during culture in IL-2 containing 
medium at various timepoints for CX3CR1 and analyzed its expression on the two subsets210. 
 
Figure 6.6 – The CD56dim NK cell subset exclusively expresses CX3CR1 and migrates towards recombinant CX3CL1. 
Do-plots depict the staining of CD56 and CX3CR1 or the respective isotype on NK cells, which have been activated with 200 
IU/ml IL-2 for one day. One representative of 5 donors is shown. B Shown is the mean ± SD of the percentage of 
CX3CR1-positive cells in the indicated subpopulations (n=4-6). C Shown is the mean ± SD of the MFI of CX3CR1 for the 
individual NK cell subpopulations (n=4-6). D Transwell migration assay of NK cells activated for 1 or 5 days with IL-2 (200 
IU/ml) against recombinant CX3CL1. Shown is the mean ± SD (n = 3) of the specific migration. One representative out of 6 
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similarily performed experiments is shown. E NK cells have been activated for one day with 200 IU/ml IL-2 and were used in 
a transwell migration assay against 1 ng/ml of CX3CL1. Migrated cells were stained and quantified. Shown is the mean ± SD 
of the specific migration calculated individually for the two subsets (n = 3). One representative out of 7 donors is shown. F 
Purified NK cells have been used in a trans-endothelium migration assay and the migrated cells were stained and assigned 
to the two main populations. Shown is the mean ± SD of the specific migration as % of input (n = 3) of one representative 
out of 3 donors. n.d., not detectable. ** p < 0.01, *** p < 0.001 (student’s t-test). 
As shown in figure 6.6 A-C, CX3CR1 indeed was expressed exclusively on the CD56dim subset. Of note, 
the MFI of CX3CR1 dramatically decreased during culture and although the percentage of 
CX3CR1-positive cells virtually remained stable (figure 6.6 B) the MFI, correlating to the 
CX3CR1-density on the cells, dropped substantially (figure 6.6 C). This finding seems to be generally 
applicable to short term exposure of NK cells to activating cytokines such as IL-2, IL-15, IL-12 or 
IL-18344. Accordingly, we tested if the migration of NK cells is affected after culture periods of 1 or 5 
days in IL-2 containing medium. Thus, we performed transwell-migration assays and the specific 
migration of NK cells towards CX3CL1 was determined. Figure 6.6 D shows that short in vitro culture 
periods maintained the specific migration towards CX3CL1 whereas NK cells cultured for 5 days or 
longer showed a significant decrease in CX3CR1-expression and thus in their migratory response 
towards CX3CL1. We found that NK cells despite the partial loss of CX3CR1 during the culture 
migrated equally well towards CX3CL1 as compared to naїve NK cells for up to three days (data not 
shown). Therefore, we cultured NK cells for a maximum of two days in IL-2 when they were used in in 
vitro or in vivo migration assays. 
Ultimately, we tested if the NK cells that migrated towards CX3CL1 truly belonged to the CD56dim 
CD16+ subset. Therefore, we performed transwell migration assays and stained the migrated cells for 
CD56 and CD16. The migrated NK cells were assigned to one of the populations based on their 
expression levels of the two markers (figure 6.6 E) and the specific migration of each subpopulation 
was calculated (also refer to materials and methods). As shown in figure 6.6 E, as compared to 
stromal cell-derived factor-1α (SDF-1α, systematic name CXCL12), a chemokine known to induce the 
migration of all NK cells, CX3CL1 specifically attracted the CD56dim subset of NK cells. We next went 
on to also test if recombinant CX3CL1 is able to recruit NK cells through a dense layer of endothelial 
cells (human umbilical vein endothelial cells, HUVEC) while maintaining the specificity for the CD56dim 
subset. As shown in figure 6.6 F CD56dim NK cells indeed were attracted towards CX3CL1 through 
endothelial cells although to a lesser extent as compared to the transwell assay without the HUVEC 
layer (figure 6.6 E). 
As we wanted to identify more than one suitable chemokine, we went on and evaluated CXCR1/2 
and CXCR3 in terms of subset distribution and their potential to attract the CD56dim CD16+ NK cell 
subset. CXCR1 and CXCR2 were of interest, as a publication by Campbell et al. showed that their 
cognate ligand CXCL8 exclusively attracted the CD56dim subset210. Furthermore, Marco Wendel, a 
former PhD student from our group, identified the CXCR3-CXCL9/10/11-axis as being crucial for NK 
cell mediated tumor control in a murine tumor model94. Thus, we also evaluated the expression of 
this receptor on human NK cells. 
As shown in figure 6.7 A and B, the receptors for CXCL8 were indeed expressed exclusively on the 
CD56dim cells, enabling specifically this subset to migrate in a dose dependent manner towards 
various concentrations of CXCL8.  
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Figure 6.7 – Human CXCL8 but not CXCL10 specifically attracts CD56dim CD16+ NK cells. A Purified human NK cells after 
overnight culture in 200 IU/ml IL-2 were stained for CXCR1 and CXCR2 or with the respective isotype control antibodies. 
Shown is one representative donor out of eight. B Purified human NK cells have been cultured overnight in 200 IU/ml IL-2 
and were used in a transwell migration assay against various doses of human CXCL8. Migrated cells were stained and 
assigned to the CD56dim CD16+ or to the CD56bright CD16- subset as described before. Shown is the mean ± SD (n = 2) of the 
specific migration of all NK cells (left panel) or the specific migration of the individual subsets (right panel). C Purified 
human NK cells after 3 days in culture in 200 IU/ml IL-2 have been stained for CXCR3 or with the respective isotype control 
antibody. Shown is one representative donor out of eight. D The experiment was performed as described under B. The NK 
cells have been cultured for three days with 200 IU/ml of IL-2.  Shown is the mean ± SD (n = 2) of the specific migration of 
one out of two donors. *** p < 0.001 (student’s t-test). 
Importantly, CXCL8, especially under hypoxic conditions, has been reported to mediate 
pro-tumorigenic functions in terms of tumor cell invasion, migration but also angiogenesis93.  As 
therefore, the overexpression of CXCL8 potentially exerts tumor-promoting effects we decided to 
select CX3CL1 for our experiments.  
Compared to CXCR1/2, the expression of CXCR3 was more specific for the CD56bright subsets with only 
a subpopulation of CD56dim NK cells expressing the receptor (Figure 6.7 C). Accordingly, only few 
CD56dim NK cells got attracted (figure 6.7 D). These data are in line with a report, showing that 
human CD56bright cells are similar to murine CXCR3+ CD27bright cells345. In the murine model, the 
majority of circulating NK cells expresses this receptor which is why it was found to be crucial for 
mediating NK cell attraction into solid transplanted tumors94. Compared to this study, only around 
10% of human NK cells in the peripheral blood express this receptor (figure 6.7 C). Thus, we excluded 
CXCR3 in our experiments.  
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6.2.2  CX3CL1-expression during tumor progression 
After the identification of CX3CL1 as a suitable chemokine to attract CD56dim CD16+ NK cells, we 
searched databases and gene arrays for information about how the expression levels of this 
chemokine either change during tumor progression or if the in situ levels differ from neighboring 
healthy tissue. Interestingly, Hyakudomi et al. investigated tissue sections of 158 patients with gastric 
adenocarcinoma346. They found that CX3CL1 levels were showing a significant positive correlation 
with the size of the CD8+ T cell and NK cell infiltrate and further that the CX3CL1high cohort had a 
significantly better prognosis as compared to the CX3CL1low group in terms of diseasae-free survival 
(figure 6.8 A). 
 
Figure 6.8 – CX3CL1 in various cancer entities frequently gets down-regulated as compared to healthy control tissue. A 
Modified figure 2 from Hyakudomi et al.. Increased expression of CX3CL1 is correlated with a better prognosis and an 
increased number of both CD8+ T cells and natural killer cells in gastric adenocarcinoma (Hyakkudomi Annals of surgical 
oncology 2008; 15(6): 1775–82). B-E CX3CL1-expression was evaluated in GDS datasets in the GEO database. Individual 
samples are presented as dots whereas the bars represent the mean ± SD. The data are derived from GDS1375 (melanoma), 
GDS1439 (prostate cancer), GDS3324 (mammary carcinoma) and GDS1650 (pulmonary adenocarcinoma). Malign., 
malignant. * p < 0.05, ** p < 0.01, *** p < 0.001 (student’s t-test). 
Notably, for several cancer entities the analysis of datasets published in the GEO database revealed 
that CX3CL1 frequently gets down-regulated during malignant transformation or tumor progression 
(figure 6.8 B-E). This is potentially indicative of a tumor immunoescape mechanism by which tumor 
cells are trying to avoid the infiltration and subsequent attack by immune effector cells. However, 
the effects of CX3CL1 might vary from entity to entity or even from patient to patient since, for 
instance, the analysis of cervical cancer samples did not show any change in CX3CL1 levels compared 
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to healthy tissue (GDS3233) and colorectal carcinoma (GDS2947) or renal cell carcinoma (GDS2881) 
even showed elevated levels of CX3CL1 as compared to healthy tissue (data not shown).  
  
6.2.3 Soluble CX3CL1 does not activate NK cells 
Various publications show that chemokines, amongst others MIP-1α, MCP-1 and RANTES, can trigger 
activation and/or proliferation of naїve human NK cells86,347. Furthermore, it has been published that 
some chemokines like CCL19 and CCL21 only exerted a beneficial effect when a primary proliferation 
stimulus such as IL-2 was present347. Therefore, we tested if soluble recombinant CX3CL1 affects NK 
cell proliferation or if increased levels of the activation marker CD69 could be detected after 
chemokine addition into the culture medium. As shown in figure 6.9 A CX3CL1 was not able to 
increase the proliferation of purified human NK cells as detected by CFSE dilution, regardless if IL-2 
was present or not. This held true for either of the two tested concentrations of recombinant 
CX3CL1. We furthermore stained NK cells for CD69. However, no significant regulation of the 
activation marker was detectable (figure 6.9 B). 
 
 
 
Figure 6.9 – Recombinant soluble CX3CL1 does not activate NK cells. A Purified NK cells have been labeled with 2 µM CFSE 
and were cultured either in the presence or absence of 200 IU/ml IL-2 for the indicated times with or without either 1 or 
100 ng/ml of recombinant CX3CL1. Plotted is the acquired CFSE signal (left panel) or the expression level of CD69 (right 
panel) for the indicated conditions. Shown is one representative out of two donors. B NK cells cultured as described under 
A were withdrawn from the culture and stained either for CD69 or with the respective isotype control antibody. Plotted is 
the MFI of CD69 corrected for the isotype expression. One of two donors is shown. C Purified NK cells have been 
pre-activated over night with IL-2 or IL-2 plus 100 ng/ml CX3CL1. Ma-Mel-86b melanoma cells were used as targets and 
plotted is the mean ± SD of the specific lysis. D Human NK cells were left untreated over night and were short-term 
activated on the next day for 2 hours with either 200 IU/ml IL-2 or 10 ng/ml CX3CL1. The CX3CL1 concentration during the 
kill was adjusted to 10 ng/ml. Shown is one of three target lines. 
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Since it was also shown that soluble CX3CL1 was able to increase lysis of cellular targets, we 
performed several 51Cr release assays to see if melanoma cell lines are lysed more efficiently in the 
presence of CX3CL186,87,348. As shown in figure 6.9 C and D, soluble CX3CL1 neither increased the 
killing of NK cells when IL-2 was present as a primary stimulus nor did it activate naїve NK cells 
compared to the control medium level. The same held true for various cell lines, including amongst 
others K562 and UKRV-Mel-02 (data not shown).  
 
 
6.2.4 Generation of CX3CL1-overexpressing cell lines 
Since we demonstrated that CX3CL1 exclusively attracted the CD56dim subset and that its expression 
was reported to a correlate with longer disease-free survival for some cancer entities, we concluded 
that CX3CL1 is a suitable chemokine for overexpression studies. Thus, next we cloned the full-length 
CX3CL1 gene into a retroviral vector for overexpression. As depicted in figure 6.10 A, the 
pGEM-T-CX3CL1 vector and the retroviral pMX-neo backbone were digested with BamHI and XhoI 
and the CX3CL1-ORF was ligated into pMX-neo. The resulting pMX-neo-CX3CL1 or the empty 
pMX-neo vector were subsequently used for super-infection of the three previously introduced 
melanoma cell lines (figure 6.4) that were already transduced with pBabe-puro-eGFP-2A-CBGr99.  
 
 
Figure 6.10 - Cloning strategy for pMX-neo-CX3CL1. A The full length ORF for human CX3CL1 was amplified via PCR using 
the pDONR construct provided by the core facility for genomics at the DKFZ as a template introducing BamHI and XhoI 
restriction sites 5` and 3’ respectively. The PCR product got ligated into the pGEM-T vector according to the manufacturer’s 
protocol. The destination backbone pMX-neo got cut with BamHI and XhoI as was the pGEM-T-CX3CL1 vector and the 
CX3CL1 gene was ligated into the backbone. B Transduced and G418-selected cell lines (all of which were transduced with 
pBabe-puro-eGFP-2A-CBGr99 previously) were stained for CX3CL1. The grey signal represents the staining of the vector 
control cells and the red line represents the staining of the pMX-neo-CX3CL1 cells. One representative out of two 
experiments is shown. 
As shown in figure 6.10 B, all three tumor cell lines showed a high and uniform expression of CX3CL1 
without sorting as determined by FACS staining for the membrane-bound chemokine. 
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6.2.5 Characterization of CX3CL1-overexpressing cell lines 
To determine if the transductants as created under 6.2.4 are also capable of shedding CX3CL1 from 
the cell surface, thus producing the chemotactic form of the protein, supernatant of vector control 
cells or the CX3CL1-overexpressing lines was harvested. The CX3CL1-concentrations were measured 
with an ELISA. As shown in figure 6.11 A for two tumor lines, melanoma cells were able to shed 
CX3CL1. We next adjusted the supernatant to the determined ideal dose of CX3CL1 for NK cell 
attraction of 1 ng/ml (figure 6.6 D) and used the diluted supernatant for a transwell-migration assay 
to investigate if the expressed chemokine was biologically active. As depicted in figure 6.11 B, the 
adjusted supernatant exerted a potent in vitro chemoattraction with high specificity for the CD56dim 
CD16+ NK cell subset. 
 
 
Figure 6.11 – CX3CL1-expressing melanoma cells shed CX3CL1 which potently attracts NK cells while exhibiting similar 
growth behavior in vitro compared to vector control cells. A 1*106 cells of the indicated cell lines were seeded in RPMI cell 
culture medium. 24 hours later the medium was removed and replaced by migration medium for further 24 hours. A 
CX3CL1-ELISA was performed according to the manufacturer’s instructions using cell-free supernatant. Plotted is the mean 
± SD of the concentration of soluble CX3CL1 (n=2). B Supernatants created as described were adjusted to the ideal 
concentration of CX3CL1 of 1 ng/ml with migration medium and used in transwell migration assays. Plotted is the mean ± 
SD of the specific migration of the indicated NK cell subsets (n=2). C Staining of Ma-Mel-86b and SK-Mel-28 for CX3CR1 or 
with the respective isotype control antibody. One of two experiments is shown. D Parental Ma-Mel-86b and SK-Mel-28 or 
the indicated transductants were seeded at 1.000 cells/well in a 96-well plate. AlamarBlueTM reagent was added and the 
absorbance at 571 nm was detected after 24 and 48 hours. Shown is the mean ± SD (n=5). ** p < 0.01, *** p < 0.001 
(student’s t test). 
 
As discussed previously, various chemokines have been investigated for their capability to induce 
growth or migration of tumor cells93,107,349. In order to exclude similar effects in our system, we 
stained all three lines for the receptor of CX3CL1, CX3CR1, and did not detect expression (figure 6.11 
C and data not shown). Accordingly, an effect on tumor growth could be observed with neither 
Ma-Mel-86b nor SK-Mel-28 (figure 6.11 D) nor with UKRV-Mel-02 (data not shown). Of note, upon 
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intravenous injection of equal numbers of vector control- or CX3CL1-transduced cells the BLI signals 
from time to time were different for the two transductants (data not shown).  
 
 
6.2.6 In vitro killing of CX3CL1-overexpressing cell lines 
As shown in figure 6.9 C and D, exogenously added soluble CX3CL1 did not elevate NK mediated 
killing of tumor targets. However, it also has been reported that cell lines expressing 
membrane-bound CX3CL1 were killed significantly better as compared to their CX3CL1-negative 
controls and in addition induced higher levels of IFN-γ in NK cells350,351. This was due to an increased 
adhesion of CX3CR1-positive NK cells to CX3CL1-bearing targets. We thus set up 51Cr release assays to 
test if our transductants expressing membrane-bound CX3CL1 were inducing higher cytotoxicity by 
IL-2 activated NK cells. However, of three cell lines we found only Ma-Mel-86b to be stronger killed 
upon CX3CL1-overexpression (figure 6.12). Of note, Ma-Mel-86b cells seemed to exhibit the highest 
expression of CX3CL1 of the three cell lines (figure 6.10 B).  
 
Figure 6.12 – CX3CL1-expression does not increase killing of melanoma cell lines. Human purified NK cells have been 
activated with IL-2 for 16 hours and were used at the indicated E:T ratios against vector control or CX3CL1-transduced 
melanoma cells in 51Cr release assays. Plotted is the mean ± SD of the specific lysis (n = 3). One representative of three 
donors is shown. ** p < 0.01.  
 
 
6.2.7 In vivo homing of intravenously injected NK cells to subcutaneous tumors 
In a next step, we investigated if the overexpression of CX3CL1 in melanoma cells could mediate the 
migration of adoptively transferred NK cells in vivo into tumor tissue. As previously described for 
various malignancies, the level of CX3CL1-expression showed a correlation with the degree of NK cell 
infiltration in the tumors of cancer patients110,346. As it was shown in a murine model of lymphoma 
that the growth of CX3CL1-overexpressing cells was controlled better as compared to control cells, 
we aimed at showing a) a higher accumulation of adoptively transferred NK cells in 
CX3CL1-overexpressing tumors and b) a more pronounced control of tumor growth in vivo in a 
xenograft model upon CX3CL1-expression112. The results of one of the approaches are depicted in 
figure 6.13. Upon injection of a tumor/matrigel-mixture, the tumor cells were allowed to settle and 
to engraft for 7 days in order to establish a tumor. After irradiation, NK cells were injected i.v. and 
supplemented in vivo with daily i.p. injections of IL-2 until the end of the experiment. We irradiated 
the mice as a) we have seen previously that irradiation is an important pre-conditioning regimen that 
led to substantial colonization of NSG mice with adoptively transferred NK cells (figure 6.2 C) and b) 
several reports indicate that γ-irradiation activates endothelial cells in terms of up-regulated levels of 
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ICAM-1, VCAM-1 and E-selectin thus supporting the adhesion and transmigration of lymphocytes352–
354. 
 
When we analyzed serum and tumor samples of the respective animals we found that serum 
samples only displayed slightly elevated levels of CX3CL1 in animals bearing CX3CL1-positive tumors. 
The tumor biopsies however showed a substantial enrichment of CX3CL1 compared to controls 
(figure 6.13 A). As chemokine receptors are known to be internalized upon engagement of their 
respective ligands, blood cells were analyzed via flow cytometry for CX3CR1-levels to see if 
circulating NK cells still expressed this receptor71. As depicted in figure 6.13 B, NK cells from animals 
that were transplanted with the CX3CL1-overexpressing tumor cells surprisingly – despite only 
slightly elevated serum levels of soluble CX3CL1 – almost entirely lost CX3CR1-expression. As NK cells 
from vector control injected animals still expressed high levels of CX3CR1 (figure 6.13 B), high dose 
IL-2 in vivo compared to in vitro, if at all, only moderately decreased CX3CR1 levels. 
 
 
Figure 6.13 – NK cells do not infiltrate into subcutaneous tumors regardless of CX3CL1-expression. 3 mice per group were 
injected subcutaneously with a 1:1 mixture of 3.3*106 SK-Mel-28 melanoma cells (vector control and CX3CL1) with matrigel. 
7 days later all mice received 2*106 NK cells (activated o.n. with 20 IU/ml IL-2) via intravenous injection 4 hours after total 
body irradiation (3.5 Gy) and 20.000 IU IL-2 i.p. per day until their sacrifice after 2 days. A Serum (from 100 µl blood) or 
tumor lysates (from pieces of 45 mg) were prepared and tested for CX3CL1 levels with a CX3CL1-ELISA according to the 
manufacturer’s instructions. Shown is the mean ± SD of the concentration of CX3CL1 (n=2). B Blood cells were either 
stained for CX3CR1 or with the respective isotype control. Gates were set on human CD45+, CD3- and 7AAD- cells. Shown is 
the mean ± SD of the MFI of CX3CR1 corrected for the isotype expression level (n=3). C and D Blood (200 µl) was 
heparinized and spleens and tumors were prepared as a single cell suspension counted and stained for various markers. 
Shown is the mean ± SD of the percentage of 7AAD- CD3- CD45+ cells of total living cells (n=3) (C) and the absolute cell 
number of cells with the same marker combination (n=3) (D). *** p < 0.001 (student’s t-test). 
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We next stained spleen, tumor and blood cells for human NK cell markers to determine their fraction 
amongst living cells via flow cytometry. With these percentages, in addition the absolute numbers of 
NK cells in the investigated organs were calculated. As shown in figure 6.13 C and D, neither in terms 
of percentages nor in terms of numbers a difference could be found in blood, spleen and the tumors. 
Most importantly, the tumors – vector control (VC)- and CX3CL1-transduced - were displaying a 
virtual absence of NK cells. We therefore next tested a different route of administering NK cells. 
 
 
6.2.8 In vivo homing of perilesionally injected NK cells to subcutaneous tumors 
As the intravenous injection of NK cells in several experiments did not allow for NK cell infiltration 
into subcutaneous tumors (figure 6.13 and data not shown), we performed an experiment in which 
the NK cells were administered subcutaneously approximately 1 cm away from the tumor injection 
site (figure 6.14). This setup was chosen as incompatibility between murine (endothelial and 
interstitial cells) and human (NK cells) adhesion molecules might be one explanation for the absence 
of NK cells in the tumors in the previous experiments. Further, some publications indicate that 
perilesional effector cell injections in xenograft experiments can lead to tumor control355,356.  
 
Figure 6.14 – NK cells do not migrate into solid subcutaneous tumors upon perilesional injection. 4 mice per group were 
subcutaneously injected with a 1:1 mixture of matrigel and 3*106 Ma-Mel-86b melanoma cells (vector control or 
CX3CL1-overexpressing). 4 days after the injection the mice received a single subcutaneous perilesional injection (ca. 1 cm 
distance to the tumor) of 1.5*106 naїve NK cells 4 hours after irradiation with 3.5 Gy. The next three days the animals 
received 20.000 IU IL-2 i.p. and were sacrificed 6 days after the NK cell injection. A and B 400 µl of heparinized blood or 
single cell suspensions of spleens and tumors were counted and stained for various human antigens. Human NK cells were 
defined as CD3- , 7AAD-, CD45+ cells. Shown is the mean ± SD of the percentage of human NK cells in living cells (A, n=4) and 
the absolute cell number of human NK cells in blood, spleens and tumors (B, n=4). VC, vector control. 
 
However, as shown in figure 6.14, this setup did not allow for the detection of intra-tumoral human 
NK cells. Like in figure 6.13, the adoptively transferred NK cells were detected in blood and spleen. 
Notably, the tumors were excised carefully and including  the close surrounding tissue – the stroma –
as it was shown that infiltrating cells, although being attracted to the tumor often reside in proximity 
to but not in the tumor tissue357. 
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6.2.9 Tumor control in vivo mediated by IL-2 activated NK cells 
As adoptively transferred human NK cells were not detected in subcutaneously growing tumors, we 
did not detect an anti-tumor effect of the transferred NK cells in subcutaneously growing tumors in 
vivo (figures 6.13, 6.14 and data not shown). We thus changed our setup and in a next step and 
injected the tumor cells intravenously. As compared to the subcutaneous injection of a high number 
of tumor cells, the intravenous injection of few tumor cells artificially mimics metastatic disease in 
which single, disseminated tumor cells are transported in the blood or lymph stream to the site of 
metastasis. Of note, this model is more likely to monitor NK cell mediated effects as NK cells are 
thought to contribute more to the control of small tumors, hematological malignancies and 
metastasizing cells as compared to large solid tumors358,359. 
 
In order to set up the experiment, we used the pBabe-puro-eGFP-2A-CBGr99 transductants that 
were generated earlier in the project (figure 6.1, 6.2 and 6.5) and injected them i.v. into irradiated 
NSG mice. In a first step, IL-2-activated NK cells and a constant dose of luciferase-positive 
CX3CL1-negative Ma-Mel-86b were injected at different E:T ratios to find a ratio at which vector 
control cells are controlled by the co-injected NK cells but still leave a substantial tumor load (figure 
6.15). 
 
Figure 6.15 – IL-2-activated NK cells upon co-injection with tumor cells decrease the tumor-load in a dose-dependent 
manner. 4 hours after total body irradiation with 3.5 Gy 7*105 Ma-Mel-86b cells transduced with 
pBabe-puro-eGFP-2A-CBGr99 and pMX-neo were injected i.v. together with IL-2-activated NK cells (2 days activated with 
200 IU/ml IL-2) at the indicated E:T ratios. The signals were quantified and plotted as mean ± SD (n=2). 
 
As depicted, with increasing E:T ratios the tumor engraftment in the lungs as detected by BLI 
subsequently decreased (figure 6.15). Based on this experiment we decided to inject NK cells at a 1:2 
E:T ratio in the following experiments. 
 
 
6.2.10 Impact of CX3CL1-expression on NK cell-mediated tumor control 
In order to investigate if CX3CL1-expression in a metastatic disease model can increase the efficacy of 
adoptively transferred NK cells, identical numbers of either vector control- or CX3CL1-transduced 
Ma-Mel-86b cells were injected together with IL-2-activated NK cells at an E:T ratio of 1:2 i.v. into 
irradiated NSG mice. 
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Figure 6.16 – CX3CL1-expression in vivo enhances NK-mediated tumor control. 4 hours after 3.5 Gy WBI 7*105 
Ma-Mel-86b vector control- or CX3CL1-transduced Ma-Mel-86b were injected i.v. into NSG mice. NK cells that were 
activated with 200 IU/ml IL-2 for two days were co-injected at a 1:2 E:T ratio. A Shown is the BLI after 8 days of the animals 
(left panel) and the mean ± SD of the signal (n=2-3, right panel). B Shown is the mean ± SD of the % growth inhibition by NK 
cells as compared to PBS control animals (n=2-3). ctrl., control; VC, vector control, * p < 0.05 (student’s t-test). 
As depicted in figure 6.16 A, both target lines engrafted less efficiently when NK cells were 
co-injected. As displayed, the Ma-Mel-86b cell line showed varying BLIs for the vector control and the 
CX3CL1-expressing line, although they were injected at similar numbers. Yet, a quantification of the 
absolute values of the BLI revealed that only the CX3CL1-expressing cell line was killed to a significant 
degree by the NK cells (figure 6.16 A). Thus, we plotted the % of the BLI decrease under the influence 
of NK cells relative to the PBS control animals (figure 6.16 B). As shown, although not significant, a 
strikingly lower tumor burden was observed, when the tumor cells were expressing CX3CL1. 
We also performed this experiment with SK-Mel-28 melanoma cells. Of note, this cell line did not 
exhibit more pronounced killing in vitro upon CX3CL1-overexpression (figure 6.12). We co-injected 
the same ratio of IL-2-activated NK cells as previously for the Ma-Mel-86b cells and acquired the 
bioluminescent signals after 4 days (figure 6.17 A). As shown, IL-2-activated NK cells exerted a 
significant decrease of the tumor load as detected by BLI regardless of CX3CL1-expression. Of note, 
CX3CL1-expressing tumor cells did not show a more pronounced growth inhibition by NK cells 
compared to vector control cells when compared to PBS treated animals (figure 6.17 B). In order to 
investigate if CX3CL1 was able to recruit more NK cells into the respective lung tissue, we sacrificed 
the animals on day 4 after the injection and prepared single cell suspensions out of spleens and lungs 
which we stained for human NK cells. As shown in figure 6.17 C, we observed less NK cells in blood 
samples and in spleens of animals that were injected with CX3CL1-overexpressing SK-Mel-28 
compared to vector control cells. Importantly, in the lungs of three out of 4 animals that have been 
injected with CX3CL1high SK-Mel-28 we detected almost twice as many NK cells when compared to 
vector control cells. Exemplary dot plots are shown in figure 6.17 D. In addition, we were staining 
blood NK cells for CX3CR1 to see if circulating cells in this model down-regulated CX3CR1 similarly as 
observed for the subcutaneous model (figure 6.13). Of note, NK cells of all mice still expressed 
CX3CR1 at high levels, thus enabling them to home towards CX3CL1-expressing cells (figure 6.17 E). 
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Figure 6.17 – CX3CL1-expression increases NK cell infiltration into tumor-harboring lungs. NSG mice were irradiated with 
3.5 Gy 4 hours prior to the i.v. injection of SK-Mel-28 vector control- or CX3CL1-transductants. NK cells that have been 
activated with 200 IU/ml IL-2 for two days were co-injected at a 1:2 E:T ratio. A Shown is the BLI 4 days after injection (left 
panel) and the mean ± SD of the signal (n=2-4, right panel). B Shown is the mean ± SD (n = 2-4) of the percentage of human 
NK cells amongst living cells and the absolute cell numbers of human NK cells (defined as 7-AAD-, CD45+, CD3-). C 
Representative dot plots showing the elevated levels of NK cells in single cell suspensions obtained from lungs. D 
Percentage of CX3CR1-positive NK cells amongst blood cells. Shown is the mean ± SD (n = 2-4). * p < 0.05, ** p < 0.01. 
 
 
 
 
IL-12/15/18-stimulated NK cells for anti-tumor immunotherapy Results 77 
6.3  Evaluation of IL-12/15/18-activated NK cells for anti-tumor 
immunotherapy 
6.3.1 In vitro characterization of IL-12/15/18-stimulated NK cells 
In 2009, Cooper et al. published a report showing that NK cells as part of the innate immune system 
memorized their history of stimulation, enabling them to react stronger upon secondary challenge284. 
This study was in line with an earlier report from O’Leary et al., who were demonstrating in a model 
of contact hypersensitivity response that NK cells were able to show elevated secondary or 
memory-like immune responses against the same antigen that was used to ‘immunize’ them288. 
However, the mode of activation of the NK cells remained unclear, the memory-like function was 
only assigned to hepatic NK cells and most importantly it remained elusive if memory formation was 
NK cell intrinsic. Compared to this study the finding by Cooper and colleagues seemed to be more 
relevant for tumor therapy as splenic NK cells upon a short pulse with IL-12/15/18 were displaying 
elevated reactivity not only against the antigen used for initial priming but against various stimuli 
such as plate-bound α-NK1.1, α-Ly49H or cytokine re-stimulation with IL-12 and IL-15284. 
As to this point no data on the effects of a mixture of IL-12, IL-15 and IL-18 on human NK cells have 
been reported, we set up experiments like schematically displayed in figure 6.18 A. 
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Figure 6.18 – IL-12/15/18-stimulated NK cells show higher IL-2 dependent proliferation in vitro, maintaining a higher 
responsiveness towards various stimuli. A Schematic representation of the experimental setup. B Staining of IL-15- and 
IL-12/15/18-stimulated NK cells for CD25 (left panel) and CD16 (right panel). Grey, filled signals represent the isotype 
stainings, red lines the respective specific staining. Data are representative of at least 8 donors. C mRNA expression levels of 
CD25 and CD16. Data were extracted from the GEO dataset GSE22919360. Plotted is the mean ± SD of relative expression 
values (n=2). D CFSE dilution of IL-15- or IL-12/15/18-stimulated NK cells at various timepoints during culture with 100 
IU/ml of IL-2. Data are representative of 4 donors. E Plotted is the mean ± SD of the absolute cell number/well at various 
timepoints during culture. Data are representative of 6 donors. F Quantification of IFN-γ either directly after the pulse or 
after re-stimulation with either 10 ng/ml IL-12 and 50 ng/ml of IL-15 or K562 at a 1:1 E:T ratio after 4 and 8 days in culture. 
Plotted is the mean ± SD of the IFN-γ concentration as detected by ELISA (n=2). Data are representative of 4 donors. * p < 
0.05, ** p < 0.01, *** p < 0.001 (student’s t-test). 
Based on experiments performed by Jing Ni from our group in a C57Bl/6 model we prolonged the 
pulse from 13-15 hours (Cooper protocol) to up to 16 hours and analyzed the surface expression of 
various receptors. Of note, the IL-2 receptor α-chain (CD25) got highly up-regulated whereas the 
FcγRIII CD16 was substantially down-regulated on protein level after 16 hours on IL-12/15/18- 
compared to IL-15-stimulated NK cells (figure 6.18 B). In addition, we analyzed the expression levels 
in a publically available dataset in which Smith et al. performed  gene-array analysis to detect 
differences between naїve NK cells and NK cells after a 24 hour pulse with IL-12/2/18 (GEO data set, 
accession number GSE22919)360. Of note, according to their activation protocol they have used 100 
IU/ml IL-2 instead of 20 ng/ml IL-15 and the pulse lasted for 24 instead of 16 hours in our protocols. 
Still, a strong induction of CD25 and a decrease in CD16 transcript levels could be detected when 
comparing naïve with cytokine-pulsed NK cells (figure 6.18 C), thus confirming our findings. 
CD25 represents the α-chain of the IL-2 receptor and upon expression increases the sensitivity of the 
low affinity IL-2 receptor consisting of CD122 and CD132 to IL-2 by decreasing the Kd of the receptor 
complex and IL-2361. Therefore, we asked if the elevated level of CD25 impacts IL-2 driven NK cell 
proliferation. In a next step, we thus labeled NK cells after the pulse with CFSE and cultured them in 
medium containing 100 IU/ml of IL-2. As shown in figure 6.18 D and E CD25high 
IL-12/15/18-stimulated NK cells diluted CFSE more quickly during culture and hence number wise 
outgrew the IL-15-stimulated control cells. Most importantly, the IL-12/15/18-stimulated NK cells 
maintained an imprint of the cytokine stimulation and reacted stronger upon stimulation with a 
combination of IL-12 and IL-15 or K562 cells in terms of IFN-γ production 4 and 8 days after the pulse 
(figure 6.18 F). These data indicate that human IL-12/15/18-stimulated NK cells react with substantial 
proliferation towards IL-2 while maintaining a more pronounced reactivity in terms of IFN-γ 
production287. Of note, the TNF-α levels were also strongly increased after the pulse (data not 
shown). 
 
6.3.2 In vivo characterization of IL-12/15/18-stimulated NK cells 
In order to test if the effects that we have seen in vitro (figure 6.18) also relate to an in vivo situation, 
we designed an adoptive transfer experiment which is schematically outlined in figure 6.19 A. As 
depicted, after the stimulation the NK cells were labeled with CFSE prior to injection to later on 
measure for proliferation in various organs. In order to provide the transplanted NK cells with a 
survival factor and proliferation stimulus, we injected the mice on a daily basis i.p with recombinant 
IL-2 or PBS as a control. Importantly, also in vivo IL-12/15/18-stimulated NK cells upon IL-2 
supplementation proliferated more pronouncedly (figure 6.19 B). This could only be seen when IL-2 
IL-12/15/18-stimulated NK cells for anti-tumor immunotherapy Results 79 
was injected. In PBS treated animals, no proliferation could be detected after 6 days as detected by 
CFSE dilution (data not shown). 
 
Figure 6.19 – IL-12/15/18-stimulated NK cells proliferate faster in vivo showing an elevated IFN-γ response upon ex vivo 
re-stimulation. A Schematic representation of the experimental setup. B CFSE dilution of IL-15 or IL-12/15/18-stimulated 
NK cells (CD45+, CD3-, 7AAD-) in various organs 6 days after the injection. Data are representative of 3 donors. C Detection 
of living human NK cells (CD45+, CD3-, 7AAD-) 6 days after injection in indicated organs. Plotted is one value for PBS and IL-2 
injected mice each. Data are representative of 3 donors. D Ex vivo restimulation of blood cells with either medium, IL-12/15 
or K562 cells. Plotted is the mean ± SD of the IFN-γ concentration extra-polated for 50.000 NK cells (n=2). * p < 0.05, ** p < 
0.01 (student’s t-test). 
As the differences in CFSE dilution not necessarily have to translate into higher cell numbers in vivo 
for instance due to different apoptosis rates, we also determined the percentages of human NK cells 
in single cell suspensions obtained from the indicated organs (figure 6.19 C). Importantly, for all 
samples analyzed, the percentages of human NK cells were higher in animals that have received 
IL-12/15/18- compared to IL-15-stimulated NK cells. However, the survival and the proliferation were 
critically dependent on IL-2. Upon substitution of the IL-2 with PBS only few NK cells were recovered 
that did not show substantial CFSE dilution (figure 6.19 C and data not shown).  
One of the striking features of the IL-12/15/18-stimulated NK cells was their elevated response 
compared to control cells upon re-challenge with either IL-12 and IL-15 or with K562 cells several 
days after the cytokine pulse (figure 6.18 F). To see if also after the transient injection into the 
bloodstream of NSG mice the cells maintained this elevated responsiveness, we used whole blood 
cells 6 days after the injection of recipient mice and challenged them with the same stimuli as 
compared to the in vitro data. Strikingly, as shown in figure 6.19 D, also after being xenotransplanted 
into animals and persisting in the circulation for 6 days the elevated IFN-γ response of 
IL-12/15/18-activated NK cells over IL-15-stimulated NK cells was maintained. 
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6.3.3 Cytotoxicity of IL-15- and IL-12/15/18-stimulated NK cells 
Up to this point, the responses of IL-12/15/18- compared to IL-15-activated NK cells were 
investigated in the context of cytokine production. In a next step, we performed various 51Cr release 
assays to determine if the stimulation with Il-12/15/18 also directly impacts cytotoxicity towards a 
panel of various tumor targets. Of note, in the panel presented in figure 6.20, Ma-Mel-86b is the only 
line lacking MHC class I-expression whereas the other lines express MHC class I at various levels (data 
not shown). 
 
Figure 6.20 – IL-12/15/18-stimulated NK cells show significantly higher killing of various target cell lines in vitro. IL-15- 
and IL-12/15/18-stimulated NK cells were tested in standard 4 hour 51Cr release assays against various MHC I positive and 
negative cell lines. A A549 lung adenocarcinoma B HCT116 colon carcinoma C U937 histiocytic lymphoma D Ma-Mel-86b 
melanoma E SK-Mel-28 melanoma, a representative kill plot is displayed on the left panel and pooled data for 7 donors on 
the right panel. Plotted is the mean ± SD (n=3) of the specific lysis [%]. Data are representative of at least 2 donors. * p < 
0.05, ** p < 0.01, *** p < 0.001. 
As depicted in figure 6.20 A-E for every cell line tested, short term IL-12/15/18-stimulated NK cells at 
almost every E:T ratio exhibited a significantly stronger lysis as compared to NK cells that have only 
been activated with IL-15. Some reports pointed out already that IL-18 and IL-12 can elicit more 
potent cytotoxic responses of either murine or human NK cells or are important to generate fully 
functional NK cells142,145,146,362. However, the used concentrations were different and none of the 
reports has investigated cytotoxicity of human NK cells in a setting in which the cytokines created a 
memory-like phenotype. 
 
6.3.4  Impact of IL-12/15/18-stimulation on KIR-expression on NK cells 
As shown in figure 6.20, we observed increased killing of virtually any tumor target in 51Cr release 
assays by IL-12/15/18- compared to IL-15-stimulated NK cells. We therefore asked, if this is due to an 
increased expression of activating or due to a decreased expression of inhibitory receptors or 
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molecules. Of note, two studies reported that signaling via IL-12 and IL-18 did not impact the 
expression levels of KIR molecules or slightly increase them363,364. However, the Chrul et al. data were 
generated using IL-2 instead of IL-15 and the data from Romee et al. using different concentrations of 
IL-15 and IL-18 as compared to our setup. Also the latter group was using NK cells that have been 
rested in IL-2 for 7 days. Thus, we analyzed cultures that received the cytokine pulse for either 16 or 
a prolonged period of 60 hours and stained these cultures together with naїve cells for flow 
cytometric analysis for KIR2DL1/S1, KIR2DL2/L3 or KIR3DL1 specific antibodies, KIRs that are present 
on virtually all caucasoid individuals365. As shown in figure 6.21 A and B, already after 16 hours a 
small but reproducible down-regulation of KIR2DL2/L3 was detectable that got more pronounced 
after 60 hours.  
Figure 6.21 – IL12/15/18 signaling decreases expression levels of various KIRs. A Representative (n=11) flow cytometric 
staining of one donor for CD56 and KIR2DL2/L3 after indicated times of stimulation.  B Cumulative data for three donors of 
one experiment. Shown is the mean ± SD of the percentage of KIR2DL2/L3-positive cells (left part) and the MFI of 
KIR2DL2/L3 of the positive population. One dot represents one donor. C Staining of indicated KIRs on purified NK cells after 
16 or D 60 hours of IL-12/15/18- or IL-15-stimulation (n=10-11). Corresponding cells from one donor are connected with a 
line. E mRNA expression levels of indicated KIRs of either naїve NK cells or cells that were treated for 24 hours with 10 
ng/ml of IL12, 100 IU/ml IL-2 and 100 ng/ml of IL-18. Data were extracted from the GEO dataset GSE22919360. Plotted is the 
mean ± SD of relative expression values (n=2). 
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Of note, the IL-12/15/18-stimulated cells exhibited substantially increased autofluorescence. The 
isotype control staining depicted in figure 6.21. A thus indicates that the IL-12/15/18-stimulated NK 
cells of this donor indeed virtually lost the expression of KIR2DL2/L3. Figure 6.21 B summarizes the 
findings of three donors of one experiment. Shown are the percentages of the KIR2DL2/L3-positive 
cells and the MFI of the positive population for the two timepoints analyzed. We concluded that 
KIR2DL2/L3, especially after prolonged stimulation periods, gets down-regulated by inflammatory 
cytokine signaling. Notably, after a 16 hour pulse and 6 days in IL-2 containing medium the KIR levels 
of IL-15- and IL-12/15/18-stimulated NK cells were similar thus arguing for a highly reversible 
mechanism. 
We further analyzed the expression of KIR2DL1/S1 and KIR3DL1. As shown cumulatively for multiple 
donors in figure 6.21 C (stimulation for 16 hours) and D (stimulation for 60 hours), after 16 hours 
usually the MFI for various KIRs already decreased whereas after 60 hours a robust reproducible 
down-regulation of all three investigated KIRs was detectable on the level of percentage of positive 
cells as well as on the MFI level. 
Furthermore, we looked the respective KIR genes up in the GEO dataset GSE22919 as described360. 
Importantly, after a 24 hour pulse with IL-12, IL-2 and IL-18 the NK cells used in the gene array of 
Smith et al. showed highly decreased mRNA levels for KIR2DL1, KIR2DL2, KIR2DL3 and KIR3DL1, 
substantiating our findings (figure 6.21 E).  
Together these data indicate that joint signaling by IL-12, IL-15 and IL-18 could represent a so far 
un-appreciated mechanism of KIR regulation. 
 
6.3.5 Regulation of activating receptors by IL-12/15/18 signaling  
As remarkable changes in the expression profile of three inhibitory KIR molecules were detected 
(figure 6.21) we extended the phenotypical analysis of IL-12/15/18-stimulated NK cells also towards 
the most important activating receptors. We analyzed cell surface expression levels of activating 
receptors on purified NK cells via flow cytometry on either naїve cells or after 16 or 60 hours of 
stimulation with either IL-15 or IL-12/15/18. The impact of inflammatory cytokines on the expression 
of activating receptors has been elucidated for some receptors and some cytokines. For instance, 
NKG2D expression has been reported to be up-regulated by IL-2 as are most of the other important 
NK cell activating receptors239,366,367. As an exemplary negative regulator, TGF- β has been shown to 
down-regulate NKp30, NKp44, NKG2D and DNAM-1239.  However, only little information is available 
on the regulation of activating NK receptors in the context of IL-12/15/18-stimulation. One exception 
is the influence of the three cytokines on NKp80 expression. Klimosch et al. recently reported that 
upon stimulation of freshly isolated NK cells with IL-12/15/18 NKp80 gets significantly 
down-regulated174. 
As shown in figure 6.22, the level of almost every receptor analyzed was changed after 16 (figure 
6.22 A) and 60 hours (figure 6.22 B) of stimulation in terms of the percentage of  cells staining 
positive for it and in terms of the MFI of the positive population. In addition, we were looking for the 
respective transcript levels in the GEO dataset GSE22919 as described360. Of note, with the exception 
of NKp44 and NKp46 the up-regulation of DNAM-1 and the down-regulations of NKG2D, NKp30, 
NKp80 and CX3CR1 could also be seen on mRNA level (figure 6.22 C). 
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Figure 6.22 – The expression of activating NK receptors is regulated by IL-12/15/18. Purified human NK cells were treated 
with either IL-15 or IL-12/15/18 and stained for the indicated activating receptors after 16 (A) or 60 hours (B). Plotted are 
the percentages of positive cells (upper panel of A and B) and the MFI of the positive population (lower panel A and B). 
Corresponding cells from one donor are connected with a line (n=2-5). C mRNA expression levels of indicated activating 
receptors. Data were extracted from the GEO dataset GSE22919360. Plotted is the mean ± SD of relative expression values 
(n=2). 
As we observed that in general the effect of IL-12/15/18-stimulation on various activating and 
inhibitory receptors was more pronounced after 60 hours as compared to 16 hours (figure 6.21 and 
figure 6.22), we were hypothesizing that the killing of target cells would be even more elevated after 
60 hours compared to 16 hours of cytokine stimulation (figure 6.20). However, IL-12/15/18- 
compared to IL-15-stimulated NK cells did not exhibit elevated levels of cytotoxicity as observed after 
16 hours of stimulation (figure 6.20 and figure 6.23). 
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6.3.6 Impact of decreased levels of KIR2DL2/L3 on NK cell functionality 
Since we detected decreased levels of several important inhibitory receptors after the stimulation 
with IL-12/15/18, we investigated if this phenomenon contributes to an enhanced recognition of 
MHC class I-positive tumor cell lines in vitro (figure 6.20 and figure 6.21). To see, if the reduced levels 
of KIR2DL2/L3 are causative for an elevated response against targets harboring the cognate ligands 
(i.e. HLA-C1-positive targets), we performed CD107a mobilization assays against 721.221 cells that 
have been transduced with various HLA class I molecules that were kindly provided by Prof. Dr. 
Carsten Watzl (IfADO, Dortmund). The mutant 721.221 (short 221) lymphoblastoid cell line per se 
does not exhibit any HLA class I-expression but is able to express selected HLA molecules upon 
transfection of the respective heavy chain368. Therefore, this model line has been widely used in 
assays where only distinct, selected HLA alleles were needed to be expressed on a target cell line. 
The various 221 cell lines were stained for pan MHC class I-expression and analyzed via flow 
cytometry (figure 6.24 A). As depicted, compared to the parental mutant 221 cells all cell lines 
transduced with one HLA class I molecule showed de novo surface expression of HLA class I exhibiting 
different expression levels. These 221 lines were used together with Ma-Mel-86b and SK-Mel-28 cells 
in a CD107a degranulation assay with NK cells that have been stimulated for 16 hours with either 
IL-15 or Il-12/15/18. Of note, Ma-Mel-86b and 221 cells did not express HLA class I molecules (figure 
6.4 and 6.24), whereas SK-Mel-28 expressed HLA-Cw*03 as ligand for KIR2DL2/L3. 221 cells 
expressing HLA-Cw*03 and -Cw*07 harboring the C1-epitope expressed a cognate ligand for 
KIR2DL2/L3 whereas HLA-Cw*04 and –Cw*15 expressing 221s bear the C2-epitope and thus are 
ligands for KIR2DL1. 
Importantly, the 16 hour pre-treatment with IL-12/15/18 reduced the surface expression of 
KIR2DL2/L3 to a significant degree (figure 6.24 B). Also, the analysis of the bulk NK cell population 
showed that NK cells that have been stimulated with IL-12/15/18 compared to NK cells that have 
only seen IL-15 showed significantly higher CD107a-mobilization regardless of the target cell line in 
line with cytotoxicity assays performed after 16 hours of stimulation (figure 6.20 and figure 6.24 C). 
Therefore, we decided to refer to the degranulation of KIR2DL2/L3-negative NK cells as an internal 
standard to assess the impact of KIR regulation on KIR2DL2/L3-positive cells.  
Figure 6.23 – IL-12/15/18-stimulated NK cells do not exhibit more 
pronounced killing of melanoma cells after 60 hours of stimulation. 
Purified NK cells were stimulated for 60 hours with IL-15 or IL-12/15/18 
and used in 51Cr release assays against SK-Mel-28 targets. Shown is the 
mean ± SD of the specific lysis (n = 3). One representative of 2 donors is 
shown. 
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Figure 6.24 – Decreased KIR2DL2/L3-expression correlates to increased reactivity of IL-12/15/18-stimulated NK cells 
towards HLA C1-expressing target cells. A Detection of total HLA class I on 721.221 cells transduced with indicated HLA C 
alleles. The grey filled signal represents the isotype staining, the red line the specific HLA staining. B Shown is the mean ± SD 
of the percentage of KIR2DL2/L3-positive cells (left part) and of the MFI of the KIR2DL2/L3-positive population (right part). 
Values were withdrawn from the stainings after the CD107a mobilization assay. C Shown is the mean ± SD of 
CD107a-positive NK cells (CD3-, CD45bright, CD56+) after a 4 hour CD107a mobilization assay (n=3). D Representative gating 
for detecting CD107a-positive KIR2DL2/L3 subsets (left part). Mean ± SD of the % of response of KIR2DL2/L3-positive NK 
cells compared to KIR2DL2/L3-negative NK cells (n=3). ** p < 0.01, *** p < 0.001 (student’s t-test). 
Co-staining of KIR2DL2/L3 and CD107a allowed for the detection of degranulating NK cells in both 
KIR2DL2/L3-positive and -negative subsets (figure 6.24 D, left part). Setting the percentage of 
CD107a-positive cells from the KIR2DL2/L3-negative subset to 100% created an internal standard 
against which the KIR2DL2/L3-positive cells could be compared. As shown in figure 6.24 D (right 
part), when no MHC class I was expressed by target cells (221 and Ma-Mel-86b) or HLA-alleles that 
do not bind to KIR2DL2/L3 (221 Cw*15) KIR2DL2/L3-positive cells reacted equally well regardless of 
the expression levels of the KIR (i.e. independent of the stimulation). However, when target cells 
expressed relevant ligands for KIR2DL2/L3 (Cw*03 on SK-Mel-28 and Cw*07 on 221 Cw*07), the 
KIR2DL2/L3-positive NK cells exhibited less CD107a mobilization. Most importantly, 
IL-12/15/18-activated NK cells showed a significantly smaller drop in degranulation compared to 
IL-15-activated NK cells, indicating that cytokine-mediated reduction of KIR levels allowed them to 
decrease inhibition by self thus creating a slightly increased reactivity towards target cells expressing 
the respective inhibitory ligands. 
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 6.3.7 In vivo killing of IL-12/15/18-stimulated NK cells 
Ultimately, we tested if IL-12/15/18-stimulated NK cells exhibit stronger tumor-control in an in vivo 
xenograft model of melanoma. Thus, in a first experiment a constant dose of SK-Mel-28 melanoma 
cells (transduced as described) was injected i.v. into NSG mice together with varying doses of 16 hour 
IL-15-stimulated NK cells (figure 6.25 A). As shown, the NK cells controlled the tumor load of 
melanoma cells in the lungs in a dose-dependent way. 
 
Figure 6.25 – IL-12/15/18- compared to IL-15-stimulated NK cells upon co-injection decrease the tumor load of SK-Mel-28 
melanoma cells to a higher degree. A 7*105 SK-Mel-28 melanoma cells transduced with pBabe-puro-eGFP-2A-CBGr99 were 
injected together with 16 hour IL-15-stimulated NK cells at the indicated E:T ratios i.v. into irradiated NSG mice. The BLI was 
determined 8 days after the injections. B Irradiated NSG mice were injected with 7*105 SK-Mel-28 melanoma cells 
transduced with pBabe-puro-eGFP-2A-CBGr99 and either IL-15 or IL-12/15/18-stimulated NK cells (16 hour pulse) at a 1:2 
E:T ratio. 8 days after the injection the BLI was determined. Shown are the acquired images of the mice (left panel) and the 
mean ± SD of the BLI (n=2-3). One of two experiments is shown. n.s. not significant, * p < 0.05 (student’s t-test). 
At the E:T ratio of 1:2 IL-15-stimulated NK cells were able to control the tumor engraftment to some 
extent but still left a significant tumor load. We thus decided to use that E:T ratio in the next 
experiments. Finally, as shown in figure 6.25 B, NK cells that have been stimulated with IL-12/15/18 
decreased the tumor load to a significant degree in this experimental setup compared to 
IL-15-stimulated NK cells. 
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7 DISCUSSION 
 
Melanoma and other neoplasia are classically treated with chemotherapy, γ-irradiation and, most 
importantly, surgery. These classical treatment regimens often are not applicable, such as surgery, or 
can cause severe side-effects in healthy tissue due to a non-specific mode of action. In this context, 
cancer patients could benefit substantially from immunotherapy as the immune system harbors 
many potent and, most importantly, highly specific effector cells such as CD8-positive CTLs, NK cells 
or γδ T cells that are known to lyse tumor cells efficiently in vitro and in vivo369–371. 
To focus on malignant melanoma, several studies have been performed, in which multiple aspects of 
immunotherapy have been investigated: 
- Antibody therapy – for instance monoclonal antibodies (mAbs) against tumor-specific 
antigens inducing ADCC or mAbs blocking immunoregulatory molecules, for example CTLA-4 
and/or PD-1372–375;   
- Vaccination – tumor antigens are delivered for example as peptides only, intact protein, DNA 
or mRNA coding for the respective antigens or peptides exogenously loaded on DCs376,377; 
- Cytokine therapy, for instance IL-2, IFN-α or IL-21378,379; 
- Adoptive transfer of effector cells, for instance CD8-positive T or NK cells229,380. 
Most of the studies focused on cells of the adaptive immune system, mostly T cells, leaving several 
key questions unaddressed that potentially could improve immunotherapeutical strategies 
harnessing NK cells. However, it is known from epidemiological studies that NK cells contribute to the 
control of human malignant disease216. In line with that, the amount of NK cell infiltration into the 
tumor tissue has been proposed to be a marker of beneficial prognosis, for instance, in squamous cell 
lung cancer, gastric adenocarcinoma or colorectal cancer217–219. Thus, we wanted to identify factors 
that potently attract NK cells into tumor tissue to enrich malignant tissue for cytotoxic effector cells. 
On the other hand, it has been shown that upon adoptive transfer of IL-2-activated NK cells the 
transferred cells rapidly lose their reactivity in vivo229. Hence, we aimed at the identification of new 
activation strategies that allow for a maintained reactivity of the transferred cells.  
Both approaches hold great promise for NK cell-based tumor immunotherapy. 
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7.1  Establishment of xenograft mouse models of melanoma 
In order to perform relevant in vivo experiments, two models of tumor xenotransplantation were 
established. To analyze homing of adoptively transferred NK cells, we set up s.c. injections of human 
melanoma cell lines and evaluated pre-conditioning regimens in two different immunocompromised 
mouse strains. In addition, we aimed at introducing a model of i.v. tumor injection with the 
possibility for optical imaging. Since tumor cells upon i.v. injection mimic artificially metastatic 
disease an experimental tumor model was created that is known to be controlled to some extent by 
NK cells358,359.  
Establishing the models, we observed a beneficial effect of γ-irradiation on tumor engraftment upon 
i.v. transfer of tumor cells (figure 6.2 B and 6.3 A). One of several reasons, for instance, could be the 
clearance of residual murine immune cells by the irradiation. In NSG mice, resident neutrophils, and 
monocytes but also defective macrophages and dendritic cells, potentially interfered with proper 
tumor engraftment. In NOD-SCID mice, in addition murine NK cells possibly caused a xeno-rejection 
of human cells. In line with the presence of additional immune effector cells in NOD-SCID compared 
to NSG mice, this mouse strain engrafted xenotransplanted cells in general less efficiently compared 
to NSGs (figure 6.2 B and C)333,336. In addition to the lymphodepleting effect, γ-irradiation has been 
shown to induce the release of the von Willebrand factor from EC381. Due to thrombus formations 
this could potentially facilitate clogging of the lung capillaries and thus assist tumor cells to get 
entrapped in the lung microvasculature thus increasing the engraftment382. Also, several adhesion 
molecules like ICAM-1 or VCAM-1 have been shown to be up-regulated on irradiated endothelial cells 
and might contribute to a higher rate of adhesion and subsequently engraftment of tumor cells in 
the lung353. These effects are not lung specific, but due to the tight vessels, the impact might be most 
pronounced in this organ. The reason for the observed lower tumor engraftment in irradiated 
animals after s.c. tumor injection (figure 6.3 B) on the other hand could be due to different effects of 
irradiation on skin- and lung-resident immune cells. Macrophages in the subcutis possibly still were 
present at the time of injection and eventually exhibited an irradiation-induced activated phenotype, 
thus clearing tumor cells. In the lungs on the other hand, the alveolar macrophages probably were 
already depleted at the same time or the effect of the endothelium activation was overcompensating 
for the macrophage activation. 
Also, we observed a better engraftment of SK-Mel-28 cells compared to Ma-Mel-86b cells, as 
detected by the BLI after injection of identical doses (figure 6.5). This effect could be derived from 
varying expression levels of the used CBGr99 luciferase, as detected in vitro (figure 6.2 A). Yet, also 
the bigger cell size of SK-Mel-28 compared to Ma-Mel-86b cells, as observed by microscopy and the 
forward scatter in flow cytometric analysis, might be a key factor determining the efficiency of 
engraftment. As the lung capillaries are the first narrow passage that cells have to pass upon i.v. 
injection, a bigger cell size confers a higher chance of clogging the lung endothelium and 
subsequently infiltrating into the tissue.  
We reported the successful establishment of subcutaneous and intravenous xenotransplantation 
protocols for human melanoma and NK cells. Importantly, we established a minimally invasive 
imaging modality, harnessing luciferase-based optical in vivo luminescent imaging. As previously 
reported, NSG mice in our study were a suitable mouse strain for performing these experiments. In 
addition, we reported that whole body irradiation improved tumor engraftment after i.v. injection of 
tumor cells but delayed the tumor growth after s.c. injections of melanoma cells. 
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7.2  CX3CL1 as a tool to attract NK cells into tumors 
NK cells are a heterogeous cell population consisting of at least two phenotypically and functionally 
distinct subsets, the CD56dim CD16+ and CD56bright CD16- NK cells125,205. Importantly, whereas the 
CD56dim CD16+ subset is considered to be the natural cytotoxic subset, displaying a more mature 
effector phenotype, it is mostly the CD56bright CD16- subset that can be detected in tumor 
tissue205,220,221,342,343. There are several explanations for the frequently observed, but poorly explored, 
accumulation of the less cytotoxic CD56bright subset in tumor tissues. Amongst others, a specific 
attraction of these cells or a better proliferation and/or survival of the CD56bright subset could be 
possible. Of note, some reports pointed towards a better survival of CD56bright NK cells compared to 
CD56dim cells in the tumor microenvironment due to a more pronounced resistance towards ROS 
which are typically enriched in proximity to and also directly in the tumor222. Also, in experiments 
performed with tumor supernatant we detected a preferential accumulation of the CD56bright subset 
(data not shown). Of note, it was recently shown that also CD56dim cells exerted pronounced cytokine 
secretion and that a CD56bright CD16+ subset was strongly involved in the control of melanoma growth 
in vivo203,383. Thus, it is not fully understood which subset might be more relevant for controlling 
tumor growth in vivo. However, in several studies that correlated NK cell infiltration and patient 
survival, NK cells were identified by the CD57 marker which is expressed on around 70% of all 
CD56dim NK cells. Still, a correlation could be found between the number of CD57-positive cells, i.e. a 
subset of CD56dim NK cells, and the survival of the patients206,217,219. This, together with the fact, that 
CD56bright NK cells in situ are often already present and CD56dim NK cells outnumber the CD56bright NK 
cells led us to aiming at recruiting preferentially the CD56dim subset into the tumors to restore full NK 
cell functionality of both subsets. 
 
7.2.1  The CX3CR1-CX3CL1 axis selectively recruits CD56dim NK cells 
As shown in the figures 6.6 and 6.11, CX3CL1 was shown to be a chemokine that exclusively 
attracted the CD56dim CD16+ NK cell subset. These findings confirmed published data about the 
chemoattracting specificities of CX3CL1210. Of note, recently a second ligand for CX3CR1 was 
published, CCL26, that was shown to cooperate with CX3CL1 for CX3CR1 triggering384,385. Yet, we 
were focusing on the CX3L1-CX3CR1 axis. Importantly, it further was reported that 
CX3CR1-expression on NK cells might be used as a marker to detect mature cytotoxic effector cells as 
the high expression of the chemokine receptor correlated with the expression of CD57 and low levels 
of CD62L and CD27344. Furthermore CX3CR1-positive NK cells or CD8+ T cells were reported to be 
more cytotoxic as compared to their CX3CR1-negative counterparts386,387. In line with these reports, 
our data indicated that all CD57-positive NK cells express the CX3CR1 receptor with CD57 
representing a marker for terminally differentiated effector immune cells (data not shown). Thus, 
attracting specifically this subset of NK cells, characterized by CX3CR1-expression, could be highly 
relevant for immunotherapeutic approaches of melanoma and malignant disease in general. Of note, 
the CX3CL1-CX3CR1 axis also could play an important role for attracting effector cells of the adaptive 
immune system such as CX3CR1-positive CTLs, thus harboring the potential to recruit cytotoxic cells 
from both branches of the immune system. 
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7.2.2  Effects of CX3CL1 on tumor cells and on NK cell reactivity 
As already introduced in 6.2.2, it is difficult to exclude side effects of chemokines that might promote 
tumor growth. Notably, various chemokines have been described to also act on tumor cells and in 
many cases promoted tumor outgrowth and metastasis92. In several studies also CX3CL1 has been 
shown to exert pro-tumorigenic effects, for instance, in prostate or breast cancer (mouse and 
human) and pancreatic ductal adenocarcinoma107,109,388,389. So Shulby et al. showed that CX3CR1 can 
be expressed by prostate cancer cells, subsequently supporting their invasion into bone marrow. 
Also, CX3CL1 upon binding to CX3CR1-positive tumor cells elicited PI3K/AKT survival pathway 
signaling, indicating the potential danger of chemokine-signalling in tumor cells107. Similarly, a study 
from Tsang et al. showed that, in a cohort of 753 breast cancer patients, the high expression of 
CX3CL1 - despite higher TIL levels - correlated with worse overall survival109. Conversely, another 
study on breast cancer - similar to the presented data in figure 6.8 A - showed that high levels of 
CX3CL1 were predictive of a good prognosis110. This would be in line with the fact that CX3CL1 was 
reported to be a direct target of p53, thus suggesting a role in tumor suppression111. Importantly, it 
has been demonstrated that high CX3CL1 levels in the tumor correlate with higher CTL and NK 
infiltration and thus with better prognosis110,390. This is also implied by the presented data in figure 
6.8 B-E that suggest that tumor cells possibly down-regulate CX3CL1-expression to escape attacks of 
the immune system. Yet, in a recent study it was shown in a spontaneous mouse model of mammary 
carcinoma that despite CX3CL1-down-regulation, adenoviral overexpression of CX3CL1 in situ 
enhanced tumor numbers in a dose dependent manner388. The example of these studies with 
controversial results shows the urgency to properly analyze patient material in terms of 
CX3CR1-expression and subsequently for responsiveness to CX3CL1 ex vivo to exclude adverse effects 
on tumor outgrowth and dissemination. As shown, all the melanoma cell lines we used lacked 
CX3CR1 and thus did not proliferate in response to CX3CL1 (figure 6.11 C and D and data not shown). 
Some chemokines have been reported to activate NK cells and/or to drive them into proliferation. In 
line with this, several studies reported that soluble recombinant348,350 as well as membrane-bound 
CX3CL1350,351 can increase NK cell mediated cytotoxicity to a significant degree. We thus performed 
experiments in which we investigated the impact of soluble CX3CL1 on the proliferation and 
cytotoxicity, as well as the influence of membrane-bound CX3CL1 on the cytotoxicity of NK cells 
(figures 6.9 and 6.12). We found that neither form of CX3CL1 activated naїve or IL-2-activated 
purified NK cells above the medium background. Only for the Ma-Mel-86b cell line a slight increase in 
killing could be found when membrane-bound CX3CL1 was expressed (figure 6.12). We thus 
performed control-experiments reproducing the published setup and we did not observe increased 
cytotoxicity. Still, we did not thoroughly exclude the possibility that CX3CR1 might be blocked by 
serum-components, for instance by serum-starvation of the NK cells. Remarkably, with similar media 
our migration assays worked thus excluding the presence of compounds abrogating CX3CL1-binding 
to CX3CR1 or the signaling of the receptor. 
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7.2.3  In vivo tumor models exploiting CX3CL1-expression 
7.2.3.1 Subcutaneous tumor injection 
To determine if overexpressed CX3CL1 attracts adoptively transferred human NK cells in vivo into 
tumor tissue, we performed animal experiments in the established mouse model of subcutaneous 
tumor transplantation (figures 6.3, 6.13, 6.14 and data not shown). Importantly, as evaluated by flow 
cytometry, we did not detect adoptively transferred human NK cells in the tumors. Transferred NK 
cells were defined as huCD45+ and huCD3- and were reliably stained in blood samples and spleens of 
the respective animals but not in the tumor plugs regardless of CX3CL1-expression. This held true for 
either intravenous or perilesional injection of NK cells (figures 6.13 and 6.14). Controversially, some 
reports demonstrated a therapeutical effect of adoptively transferred human NK cells against 
subcutaneously growing tumor cells or detected them in the tumor tissue391–393. Although 
incompatibilities between some human and murine adhesion molecules exist, in vivo tumor 
infiltration seem to be possible394. One issue in our experiments could be the injected NK cell 
numbers, since in some studies compared to our experiments up to 10 times more NK cells were 
injected. We cannot exclude that a certain NK cell count needs to be exceeded to allow for efficient 
extravasation of NK cells and their subsequent infiltration into transplanted tumors. However, as we 
used fresh or short-term cultured NK cells in our experiments we were restricted in this context. As 
NK-92, a well-characterized NK cell line, did not express CX3CR1 (data not shown) we will screen 
other lines to switch from polyclonal NK cells to large effector cell numbers using a NK cell line. 
Another difference compared to many published studies was that we used NSG mice in our 
experiments whereas most of the other groups used SCID or nude mice. However, since NSG mice 
are directly derived from NOD-SCID mice that have successfully been used for similar experiments, 
we have no explanation why we could not detect NK cells in the tumors. Of note, the discrepancy 
between cell homing and localization in human tissues, as compared to humanized mouse models, is 
one of the most important issues in pre-clinical mouse models395. 
 
7.2.3.2  Intravenous tumor injection 
As we did not detect an accumulation of adoptively transferred NK cells in subcutaneously 
transplanted human melanoma cell lines, we decided to switch to a model in which the tumor cells 
were injected i.v. to mimic metastatic disease (figure 6.2, 6.5, 6.15, 6.16 and 6.17). This approach 
potentially is advantageous since NK cells do not have to migrate through murine tissue, possibly 
struggling with incompatible adhesion molecules, but make contact with tumor target cells directly in 
the blood stream of the animals. Likewise, NK cells in a dose-dependent manner decreased the 
tumor load in the mice, an effect that we observed for Ma-Mel-86b and SK-Mel-28 melanoma cells 
with IL-2- as well as IL-15-stimulated NK cells (figure 6.15 and 6.25 A). Importantly, as shown in 
figure 6.16, we also observed a more pronounced rejection of CX3CL1-positive Ma-Mel-86b tumor 
cells compared to vector control cells. Controversially, with SK-Mel-28 melanoma cells we could not 
detect this preferential killing of the CX3CL1-expressing line (figure 6.17 A). Due to the sub-optimal 
condition in the tubes prior to the injection, a killing in vitro before the injection could be excluded. 
In line with this, in previous in vitro experiments, we did not observe increased killing of tumor cell 
lines expressing membrane-bound CX3CL1 (figure 6.12). Only Ma-Mel-86b cells out of three tested 
lines showed a small, yet significant increase of specific lysis in standard 51Cr release assays. Thus, a 
difference in in vitro killing seems to be indicative of a more pronounced NK cell-reactivity towards 
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CX3CL1-expressing targets in vivo. The reasons for this phenomenon remain elusive. Notably, 
expression levels of CX3CL1 seemed to be higher in Ma-Mel-86b compared to SK-Mel-28 cells (figure 
6.10). This possibly indicates that a certain threshold of CX3CL1-expression might exist that is 
decisive if NK cells can control CX3CL1-expressing targets in vivo to a higher degree. Other studies 
reported that membrane-bound CX3CL1 served as a bona fide adhesion molecule for 
CX3CR1-positive effector cells386. Thus, depending on the expression level of CX3CL1 this could 
increase the adhesion of NK cells to target cells under flow which subsequently can lead to a more 
frequent delivery of lytic hits and thus to a more pronounced control of tumor growth350. One further 
point to explain the discrepancy between Ma-Mel-86b and SK-Mel-28 could be that shedding of 
CX3CL1 by SK-Mel-28 cells is faster compared to Ma-Mel-86b cells. Importantly, the adhesion of NK 
cells to CX3CL1-coated membranes was shown to be highly blockable by soluble CX3CL1350. 
Therefore, faster shedding of CX3CL1 from SK-Mel-28 cells could have possibly decreased the 
adhesion of NK cells and thus annihilated the previously observed beneficial effect. In addition, 
Zhang et al. already proposed that the presence of further co-stimulatory or stimulatory signals on 
the target cells might be required to translate a CX3CL1bright phenotype into stronger killing by NK 
cells. Thus, Ma-Mel-86b cells compared to SK-Mel-28 cells might express another ligand that triggers 
a superior NK cell-response against CX3CL1-positive transductants. Further experiments with an 
increased panel of CX3CL1-expressing cells will be needed to clarify what the determinants for 
elevated NK cell-responses against CX3CL1bright targets in vitro and in vivo are. 
Importantly, we were able to demonstrate a higher infiltration of NK cells into the lungs of animals 
that were injected with CX3CL1high SK-Mel-28 cells compared to animals that were injected with 
vector control cells (figure 6.17 C and D). This experiment demonstrated that the over-expression of 
CX3CL1 in tumor cells in vivo can lead to the accumulation of adoptively transferred NK cells in 
tumor-harboring organs. Of note, we did not stain single cell suspensions of the lungs for the 
presence of NK cells when we used Ma-Mel-86b (figure 6.16). It is currently unknown to us why, 
despite a stronger infiltration of NK cells, CX3CL1-expressing SK-Mel-28 cells were not rejected more 
potently in vivo. Possibly, NK cells that infiltrated into the tumor-harboring lungs rapidly succumbed 
to immunosuppression by the tumor cells. As SK-Mel-28 cells got killed less efficiently compared to 
Ma-Mel-86b cells (figure 6.4) it is possible that NK cells have longer contact times with SK-Mel-28 
cells compared to Ma-Mel-86b cells and are thus more exposed to tumor-derived 
immunosuppressive factors, such as TGF-β. This could lead to a more pronounced inhibition of NK 
cells upon co-injection with SK-Mel-28 compared to Ma-Mel-86b cells enabling tumor growth in vivo 
regardless of NK cell infiltration. This hypothesis could be tested by supplementing the animals 
exogenously with high doses of NK cell-activating cytokines such as IL-2 or IL-15 which subsequently 
might translate the elevated NK cell numbers into a decreased tumor burden (figure 6.17 C and D). 
Of note, these data obtained from xenotransplantation experiments in general resemble the main 
observations after transfer of autologous IL-2-activated NK cells into melanoma patients. In both 
cases, adoptively transferred NK cells persisted but no beneficial effect was observed possibly due to 
suppression of NK cell responses by tumor-derived factors229.  
Notably, this model of co-injection is not a clinically relevant setting. Therefore, in a next step, we 
want to set up a therapeutical model in which the tumor cells will be injected prior to the NK cells 
and hence the NK cells will have to actively migrate to the vector control- or CX3CL1-transduced 
tumor cells. As pointed out, by supplementation with high dose IL-2 we will be able to more stably 
maintain the activation of the injected NK cells to get more conclusive results on the combinatorial 
effects of CX3CL1 gene therapy and the adoptive transfer of NK cells.  
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7.2.4  Aspects for clinical translation 
One possibility to translate these findings into clinics would be the expression of CX3CL1 in the 
cancer tissue of melanoma-bearing patients using genetically designed adenoviruses as vectors for 
gene therapy. By molecular biological means the replication of these viral vectors can be restricted to 
tumor cells396,397. This can be achieved by cloning genes essential for the replication of the virus 
behind a promoter that is, if possible, exclusively used in tumor cells. This technique allowed for the 
over-expression of certain molecules of interest that can subsequently modulate the tumor 
microenvironment to improve for instance immune cell infiltration or effector cell activation398. For 
the application in melanoma patients, for instance, a mutated E1A gene, which is essential for the 
replication of the virus, was cloned behind a tyrosinase promoter and was only expressed in cells 
exhibiting inactive pRb, thus allowing replication, oncolysis and also transgene-expression only in 
malignant tissue399. Thus, a melanoma-specific virus potentially could be created and armed with the 
full-length CX3CL1 gene to attract CD56dim NK cells into melanoma tissue. 
Most importantly, as discussed in 7.1.2, a thorough analysis of patient material ex vivo needs to be 
done in order to exclude growth or metastasis promoting effects of the chemokine. This analysis 
needs to include staining for CX3CR1 on the tumor cells and, if possible, an ex vivo proliferation and 
migration assay of tumor cells in the presence or absence of recombinant CX3CL1. 
Furthermore, CX3CL1 attracted exclusively CD16-positive NK cells. This is of particular interest as in 
several studies it has been shown that tumor infiltrating NK cells can exhibit decreased expression 
levels of several activating receptors rendering them inert towards activation by binding their 
cognate ligands. Despite this profound inhibition it has been shown for various cancer entities that 
ADCC mediated by the Fc receptor CD16 was not affected and remained functional without IL-2 
re-stimulation of tumor infiltrating NK cells. Therefore, the attraction of CD16-positive NK cells 
should ideally be combined with the application of tumor-antigen specific antibodies to possibly 
enhance the therapeutic effect of attracted endogenous or adoptively transferred NK cells229,320. 
Of note, besides NK cells also monocytes, Th1 CD4-positive T cells, CD8-positive CTLs and mast cells 
express CX3CR1, indicating that a broad panel of anti-tumor effector cells can get recruited to 
CX3CL1bright tumors400. Reports, which investigated T cell infiltration into melanoma metastases, 
suggested a critical role for CCL2-5 and CXCL9 and CXCL10401. These chemokines were identified by 
hierarchical clustering of gene expression of infiltrated and non-infiltrated metastases. Importantly, it 
is unclear if the expression correlated with a better prognosis. Moreover, as shown for CXCL10 
(figure 6.7) these chemokines do not always efficiently support the attraction of NK cells or other 
effector cells. Thus, the usage of CX3CL1 possibly provides the advantage of attracting multiple 
cytotoxic effector cells of various lineages such as CTLs, γδ T cells and T cells that express high levels 
of intracellular perforin and granzyme B386.  
We identified CX3CL1 as a promising candidate for immunotherapy attracting a broad array of 
ant-tumor effector cells. Importantly, the possibility of the attracted NK cells to mediate ADCC should 
be investigated in terms of combinatorial therapies, using NK cells and antibody therapy.  
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7.3 Evaluation of IL-12/15/18-stimulated human NK cells for anti-
tumor immunotherapy 
In in vitro assays, pre-clinical in vivo models and clinical trials it has been shown that NK cells are 
capable of controlling tumor growth. Further, several modes of activation have been evaluated in 
terms of identifying the prime regimen leading to a more pronounced and sustained activation of NK 
cells310,340. Some of the obtained results are summarized in the following table: 
Used mode of activation Important observation Entity Reference 
IL-2 Other strategies to augment persistence are needed 
Recurrent ovarian and breast 
carcinoma, melanoma 
229,402,403 
IL-15 (+ hydrocortisone) IL-2 and IL-15 both better than IL-7 
Advanced non-small cell lung 
cancer 
311,403 
IL-21 i.v. as bolus IL-21 is safe and induces higher cytotoxicity in vivo Melanoma and RCC 
379,404 
HSC KIR-HLA mismatch in GvH direction extremely beneficial  AML 
308 
IL-12/15/18 Pronounced proliferation, more sustained reactivity Lymphoma, leukemia 
287,363 
IL-12/15/18 Trial, start 09/2013 Relapsed and refractory AML NCT01898793 
  
Of note, it was recently published for a cohort of melanoma and renal cell carcinoma (RCC) patients 
that the infusion of pre-activated NK cells – activated ex vivo by IL-2 and irradiated autologous feeder 
cells - led to high numbers of circulating transferred NK cells, yet those cells did not show any clinical 
effect due to the rapid loss of responsiveness or activation in vivo229. Parkhurst et al. showed in this 
study that the expression levels of NKG2D on NK cells 1 week after the infusion into melanoma 
patients were down-regulated, explaining in part the decreased ex vivo reactivity against melanoma 
cell lines, unless the cells were re-activated with IL-2. Thus, regardless of the activation of NK cells 
prior to infusion, one major obstacle for successful NK cell-based immunotherapy is that the 
transferred NK cells often do not respond efficiently to tumors in vivo. This is partially due to the 
enrichment of immunosuppressive factors and cells in the tumor microenvironment. For instance, it 
was shown that Treg inhibit autologous or transferred NK cells at various levels or affect their 
recruitment to the tumor94,405,406. Also, elevated TGF-β or IL-10 serum levels in tumor patients can 
systemically down-regulate NKG2D and other activating receptors on NK cells leading to decreased 
responses against tumor cells239,367.  
These data support the need of a more sustained reactivity of the transferred NK cells or a blockade 
of inhibitory mechanisms to overcome various immunosuppressive factors in situ and thus to 
enhance the therapeutic effect of transferred NK cells. Repeated injections with high dose IL-2 have 
been shown to be partially efficient, however severe toxic side effects were observed leading to 
death in 1.5% of the patients due to capillary leak syndrome and thus organ failure296. IL-15 
compared to IL-2 seems to be less cytotoxic, does not activate Treg and especially in the complexed 
form with the IL-15Rα is a potent inducer of NK cell activation407,408. Therefore, it is currently being 
tested in clinical trials. Also, efforts have been made to break immunosuppressive 
microenvironments, for example by antibody-neutralization or blockade of molecules that reportedly 
contribute to immunosuppression, for instance VEGF or CTLA-4373,409,410. 
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7.3.1 Sustained effector function of IL-12/15/18-stimulated NK cells 
To overcome immunosuppressive mechanisms exerted on NK cells in vivo, we aimed at generating 
NK cells that maintain their reactivity after the primary activation. Therefore, we used IL-12/15/18 in 
combination to induce more potent effector cells based on a previous publication from Cooper et 
al.284. We showed that 16 hours of stimulation with IL-12/15/18 were sufficient to induce CD25 (IL-2R 
α)-up-regulation, a process that in murine NK cells was reported to be mainly dependent on IL-12411. 
The elevated expression of the IL-2R α-chain rendered IL-12/15/18-stimulated NK cells highly 
responsive to IL-2 yielding significantly higher cell recoveries after culture in IL-2 containing medium 
(figure 6.18). Importantly, not only the cell numbers were increased but also the levels of secreted 
IFN-γ upon restimulation were significantly higher compared to IL-15-stimulated NK cells (figure 6.18 
F)287. These data indicate that for a period of up to 8 days after the cytokine stimulation the cells 
were still functionally superior. Notably, CD4-positive T cells stimulated with plate-bound 
α-CD3/CD28 were also able to drive the preferential expansion of IL-12/15/18-stimulated NK cells 
and to maintain their significantly higher reactivity compared to IL-15-stimulated control cells (data 
not shown).  This was mostly due to the secretion of IL-2 upon stimulation. Remarkably, Romee et al. 
published similar findings in a highly related in vitro model of cytokine activation and 
restimulation363. Compared to our setup Romee et al. were using IL-15 for the culture of 
IL-12/15/18-stimulated NK cells. Of note, in earlier experiments we were also using IL-15 instead of 
IL-2 for the culture of stimulated NK cells and observed similar effects in terms of proliferation and 
IFN-γ production of NK cells (data not shown). This indicates that usage of the up-regulated IL-2R 
α-chain was not the exclusive mechanism that drove the proliferation of IL-12/15/18-stimulated NK 
cells and by which these maintained their higher reactivity. Importantly, no staining of the IL-15R 
α-chain CD215 was performed to compare the expression on IL-12/15/18- with IL-15-stimulated NK 
cells. However, since on the mRNA level the expression of the IL-15R α-chain, similarly to the IL-2R 
α-chain, was highly up-regulated (data not shown) it is likely that the sensitivity of 
IL-12/15/18-stimulated NK cells is higher towards both IL-2 and IL-15. Due to the similarity of the 
signaling pathways of IL-2 and IL-15, similar phenotypes were observed after culture of 
IL-12/15/18-stimulated NK cells in either IL-2 or IL-15. This could potentially be important, since IL-2 
in vivo is known to exert toxic side effects and to promote Treg expansion296,412. Importantly, we 
observed a more pronounced proliferation of IL-12/15/18-stimulated NK cells together with a 
stronger induction of IFN-γ upon restimulation also in an in vivo mouse model. We injected either 
IL-15 or Il-12/15/18-stimulated NK cells i.v. into NSG mice (figure 6.19) and supplemented the 
animals repeatedly with IL-2 by i.p. injections. In both the in vitro and in vivo setup the more 
pronounced proliferation and the elevated reactivity in terms of IFN-γ production depended on the 
presence of an activating inflammatory cytokine. We did not test if IL-15 maintains the reactivity of 
IL-12/15/18-stimulated NK cells in vivo. Here, further experiments will be performed to investigate if 
the use of IL-2 in vivo can be circumvented. 
Importantly, Romee et al. showed in their model, that after 7 days in culture, IFN-γ mRNA levels did 
not differ in the NK cells regardless of the stimulation (IL-15 and IL-12/15/18) thus making similar 
observations as Cooper et al. with murine cytokine activated NK cells284,363. These findings imply that 
the higher production of IFN-γ might be mainly regulated at a posttranscriptional level. Also, the 
levels of the IL-12 receptor were similar between IL12/15/18- and IL-15-stimulated NK cells, thus not 
explaining why upon re-stimulation with IL-12/15 the IL-12/15/18-stimulated NK cells showed a more 
robust IFN-γ production compared to control cells. Notably, also restimulation with K562 cells 
induced an increased response. However, the higher levels of IFN-γ production after tumor cell 
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restimulation could be due to an elevated expression of NKp46 on IL-12/15/18-stimulated NK cells 
that was described in the same paper363. One potential regulatory mechanism for the elevated IFN-γ 
responses could thus be the repression of translation via miRNAs that were described to regulate 
IFN-γ protein expression and could be decreased after IL-12/15/18-stimulation413,414. A stably 
decreased expression of such inhibitory miRNAs could for instance result from epigenetic regulation. 
Furthermore, a more efficient formation of IFN-γ loaded intracellular vesicles could explain the 
higher secretion of the cytokine despite similar levels of mRNA. However, our preliminary data 
indicate though that intracellular IFN-γ levels are similar after 8 days in culture (data not shown) thus 
excluding the possibility of a higher abundance pre-formed IFN-γ-loaded secretory vesicles. Notably, 
we also detected highly elevated levels of TNF-α in IL-12/15/18-stimulated NK cells (data not shown). 
This cytokine has been shown to be involved in NK cell apoptosis after cytokine stimulation thus 
preventing overproduction of IFN-γ141. Likewise, TNF-α induction could possibly serve as a cell-
intrinsic negative control element to prevent immunopathology. These issues need to be 
investigated in the future.  
As described (section 3.3.7), the term memory-like has been introduced for NK cells stimulated with 
certain cytokines such as a combination of IL-12, -15 and -18 as they exhibit elevated responses 
against various stimuli whereas virus-induced memory seems to be antigen-specific. Notably, in a 
murine cytomegalovirus (CMV) infection model it was shown that IL-12 signaling was crucial for the 
induction of NK cell memory. When IL-12 signaling was abrogated by using IL-12R-/- mice, no 
expansion of Ly49H+ NK cells, which are specific for the viral m157 protein, was detected415. Also 
during human CMV infection or re-activation the expansion of a NKG2C-positive NK cell subset was 
observed  that produced elevated levels of IFN-γ and exhibited features of recall responses thus 
indicating memory features416. To date, the factor driving this expansion is unclear but unpublished 
data from our group point towards a contribution of IL-12. These data indicate that IL-12 signaling 
might be one of the key factors for inducing long-lasting NK cell responses. Due to the potential 
clinical relevance of these findings for NK cell-mediated protection from virus infections but possibly 
also for the treatment of malignant disease, comprehensive investigations are needed to delineate 
the exact molecular details granting NK cells this sustained either antigen-specific or -unspecific 
reactivity. 
 
7.3.2 IL-12/15/18-activated NK cells exhibit increased cytotoxicity and a display a distinct 
phenotype 
To gather comprehensive data on how IL-12/15/18-stimulation potentially impacts NK cell reactivity 
we did not only monitor cytokine secretion but also performed 51Cr release assays against various 
tumor targets to measure for cellular cytotoxicity. As depicted in figure 6.20, IL-12/15/18-stimulated 
NK cells exhibited stronger killing against any investigated tumor cell line compared to control cells. 
Of note, this effect was not dependent on the expression of MHC class I. IL-12, IL-15 and IL-18 have 
been described individually to act as NK cell activating cytokines yet little or no mechanistic studies 
have been performed142,145,146,362,418.  
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7.3.2.1 KIR phenotype after IL-12/15/18-stimulation 
So far, no systematic analysis of the expression levels of various inhibitory and activating NK cell 
receptors directly after 16 hours of stimulation with IL-12/15/18 has been performed. Importantly, 
we detected a slight decrease in the expression levels of various KIRs after 16 hours of cytokine 
stimulation that got more pronounced after 60 hours (figure 6.21). As indicated by the analysis of the 
available gene array data (GEO dataset, GSE22919) this deregulation was also obvious at mRNA level, 
pointing towards a transcriptional regulation of the three KIR molecules by IL-12/15/18 (figure 6.21 
E)360. Most importantly, to our knowledge, signaling via inflammatory cytokines is a novel regulatory 
mechanism of KIR expression. In fact, Chrul et al. published that the combinatorial treatment of naїve 
NK cells for 72 hours with IL-12 and IL-18 led to a significant increase of the percentage of KIR2DL1- 
and KIR2DL2-positive cells compared to naїve NK cells KIRs364. Controversially, in our study, NK cells 
after the stimulation with IL-12/15/18 expressed less KIR than naїve and IL-15-stimulated NK cells 
(figure 6.21 A). The fact that Chrul et al. did not observe the substantial down-regulation that we 
observed might be due to the lack of IL-15 in their setup. Of note, IL-15 has been shown to 
up-regulate KIR levels, but still its effects in combination with IL-12 and IL-18 as in our setup might 
have been adverse or simply be dominantly counteracted by the combined signaling of IL-12 and IL-
18. Hence, in our setup, IL-12/15/18-stimulation seemed to decrease inhibition by KIR signaling, 
possibly contributing to the observed significantly higher killing of various MHC class I-positive tumor 
targets (figure 6.20). However, de-sensitization for self HLA and simultaneous up-regulation of 
perforin and activating NK cell receptors such as NKG2D or the NCRs mediated by IL-15 and IL-18 
could potentially have a negative impact in terms of autoimmunity418. Notably, our preliminary data 
suggest that IL-12 or IL-18 alone are sufficient to prevent IL-15-induced up-regulation of KIRs. This is 
of particular interest, as the two cytokines use very distinct signaling pathways (introduced in section 
3.3.2). Thus, for MHC class I-positive targets, IL-12- or IL-18- together with IL-15-stimulation might 
ideally activate NK cells by inducing relevant cytotoxic molecules such as perforin but simultaneously 
decreasing the expression of inhibitory receptors. Importantly, further phenotypical and most 
importantly functional studies are required to determine the cytokine combination and 
concentration to ideally activate NK cells. Of note, the down-regulation of KIR after stimulation with 
IL-12/15/18 was reversible. After 6 days in IL-2-containing medium, the levels of the investigated KIRs 
were detectable at similar levels, indicating a reversible mechanism (data not shown). 
There are several mechanisms for the observed KIR regulation in these in vitro stimulation 
experiments. As shown in figure 6.21 E, the decreased mRNA levels of the investigated KIR molecules 
in IL-12/15/18-stimulated compared to naїve NK cells suggest a transcriptional regulatory 
mechanism. Most importantly, it was recognized shortly after the discovery of KIRs that DNA-
methylation as well as histone acetylation and methylation are key mechanisms to regulate the 
expression levels of various KIR alleles419,420. The regulation is recognized to be very complex 
including promoter elements in intergenic fragments, antisense RNAs and an array of involved 
transcription factors like c-Myc in multi-promotor-controlled genes421,422. Notably, all KIR genes do 
have a p300/CBP binding site in the distal promoter. This protein upon binding is able to acetylate all 
4 nucleosomal core histones and thus could be a powerful inducer of KIR expression423. Furthermore, 
all expressed KIR genes have a potential AML/Runx binding site what led to the hypothesis that AML 
proteins might also be contributing to regulate KIR expression424. Importantly, Runx and p300 are 
epigenetic regulators and NK cells have been shown to up-regulate previously silenced KIR genes 
after treatment with the methyltransferase inhibitor 5-Aza-dC419. A preliminary search for altered 
expression levels of DNA methyltransferases or potentially KIR-expression modifying proteins in the 
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publically available array data (GEO dataset, GSE22919) on IL-12/2/18-stimulated NK cell did not 
reveal any targets, yet360. Notably, not only expression levels of these proteins but also their 
biological activity that could potentially be regulated by IL-12/15/18 could affect the expression 
levels of KIR molecules. It will be crucial to stimulate purified NK cells with IL-12/15/18 in the 
presence of a panel of inhibitors for various DNA or nucleosome modifying proteins, such as DNA 
methyltransferases or histone methylating, acetylating or phosphorylating proteins. It thus can be 
analyzed what epigenetic pathways are crucial for decreasing KIR protein levels by interfering with 
gene transcription. These experiments are ongoing in our laboratory and the data will clarify the 
contribution of individual epigenetic mechanisms to the observed KIR regulation by IL-12/15/18.  
Importantly, the down-regulation of KIR expression levels by inflammatory cytokines - regardless of 
the mechanism - is of particular interest. Blocking of KIR molecules with mAbs, which decreased 
inhibition by self HLA, yielded promising results in NK cell-based therapies of leukemia in pre-clinical 
mouse models312. More importantly, absence of KIR signaling introduced by KIR-HLA mismatching in 
allo-HSCT settings against AML improved the prognosis significantly308. If IL-12/15/18-stimulation 
should represent a possibility to ex vivo activate NK cells to transiently exert less inhibition by self 
HLA, this would be of high translational importance.  
 
7.3.2.2 Activating receptor phenotype after IL-12/15/18 stimulation 
To obtain comprehensive data concerning the phenotype of IL-12/15/18-stimulated NK cells, we 
stained purified NK cells after 16 and 60 hours of cytokine-stimulation for a panel of activating NK 
receptors. We observed that most of the analyzed receptors (NKG2D, NKp30, NKp44 and NKp80) 
were expressed less abundantly on IL-12/15/18-stimulated NK cells compared to control cells, with 
DNAM-1 being the only receptor that showed up-regulation (figure 6.22). Several mechanisms can be 
responsible for the observed regulation of the investigated activating receptors. Yet, the changes we 
observed on protein level for most receptors were evident as well on the mRNA level of naїve and 
IL-12/15/18-stimulated NK cells as revealed by analysis of available gene array data (GEO dataset, 
GSE22919) (figure 6.22)360. These findings argue for transcriptional regulation mechanisms. Of note, 
IL-12/15/18-activated NK cells exhibited a decreased expression of NKp44 on protein level compared 
to IL-15-stimulated NK cells whereas the mRNA expression compared to naїve cells was up-regulated 
(figure 6.22 C). This is in line with a de novo induction of NKp44 in IL-12/15/18-treated NK cells (data 
not shown). Thus, IL-12/15/18-stimulated NK cells up-regulate NKp44 compared to naїve cells albeit 
to a lower degree compared to IL-15-stimulated cells explaining the seemingly controversial data 
plotted in figure 6.22. In line with the suggested transcriptional regulation of some of the molecules, 
epigenetic mechanisms have been described to be involved in the regulation of the expression levels 
of certain receptors in mice or humans425,426. NKG2D transcription for instance was described to be 
negatively regulated by DNA-methylation whereas histone acetylation increased transcription of the 
gene. Furthermore, in another study, the hypomethylating agent decitabine increased NKp44 and 
inhibitory KIRs in a dose-dependent manner whereas in the same study decitabine down-regulated 
NKG2D427. Despite the discrepancy with regards to the impact of DNA methylation on NKG2D 
expression these two studies point out that epigenetic mechanisms might be either causative or 
contributing to the phenotype that we detected. Further, it has been reported, that recombinant 
IL-12 or type I IFNs decreased DAP-10 and NKG2D mRNA thus leading to decreased NKG2D levels 
which is in line with our findings (figure 6.22)428. Notably, in this study, Muntasell et al. did not 
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observe IL-12-mediated regulation of other activating receptors like NKp30 or NKp46. Still this study 
further emphasizes the complex regulatory network underlying the expression of activating 
receptors429. It is unclear why DNAM-1 is the only activating receptor being up-regulated by the three 
cytokines. Again, little information is available on the regulation of expression of this molecule. 
Deciphering the regulatory mechanisms behind the dynamic expression of activating receptors could 
greatly contribute to a better understanding of NK cell biology and subsequently to more tailored NK 
immunotherapies against for example malignant disease.  
In addition to the mentioned regulatory elements that act on the suggested transcriptional level, 
further possibilities exist that might contribute to the regulation of cell surface expression of some of 
the receptors. For instance, one of the mechanisms that was previously shown to impact the surface 
expression of CD16 was matrix metalloproteinase 25 (MMP25)-mediated shedding of the receptor 
from the cell surface430. The contribution of similar mechanisms to the down-regulation of other 
receptors after stimulation with IL-12/15/18 currently cannot be ruled out.  
Physiologically, this coordinated down-regulation of activating receptors together with inhibitory 
receptors on IL-12/15/18-stimulated NK cells potentially prevents immunopathology. Inflammatory 
cytokines such as DC-derived IL-12 and IL-18 may increase in vivo the expression of NKG2D or NCR 
ligands also on healthy tissue. Moreover, since NK cells after IL-12R and IL-18R signaling down-
regulate activating receptors, bystander cells expressing low levels of cytokine-induced activating 
ligands might be protected from taking collateral damage431–433. Furthermore, in line with Klimosch et 
al., highly cytokine-activated NK cells could down-regulate activating receptors and simultaneously 
express elevated levels of activating ligands174. Killing of highly cytokine-stimulated cells by activated 
NK cells, a mechanism known as fratricide might further negatively regulate over-stimulated NK cells. 
Notably, comprehensive stainings of various activating ligands on cytokine-activated NK cells still 
need to be performed and functional consequences to be elucidated. 
 
7.3.2.3 Functional consequences of IL-12/15/18-stimulation 
The phenotypic analysis of several receptors revealed that the different expression levels after 16 
hours got even more pronounced after 60 hours of stimulation with IL-12/15/18 or IL-15. Still, 
already after 16 hours a significant difference in SK-Mel-28 killing has been observed (figure 6.20). 
Thus, we were speculating to see an even stronger killing of SK-Mel-28 cells by 
IL-12/15/18-stimulated NK cells after 60 hours of cytokine activation. Remarkably, the difference in 
killing between the IL-15- and IL-12/15/18-activated NK cell populations was virtually gone (figure 
6.23). Both IL-15- and IL-12/15/18-stimulated NK cells exhibited a specific lysis of around 40% (E:T 
ratio of 25:1). Seemingly, IL-12/15/18-stimulation did not increase the cytotoxicity towards 
SK-Mel-28 substantially after more than 16 hours of activation (compare figure 6.20 E). However, 
IL-15-stimulated NK cells were further activated and after 60 hours exhibited similar levels of killing 
compared to IL-12/15/18-stimulated NK cells. The fact that NK cells after 60 hours of activation with 
IL-12/15/18 were not exhibiting increased cytotoxicity is intriguing. Possibly, prolonged stimulation 
further dampened inhibition by cognate HLA molecules via down-regulation of the respective KIRs 
but also decreased activating signals - via down-regulation of the respective activating receptors – 
potentially maintaining the ratio of inhibitory and activating signals and thus the lysis efficiency. 
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As the impact of inflammatory cytokine signaling on the expression of inhibitory KIRs was highly 
remarkable and so far not described, we wanted to investigate if the decreased KIR levels translate 
into an increased function of target cells bearing the cognate ligands. Therefore, we made use of 
721.221 cells that do not express HLA class I molecules (from now on called 221 cells) or various 
transductants of 221 cells expressing single HLA alleles. With these cells we performed CD107a 
mobilization assays and analyzed the results as described previously. Most importantly, the 
decreased KIR2DL2/L3 levels caused a less pronounced inhibition of KIR2DL2/L3-positive NK cells by 
C1 ligands (figure 6.24 D). As already mentioned, this elevated response against self-HLA expressing 
cells could have a big impact on NK cell based immunotherapy. For instance, the requirement for 
suitable donors for allo-HSCT would omit as allo-reactive-like functionality could be introduced in an 
autologous setting by stimulating NK cells with the three cytokines. Most importantly, one phase I 
trial featuring IL-12/15/18-stimulated NK cells is already set up under the identifier NCT01898793 at 
the Washington University School of Medicine in the context of refractory and relapsed AML. It will 
evaluate the safety of the infusion of IL-12/15/18-activated NK cells as a primary readout and their 
possible beneficial effect as scondary measures and hence provide the first in vivo data generated in 
human subjects. 
 
7.3.3 IL-12/15/18-stimulated NK cells exhibit stronger anti-tumor effects in vivo 
To investigate the impact of the short-term activation of NK cells with IL-12/15/18 in an in vivo 
model, we injected CBGr99-positive melanoma cells together with IL-15- or IL-12/15/18-stimulated 
NK cells i.v. into NSG mice. Importantly, we found that IL-12/15/18-stimulated cells controlled the 
engraftment of the melanoma cells in the lungs to a higher degree compared to IL-15-stimulated NK 
cells (figure 6.25). This effect was already observed after 4 days and most likely was due to a) an 
elevated cytotoxicity of IL-12/15/18-activated NK cells towards SK-Mel-28 cells and b) higher NK cell 
numbers due to proliferation (not analyzed, compare to figure 6.19). It will be interesting to dissect 
the effects of these two factors.  
A combination of the two approaches introduced in this dissertation – CX3CL1-overexpressing tumor 
cells and IL-12/15/18-stimulated NK cells as effector cells – might be a promising approach. Yet, as 
CX3CR1 upon IL-12/15/18-stimulation got substantially down-regulated (figure 6.22) we did not 
perform this experiment. 
 
7.3.4  Aspects for clinical translation 
Several previous studies showed that the responsiveness of NK cells gradually declined after infusion 
into tumor patients. In this study, we showed that NK cells activated with IL-12/15/18 exhibited a 
more sustained reactivity and thus could contribute to more long-lasting NK responses in vivo.  
Still, several issues need further investigation. First of all, it is to date unclear how the decreased 
levels of KIR molecules impact the reactivity of stimulated NK cells towards healthy cells. Uninfected 
and untransformed tissue should theoretically not harbor activating NK cell ligands. However, since 
inflammatory cytokines might induce low levels of for instance NKG2D ligands in proximity to 
inflamed tissue, auto-reactivity of KIRlow NK cells needs to be excluded prior to clinical application to 
prevent auto-immunity. Second, we only observed that IFN-γ and TNF-α (not shown) were produced 
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and secreted at high levels. Yet, in our reductionistic model in which we only transferred NK cells, a 
cross-talk with other cells is not occuring. Here, it will be important to investigate the impact of 
elevated levels of IFN-γ on the adaptive immune system. For instance, it potentially potently 
activates dendritic cells that subsequently drive T cell responses into a Th1 and CTL type of 
response434,435. Importantly, this induction of CTL immunity via DC activation was already reported to 
be an important feature of IL-18-primed NK cells436,437. Indeed, IL-18-stimulation of NK cells after 
tumor cell contact were shown to attract immature DCs via CCL3 and CCL4 secretion. Subsequently, 
these helper NK cells induced high expression of CXCR3 ligands in DCs by which CD8-positive T 
effector cells were recruited and efficiently primed. We further did not perform experiments on the 
impact of various secreted cytokines on tumor cells. Importantly, it has recently been shown that the 
presence of the Th1 cytokines IFN-γ and TNF-α can induce senescence in tumor cells198. Thus, besides 
classical cytotoxicity and boosting adaptive responses, the cytokine profile of IL-12/15/18-stimulated 
NK cells potentially allows them to arrest tumor growth without forming immunological synapses 
with their targets, rendering them multi-functional in terms of anti-tumor effector mechanisms. 
Due to the well-known NK cell-activating properties of IL-12 and IL-18 several studies have been 
published in which the two cytokines have been combined in in vivo models. The injection of 
therapeutical amounts of the cytokines alone or in combination was reported to cause severe side 
effects in mouse models and in clinical studies438–440. In one setup, 100% of the mice died after 4-8 
days of daily injections of IL-12 and IL-18 due to sepsis-like symptoms439. Thus, it will be important to 
either carefully evaluate a proper dosing-schedule or to infuse pre-stimulated, expanded NK cells 
without the need for exogenous systemic application of IL-12 and IL-18. Importantly, IL-12 and IL-18 
also have already been used together in tumor models and proved to be potent inducers of NK 
cell-depending anti-tumor responses441. Of note, in the tumor model mentioned IL-12-expression 
was restricted to the tumor by genetic means. Therefore these data suggest that the cytokines 
should not be applied systemically to prevent general inflammation but high levels should be 
generated exclusively at the tumor site. This could be achieved for instance by using tumor targeted 
viruses as vectors as introduced in chapter 7.2.4. 
In conclusion, stimulation of NK cells with IL-12/15/18 harbors the possibility to generate effector NK 
cells that respond to low doses of IL-2. Accordingly, these cells rapidly expand when supplied with 
IL-2 and exhibit sustained reactivity towards various stimuli. Importantly, the unique potential to 
induce allo-reactive-like behavior in autologous NK cells potentially harbors high relevance for the 
future design of NK cell-based therapies. 
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7.4  Therapeutic implications and concluding remarks 
With the exception of the treatment of certain hematological malignancies, NK cell-based 
immunotherapies did only show moderate success308. Reasons for the discrepancies between the 
observed in vitro functionality of NK cells against tumor targets and the lack of tumor control in vivo 
could be multifaceted. For instance, autologous NK cells as used in a study performed by Parkhurst et 
al. acquired a self-tolerant and thus quiescent status which was detected by the means of NKG2D 
downregulation229. This could for instance be achieved by a tumor microenvironment enriched for 
immunoregulatory or -suppressive cells and factors442–444. Also, defective homing of cytotoxic 
effector cells into the tumor could contribute to the low success rate of NK cell-based therapies224,445.  
We wanted to approach these two problems that NK cells in tumor-immunotherapeutical settings 
are likely to face: 
a) Little infiltration into solid tumor tissue. Here, CX3CL1-overexpression in the tumor tissue 
potentially holds great promise if the patients are selected thoroughly based on 
tumor-reactivity towards the chemokine; 
b) Loss of reactivity due to immunosuppressive milieus in situ. We propose 
IL-12/15/18-stimulation as a superior activation regimen. Not only do NK cells react in a 
more sustained way towards tumor cells but they also kill tumor targets more efficiently and 
proliferate robustly upon supplementation with IL-2 or IL-15. 
Most importantly, both approaches were tested successfully in pre-clinical in vivo mouse models in 
which for a) upon CX3CL1-expression a better tumor control and higher migration of NK cells into the 
tumor bearing lungs was detectable and b) IL-12/15/18-stimulated NK cells demonstrated higher 
efficiency against injected human melanoma cells compared to IL-15-stimulated NK cells. Therefore, 
we propose that CX3CL1-overexpression in situ (for instance via adenoviral tumorspecific vectors) 
and activation of NK cells with IL-12, IL-15 and IL-18 are promising novel strategies for NK cell based 
immunotherapy against cancer. These findings should be incorporated into novel strategies 
harnessing NK cells for immunotherapy of melanoma or malignant disease in general. 
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9 ABBREVIATIONS  
 
221    721.221 EBV transformed lymphoblastoid cell line 
7-AAD   7-aminoactinomycin D 
ACK   Ammonium-Chloride-Potassium 
ACT    Adoptive cell therapy 
ADAM   A disintegrin and metalloproteinase domain-containing protein 
ADCC  Antibody-dependent cytotoxicity 
AF647   Alexa Fluor 647 
AICL   Activation-induced C-type lectin 
AML    Acute myeloid leukemia 
AP-1   Activator protein 1 
APC    Antigen presenting cells or  
ATP   Adenosine triphosphate 
BAT-3   HLA-B-Associated Transcript 3 
BCA   Bicinchoninic Acid Protein 
BCA1   B-cell-attracting chemokine 1 
BCG   Bacille Calmette-Guérin 
Bcl-2   B-cell leukaemia/lymphoma 2 
BCR   B cell receptor 
BH3   Bcl-2 homology 3 
Blast   Basic local alignment search tool 
BLI   Bioluminescent intensity 
BP    Binding protein 
BSA   Bovine serum albumin 
Btk   Bruton’s tyrosine kinase 
CCRL1   C-C chemokine receptor type 11 
CCRL2   C-C chemokine receptor-like 2 
CD   Cluster of differentiation 
CEA   Carcinoembryonic antigen 
c-FLIP   Cellular FLICE (FADD-like IL-1β-converting enzyme)-inhibitory protein 
CFSE   Carboxyfluorescein succinimidyl ester 
Cm2   Square centimeter 
Cm3   Cubic centimeter 
CMV   Cytomegalovirus 
CSF   Cerebrospinal fluid 
CT   Computed tomography 
CTACK   Cutaneous T-cell-attracting chemokine 
CTL   Cytotoxic T lymphocytes 
CTLA-4     Cytotoxic T lymphocyte-associated antigen 4 
cpm   Counts per minute 
CRP   C-reactive protein 
DAG   Diacylglycerol 
DAMP   Damage-associated molecular pattern 
DAP   DNAX activation protein 
DARC   Duffy antigen/receptor for chemokines 
DC   Dendritic cell 
ddH2O   Double-distilled H2O 
dim   Diminished 
DISC  Death-inducing signalling complex 
DKFZ  Deutsches Krebsforschungszentrum/German Cancer Research Center 
DMEM  Dulbecco/Vogt modified Eagle's minimal essential medium 
DMSO  Dimethyl sulfoxide 
DNA  Deoxyribonucleic acid 
DNAM-1  DNAX Accessory Molecule-1 
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dNTP   Deoxynucleotide   
EAE   Experimental autoimmune encephalomyelitis  
EBV    Epstein-Barr virus 
ECM   Extracellular matrix 
EDTA   Ethylenediaminetetraacetic acid 
eGFP   Enhanced green fluorescent protein 
EGFR    Epidermal growth factor receptor 
ELC   Epstein–Barr-virus-induced gene 1 ligand chemokine 
ELISA   Enzyme-linked immunosorbent assay 
ENA78   Epithelial-cell-derived neutrophil-activating peptide 78 
EOMES   Eomesodermin 
ESAM   Endothelial cell specific adhesion molecule 
E:T   Effector-to-target 
FACS   Fluorescence-activated cell sorting 
FcγR   Fragment, crystalizable γ-receptor 
FcR   Fragment, crystalizable-receptor 
FCS   Fetal calv serum 
FDA    Food and drug administration 
FITC   Fluorescein isothiocyanate 
For   Forward 
FSC   Forward scatter 
g    Gram(s) 
G    Gauge 
GAG   Glycosaminoglycans 
gah   Goat-anti-human 
gam   Goat-anti-mouse 
GCP-2    Granulocyte chemotactic protein 2 
GDS   GEO data set 
GEO   Gene expression omnibus 
GLUT-1   Glucose transporter-1 
GM-CSF   Granulocyte macrophage colony-stimulating factor 
gp100    Glycoprotein 100 
GPCR   G protein-coupled receptor 
Gro    Growth- regulated oncogene 
GvH    Graft versus host 
Gy    Gray 
h    Hour(s) 
HA   hemagglutinin 
HBS    HEPES buffered saline 
HBV    Hepatitis B virus 
HEPES   4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
Her2   Human epidermal growth factor receptor 2 
HIF1α   Hypoxia-inducible factor 1 alpha 
HIV   Human immunodeficiency virus type-1 
HMGB1   High-Mobility-Group-Protein B1 
HPV   Human papillomavirus 
HSC   Hematopoietic stem cell 
HSCT   Hematopoietic stem cell transplantation 
Hsp   Heat shock protein 
Hu   Human 
huIgG   Human Immunoglobulin 
HUVEC   Human umbilical vein endothelial cells 
ICAM-1   Intracellular adhesion molecule-1 
IDO   Indoleamine 2,3-dioxygenase 
IFN-γ   Interferon-γ 
IFN-γR   Interferon-γ receptors 
Ig   Immunoglobulin 
IL   Interleukin 
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IL-12/15/18  IL-12, IL-15 and IL-18 
InsP3   Inositol-1,4,5-trisphosphate
 
i.p.   Intraperitoneal 
IP-10    Interferon- inducible protein 10 
iPSC   Induced pluripotent stem cells 
IRAK   Interleukin-1 receptor-associated kinase 
I-TAC    Interferon-inducible T-cell α chemoattractant 
ITAM    Immunoreceptor tyrosine-based activating motif 
ITIM   Immunoreceptor tyrosine-based inhibitory motif 
IU   International unit(s) 
i.v.   Intravenous 
IVIS   In vivo imaging system 
Jak   Janus kinase 
JAM   Junction adhesion molecule 
KACL   Keratinocyte-associated C-type lectin 
KIR   Killer cell immunoglobulin-like teceptor 
KLRG1   Killer cell lectin-like receptor G1 
L   Liter(s) 
LAK   Lymphokine-activated killer 
LB   Lysogeny broth 
LFA1   Leukocyte functional antigen 1 
LILRB2   Leukocyte immunoglobulin-like receptor B2 
LPS   Lipopolysaccharid 
mAb    Monoclonal antibody 
MACS   Magnetic assisted cell sorting 
MAdCAM1  Mucosal vascular addressin cell adhesion molecule 1 
Malign.   Malignant 
MART1    Melanoma antigen recognized by T cells 1 
MBL   Mannose binding lectin 
MCA   3-methylcholanthrene 
MCP    Monocyte chemoattractant protein 
MCMV   Murine cytomegalovirus 
MDC    Macrophage-derived chemokine 
MDSC   Myeloid-derived suppressor cell(s) 
MEC    Mucosae- associated epithelial chemokine 
MFI    Mean fluorescence intensity 
mg   Milligram(s)  
MHC   Major histocompatibility complex 
MIC   MHC class I–related chain 
µCi   Micro-Sievert 
µg   Microgram(s) 
MIG    Monokine induced by interferon γ 
Min   Minute 
MIP    Macrophage inflammatory protein 
ml   Milliliter 
MLL-5   Mixed lineage leukemia 5 
mM   Millimolar 
µM   MIcromolar 
MMP   Matrix metalloproteinase 
moDC   Monocyte-derived dendritic cell 
MΦ   Macrophage(s) 
MRI   Magnetic resonance imaging 
(m)RNA   (messenger) ribonucleic acid 
miRNA   Micro RNA 
MS   Multiple sclerosis 
MTOC   Microtubule-organizing center 
MULT-1   Murine UL16-binding protein-like transcript-1 
MyD88   Myeloid differentiation primary response gene (88) 
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NAD+   Nicotinamide adenine dinucleotide 
NAP-2    Neutrophil-activating peptide 2 
NCR   Natural cytotoxicity receptors 
n.d.    Not detectable 
NF-κB   Nuclear factor-κB 
ng   Nanogram(s) 
NHL    Non-Hodgkin lymphoma 
NK cell   Natural killer cell 
NKDI   NK cell developmental intermediates 
nm   Nanometer  
NKR   NK cell receptor 
NOD-SCID  Nonobese Diabetic/Severe Combined Immunodeficiency 
NSG    NOD-scid gamma  
P2A   Porcine teschovirus-1 2A 
PAMP   Pathogen associated molecular pattern 
PCNA   Proliferating-cell-nuclear-antige 
PCR   Polymerase chain reaction 
PD-1    Programmed cell death protein 1 
PD-L1    Programmed cell death ligand 1 
PE   Phycoerythrin 
PECAM1  Platelet endothelial cell adhesion molecule 
PET   Positron emission tomography 
PerCP-Cy5.5  Peridinin-chlorophyll-protein-complex-cyanine 5.5 
PGE2   Prostaglandin E2 
PhD   Philosophiae doctor 
PI3K   Phosphatidylinositide 3-kinase 
PLGF    Placental growth factor 
PLN   Peripheral lymph node 
PMA   phorbol 12-myristate 13-acetate 
pRb   Retinoblastoma protein 
proIL-18   IL-18 pro-protein 
PRR   Pattern-recognition receptor 
PSGL1   P-selectin glycoprotein ligand 1 
PTEN   Phosphatase and tensin homolog 
Puro   Puromycin 
PVR   Poliovirus receptor 
RA   Rheumatoid arthritis 
Rae-1   retinoic acid early inducible-1 
RAG   recombination activating gene 
RAGE   Receptor for Advanced Glycation Endproducts 
RANTES    Regulated on activation, normal T-cell expressed and secreted 
RCC    Renal cell carcinoma 
rev    Revers 
rIgG   Rat immunoglobulin G 
RLU   Relative light unit(s) 
ROI   Region of interest 
ROS   Reactive oxygen species 
rpm   Rotations per minute  
RPMI   Roswell park memorial institute medium 
RT   Room temperature 
s    Second 
S1-P5   sphingosine 1-phosphate receptor 
s.c.   Subcutaneous 
SCGM   Stem cell growth medium 
SD    Standard deviation 
SDF-1α    Stromal cell-derived factor-1α 
SH2   Src Homology 2 
SHP   Src homology region 2 domain-containing phosphatase 
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SLC    Secondary lymphoid-tissue chemokine 
SOC   Super Optimal broth with Catabolite repression 
SSC   Side scatter 
STAT   Signal transducers and activators of transcription 
Sr    Steradian 
TAE   Tris-acetate-EDTA 
TARC    Thymus and activation-regulated chemokine 
TCR   T cell receptor  
TECK   Thymus-expressed chemokine 
Temp   Temperature 
TGF-β   Transforming growth factor-β 
TIGIT   T cell immunoreceptor with Ig and ITIM domains 
TIL    Tumor-infiltrating lymphocytes 
TLR   Toll-like receptor 
TNF-α   Tumor necrosis  factor-α   
TRAF   TNF receptor associated factors 
TRAIL   Tumor necrosis factor related apoptosis inducing ligand 
Treg   Regulatory T cell 
ULBP   UL16-binding protein 
UV   Ultraviolet 
VCAM1   Vascular cell adhesion molecule 1 
VEGF   Vascular endothelial growth factor 
VIN    Vulvar intraepithelial neoplasia 
VLA4   Very late antigen 4 
VLP   Virus-like particle 
VSV   Vesicular stomatitis virus 
VVO   Vesiculo-vacuolar organelles 
WBI   Whole body irradiation 
w/o   Without 
wt   Wild-type 
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